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General introduction
Bart Lammers
Cardiovascular diseases (CVD) are still a leading cause of death in 
the Western society. Atherosclerosis is the underlying cause of most 
cardiovascular diseases. Lipid accumulation in the arterial wall leads to 
an inflammatory condition clinically causing occlusive vascular disease, 
myocardial infarction (MI), and stroke.1 In 2010, 39735 people were 
documented to have died of the consequences of CVD in the Netherlands, 
accounting for 29% of all reported deaths.2 This clearly illustrates the CVD 
problem in the Dutch society. In the last decades, several risk factors for 
atherosclerosis have been identified including smoking, hyperlipidemia, 
hypertension, physical inactivity, and being male.3 To date, treatments 
are mostly based on the elimination of these identified risk factors and 
mainly consist of lowering of serum lipid levels by statins, reduction 
of blood pressure, and decreasing blood thrombosis. However, these 
interventions cannot prevent that CVD still remain a leading cause of 
death in the Western society. Therefore, there is an urge to develop 
new therapies targeting the different molecular pathways and stages of 
atherogenesis.
Myocardial infarction (MI), commonly known as a heart attack, results 
from the interruption of blood supply to a part of the heart. This commonly 
occurs when an atherosclerotic plaque slowly builds up in the inner lining 
of a coronary artery. Rupture of these plaques may result in thrombus 
formation, leading to occlusion of a coronary artery and preventing blood 
flow downstream. The resulting ischemia can cause damage or death 
of myocardial tissue. Although cases of ischemic heart disease have 
been described for two centuries,4 the factors responsible for the sudden 
thrombotic occlusion of a coronary artery have only been elucidated in the 
last two decades.5–7 In at least 70% to 80% of cases, acute myocardial 
infarction is attributable to rupture of a vulnerable plaque, resulting in 
local thrombus formation and acute disruption in the coronary blood 
supply in the affected area.8 Many important predictors of early clinical 
outcome in myocardial infarction are independent of treatment. Most of 
the early mortality is explained by factors such as the age of the patient, 
initial heart rate and blood pressure. However, the time to administration 
of reperfusion therapy is a critical adjustable determinant. Several 
studies have revealed that patients with myocardial infarction treated 
most rapidly have a lower mortality and, among survivors, reduced 
infarct size.9 Another important risk factor is the composition of the 
atherosclerotic lesion. Independent of its severity, vulnerable plaques 




Processes involved in the initiation of atherosclerosis have been debated for 
many years and several hypotheses have been proposed. The “response-to-
injury” hypothesis was one of the first to state that endothelial injury leads to 
an inflammatory response as part of a healing process in the arterial wall.10 
Under normal conditions, the healthy endothelium is able to respond to physical 
and chemical signals by the production of a wide range of factors that regulate 
vascular tone, cellular adhesion, thrombus resistance, smooth muscle cell 
proliferation, and vessel wall inflammation.11 Endothelial activation caused by 
hyperlipidemia, hypertension, diabetes, and smoking, results in an increased 
migration of monocytes and T-lymphocytes from the circulation into the intima of 
the arterial wall. The attracted leukocytes transmigrate through the endothelial 
layer in a multi-step process in which the following stages can be identified; rolling 
on the endothelium, firm adhesion, and transmigration into the sub-endothelial 
space.12,13 Under hypercholesterolemic conditions, the transmigrated monocyte-
derived macrophages start to accumulate lipids, including cholesterol, and 
transform into macrophage foam cells.14 The accumulation of these macrophage 
foam cells is the hallmark of the development of the so called fatty streak: the first 
step in the pathogenesis of atherosclerosis (Fig. 1).15,16 The atherosclerotic plaque 
is a dynamic tissue, where increases in cell number (driven by cell proliferation 
and migration) and decreases in cell number (driven by cell death and possibly 
emigration) are continuous processes.17
Although macrophages are able to release their cholesterol through efflux (see also 
chapter 2), they cannot limit the uptake of cholesterol. Therefore, atherosclerotic 
lesion development will progress with time. In more advanced atherosclerotic 
lesions, smooth muscle cells (SMC) contribute to foam cell formation by also taking 
up lipids. In addition, SMC can synthesize large amounts of collagen, elastin, 
and proteoglycans, resulting in the fatty streak to evolve into an intermediate 
(fibrofatty) lesion. SMC cover the core of these lesions, which are constituted 
of extracellular lipids, foam cells, and T-lymphocytes, surrounded by a poorly 
developed matrix of connective tissue.3 Further progression of the lesion severity 
subsequently results in the formation of an advanced fibrous lesion, characterized 
by a fibrous cap covering a core of extracellular lipid and necrotic debris, together 
with macrophages, T-lymphocytes, SMC and sometimes calcification.18,19 Activated 
macrophages play a key role in atherosclerotic plaque stability and thrombotic 
complications by producing several proteases, including matrix metalloproteinases 
(MMP).20 These MMP can degrade extracellular matrix, which strengthens the 
fibrous cap of the plaque. In addition, macrophages can secrete collagenases and 
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induce apoptosis of vascular SMC, thereby negatively infl uencing the collagen 
production and thus plaque stability.21–23 Subsequent plaque rupture can result 
in secondary hemorrhage and thrombosis. This in turn leads to occlusion of the 
artery, and may lead to clinical symptoms such as MI and cerebral stroke.24–26
Monocytes, macrophages and atherogenesis
It is generally accepted that macrophages play an essential role in all stages of 
atherosclerotic lesion development. The fatty streak is predominantly composed of 
macrophages, whereas more advanced atherosclerotic lesions consist of clusters 
of macrophages surrounding a core of lipid and necrotic material.27 In addition, 
mice lacking macrophages (due to macrophage colony-stimulating factor (M-CSF) 
defi ciency) exhibit a marked reduction in atherosclerotic lesion development, 
even despite severe hypercholesterolemia, underlining the important function of 
macrophages in atherosclerotic lesion development.28,29 
Monocytes, derived from pluripotent hematopoietic stem cells in the bone marrow, 
migrate into the blood circulation within 24 hours after production in the bone 
marrow.30 Subsequently, they either remain in the blood stream or migrate from 
the circulation into tissues and body cavities. Monocytes can then, upon stimulation 
with M-CSF, differentiate into macrophages and become foam cells after excessive 
accumulation of lipids, which results in the initiation of atherosclerosis. The 
accumulation of monocyte-derived macrophages is progressive and correlates to 
initial atherosclerotic lesion formation.31 In addition to infl ux of monocyte-derived 
macrophages, some studies have suggested that macrophages in the arterial wall 











Time / Endothelial Dysfunction
Figure 1. Atherosclerotic lesion progression over time. See text for explanation. Adapted from Pepine 
CJ.193
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renewal of resident macrophages in body cavities and tissues have been shown to 
depend on macrophage proliferation.33
The “response-to-injury” hypothesis suggests the importance of local endothelial 
injury for the pathogenesis of atherosclerosis. Damaged, and thus activated 
endothelial cells produce chemokines, cytokines and adhesion molecules 
designed to interact with leukocytes and platelets to direct these inflammatory 
cells to specific tissues in response to vascular injury.34 Activated endothelial cells 
express adhesion molecules, such as vascular cell adhesion molecule-1 (VCAM-
1), intercellular adhesion molecule-1 (ICAM-1), P-selectin and E-selectin.14,35 
Leukocytes express counter receptors for these adhesion molecules and decelerate 
in the bloodstream via interaction with P- and E-selectin. Once slowed down, a 
more firm adhesion is facilitated via VCAM-1 and ICAM-1.36,37 When firm adhesion 
is established, leukocytes migrate through the interendothelial junction into the 
subendothelial space (diapedesis). This process is facilitated by additional adhesion 
molecules, like platelet/endothelial cell adhesion molecule-1 (PECAM-1) and 
junctional adhesion molecule-1 (JAM-1).38,39 Specific blockade of the interaction of 
monocytes with these adhesion molecules completely abolishes the accumulation 
of monocytes in the subendothelial space, demonstrating the importance of these 
adhesion molecules in monocyte migration and atherogenesis.40,41 
Furthermore, activated endothelial cells produce several chemokines and 
interleukins (IL), which enhance diapedesis,42 and the recruitment of leukocytes 
into the lesion. The deficiency of monocyte chemoattractant protein-1 (MCP-
1),43 or its receptor CC-chemokine receptor 2 (CCR2)44 results in dramatic 
protection from monocyte recruitment and atherosclerotic lesion formation. 
Different environmental signals, like microbial products and cytokines activate 
macrophages diversely, leading to macrophage heterogeneity. In the mouse, one 
subset of monocytes with high expression of Ly6C promotes inflammation while the 
other subset with low expression of Ly6C attenuates inflammation and promotes 
angiogenesis in models of tissue injury.45 Moreover, upon activation, macrophages 
can either turn into a pro-inflammatory phenotype (M1), producing TNF-α and 
IL-6,46 or an anti-inflammatory phenotype (M2), secreting IL-10 and TGF-β.47 
Besides the amount of monocyte-derived macrophages, it is the phenotype of the 
macrophages that can greatly affect atherosclerotic lesion development.48–50
Macrophages play an important role in a wide variety of inflammatory reactions 
and diseases. They scavenge debris and subsequently migrate away from the 
site of injury into the blood circulation, thereby removing tissue debris. In 
atherosclerosis, however, the turnover of macrophages seems to be impaired 
as macrophages remain in the intima of the arterial wall for a prolonged period 
of time, resulting in a prolonged inflammatory response, and thus an increased 
severity of the atherosclerotic lesion. Although it is demonstrated that macrophage 
foam cells are able to leave the intima of the arterial wall and return to the blood 
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circulation,51 most macrophages remain in the atherosclerotic lesion until they 
die.52 This might be the result of the formation of a fibrous cap which makes 
it more difficult for a macrophage foam cell to leave the atherosclerotic lesion. 
On the other hand, the presence of a fibrous cap also results in an attenuated 
recruitment of monocytes to the atherosclerotic lesion.53,54
Large atherosclerotic plaques are often associated with increased risk for clinical 
manifestations. However, the major cause of these manifestations is rupture of 
the atherosclerotic plaque and the subsequent development of thrombosis. The 
statistic possibility for an atherosclerotic plaque to rupture highly correlates with 
its cellular composition. In general, plaques can be defined as stable or unstable. 
The stability of the plaque is mainly determined by the integrity of the fibrous 
cap overlying the lesion. A thick fibrous cap with low amounts of macrophages 
is highly stable. Stability of the fibrous cap is achieved by SMC that synthesize 
extracellular matrix. 
On the contrary, large amounts of macrophage foam cells, together with a thin 
fibrous cap overlying a large lipid pool are known to be unstable.55,56 Macrophage-
derived MMP and collagenases can degrade the extracellular matrix and collagen, 
thereby reducing the stability of the atherosclerotic plaque.21–23 Although the 
evolution of an atherosclerotic plaque is a complicated and multifactorial process, 
macrophages have differential adverse effects on the pathology, which may 
ultimately lead to a clinical event.
Besides their primary scavenging role, macrophages also produce many different 
proteins, which are potentially involved in the initiation and progression of 
atherosclerotic lesion formation. Important machophage-derived proteins in 
lipoprotein metabolism relevant to this thesis will be discussed in more detail 
below. Specific details on macrophage-derived apolipoprotein E (apoE) and adipose 
triglyceride lipase (ATGL) are also described in this introduction, whereas ABCA1, 
ABCG1, and macrophage reverse cholesterol transport are defined in chapter 2.
Lipids, lipoproteins and lipid metabolism
Although elevated plasma lipid levels are strongly correlated with an increased 
susceptibility to atherosclerosis, they also play an important role in healthy 
individuals. Plasma lipids are essential for every cell in order to maintain membrane 
fluidity. The major lipids in human plasma are cholesterol, cholesteryl esters (CE), 
triglycerides (TG), and phospholipids (PL). Cholesterol is of critical importance for 
all eukaryotic organisms, as it modulates membrane fluidity and is essential for 
steroid hormone synthesis, whereas TG are used as an energy source for muscles 




Since lipids are insoluble in blood, they are transported by lipoproteins. 
Lipoproteins are water-soluble protein-lipid complexes, which consist of a 
hydrophobic core of neutral lipids (CE and TG), surrounded by a monolayer of PL, 
unesterified cholesterol and specific apolipoproteins (apo).57 Apolipoproteins are 
required for the assembly, structure, and function of lipoproteins. Furthermore, 
they activate enzymes important in lipid metabolism and act as ligands for cell 
surface receptors. Several different lipoproteins can be distinguished based upon 
their lipid and apolipoprotein composition and size: chylomicrons (CM), very low-
density lipoproteins (VLDL), intermediate-density lipoproteins (IDL), low-density 
lipoproteins (LDL), and high-density lipoproteins (HDL)(Table 1).57 In more detail, 
CM and VLDL are the major carriers of TG in the blood, while plasma cholesterol is 
mainly transported as CE in LDL and HDL. Furthermore, CM, VLDL and LDL have 
apoB as their primary apolipoprotein, comprising approximately 30, 60, and 95% 
of these lipoproteins, respectively, whereas apoA-I is the principal apolipoprotein of 
HDL, comprising 75% of the protein mass.58,59 HDL is a universal plasma acceptor 
for cholesterol efflux and comprise a complex lipoprotein class containing different 
subclasses of HDL varying in size, density, and lipid composition. Generally, HDL 
can be classified into lipid-poor/lipid-free discoidal nascent pre-β HDL and lipid-rich 
spherical mature HDL, based on their difference in electrophoretic mobility.60 Pre-β 
HDL mainly contains apoA-I and PL with small amounts of cholesterol, whereas 
mature HDL encompasses two main density classes: Large CE-rich HDL2 and small 
CE-poor HDL3.
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A-I, A-II, A-IV; 
C-I, C-II, C-III; E
HDL2b      10.4 1.099      0.41 4 33 30 “
HDL2a      10.3 1.107      0.4 4 30 33 “
HDL3a        9.9 1.123      0.36 3 27 29 “
HDL3b        8.0 1.155      0.2 2 24 24 “
HDL3c        7.3 1.186      0.16 1 17 16 “
Table 1. Physical properties and composition of human plasma lipoproteins.194-196
* Values are expressed as percentage of total weight
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changes in the interaction with different tissues, thereby influencing lipoprotein 
metabolism.
Lipoprotein metabolism
The plasma lipid levels depend on the integrated balance of the exogenous and 
endogenous pathways of lipoprotein metabolism, in which the liver plays an 
essential central role.
Exogenous lipid metabolism
The exogenous pathway describes the metabolic route of dietary lipids after their 
absorption by the intestine (Fig. 2). The amount of cholesterol and TG absorbed 
from the diet is a major contributor to lipid levels in the blood circulation. Dietary 
TG and CE are hydrolyzed in the proximal small intestine and subsequently 
assembled into CM. These large TG-rich CM are transported from the lymph to 
the blood circulation. Upon entering the circulation, the TG in the core of CM are 
hydrolyzed by lipoprotein lipase (LPL).63,64 The released free fatty acids (FFA) are 
taken up by peripheral tissues such as adipose tissue (for storage as TG), skeletal 
muscle and heart (as energy source), and the liver (for storage or generation of 
lipoproteins).65 Progressive hydrolysis of TG from CM is accompanied by exchange 
of TG for CE, mediated by cholesteryl ester transfer protein (CETP).66,67 As a result, 
CM shrink in size and turn into CM remnants. These CM remnants, relatively 
enriched in CE and apoE, are rapidly removed from the circulation by the liver 
via the LDL receptor (LDLr), LDL receptor related protein-1 (LRP-1), remnant 
receptors, heparin sulphate proteoglycans, and scavenger receptor class B type I 
(SR-BI),68–70 finally resulting in the uptake of dietary cholesterol by the liver. 
Endogenous lipid metabolism
The endogenous pathway describes the distribution of lipids from the liver to 
peripheral tissues (Fig. 2). VLDL is synthesized in the liver from cholesterol and 
TG derived from de novo synthesis or lipoprotein uptake.71,72 Human nascent VLDL 
contains a single copy of apoB100 as well as newly synthesized apoE and apoC’s. 
ApoE is of particular importance for VLDL and CM remnants since it plays a role in 
the secretion,73,74 as well as in the metabolic fate of these particles, the latter due 
to its interaction with specific receptors.75 Upon its secretion into the circulation, 
TG-rich VLDL particles acquire additional apoE and apoC. The TG in the core of 
VLDL are subject to lipolysis by LPL,63 leading to the formation of VLDL remnants 
or IDL, which is partly cleared by the liver, mediated by apoE.76 The remaining IDL 
undergoes further lipolysis via LPL and hepatic lipase (HL) to become cholesterol-
rich LDL with apoB100 as its sole apolipoprotein, which is recognized by the LDLr 
on the liver and peripheral tissues.77 The liver thus serves as the major site for 
both cholesterol synthesis and catabolism of apoB-containing lipoproteins. 
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Figure 2. Exogenous and endogenous lipid transport. See text for explanation. CM, chylomicrons; apo, 
apolipoprotein; VLDL; very low-density lipoprotein; LDL, low-density lipoprotein; IDL, intermediate-
density lipoprotein; HDL, high-density lipoprotein; FC, free cholesterol; TG, triglycerides; CE, cholesteryl 
esters; CETP, cholesteryl ester transfer protein; LCAT, lecithin: cholesterol acyltransferase; SR, scavenger 




Reverse cholesterol transport (RCT)
All nucleated cells synthesize cholesterol. However, only hepatocytes and 
enterocytes are able to efficiently excrete cholesterol from the body into feces. 
RCT is a pathway by which excess of cholesterol from peripheral tissues, including 
macrophages, is transported back to the liver for excretion, and thus of potential 
interest for the prevention of atherosclerosis (Fig. 3). In the liver, cholesterol 
can be recycled or irreversibly converted to degradation products like bile acids 
and subsequently excreted from the body. Although cellular RCT is not a major 
contributor in the mass excretion of cholesterol into the feces, it does play a 
pivotal role in the cholesterol homeostasis in arterial macrophages. The removal 
of cholesterol via hepatobiliary secretion was considered as the sole route in the 
RCT process. However, a novel non-biliary RCT pathway called transintestinal 
cholesterol efflux (TICE), has been recently identified.78
The classical process of RCT is mediated by HDL.79 Small discoidal HDL particles 
are synthesized and secreted by the intestine and the liver.80 These nascent HDL 
particles are potent acceptors of excess cholesterol from peripheral cells. The ATP-
binding cassette transporter ABCA1 specifically mediates the lipidation of nascent 
HDL particles with PL and FC, leading to the generation of pre-β HDL particles.81,82 
The subsequent esterification of FC into CE in pre-β HDL by lecithin:cholesterol 
acyltransferase (LCAT) generates spherical mature HDL.83 The esterification of 
cholesterol inside the core of the HDL particle creates an unesterified cholesterol 
concentration gradient between HDL and cell membranes, allowing the HDL3 particle 
to accept more FC. This process is considered critical for efficient cholesterol efflux 
from cells to HDL.84 Another ABC transporter, ABCG1, as well as SR-BI, are able 
to efflux cellular cholesterol to these larger HDL3 particles (Fig. 3). In combination 
with additional LCAT activity, this leads to the formation of large, CE-rich HDL, 
converting HDL3 to larger HDL2.
85,86 
HDL1 is the largest HDL particle found in serum, and is enriched in apoE. Since 
apoE is a ligand for the LDLr, HDL1 is able to transport its cholesterol to the liver via 
the LDLr.87 Whereas the LDLr engulfs the whole HDL particle, SR-BI mediates the 
selective uptake of CE from HDL, without taking up the HDL particle.88 Alternatively, 
CETP can transfer CE to TG-rich lipoproteins like VLDL in exchange for TG,89 which 
can be taken up by the liver through their lipoprotein receptors, such as the LDLr 
and LRP-1.90 Importantly, except for hamsters, CETP is not expressed in rodents. 
Upon delivery of HDL-cholesterol to the liver, CE are hydrolyzed and reused for 
lipoprotein assembly. Excess cholesterol can also be secreted into the bile, either 
as neutral sterols via ABCG5/8 or as bile salts via ABCB11.91 Overall, HDL plays a 
crucial role in the transport of excess cholesterol from peripheral tissues back to the 
liver. The RCT pathway may be of great importance with respect to atherosclerotic 
lesion development. Targeting its key mediators can hopefully contribute to the 
development of new therapies protecting against CVD. More recent advances 
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regarding RCT, as well as the structure, expression, and regulation of ABCA1 and 
ABCG1 will be discussed in chapter 2 of this thesis.
Apolipoprotein E
Apolipoprotein E (apoE) is an apolipoprotein that coats the surface and mediate 
the metabolism of lipoprotein particles.75 ApoE serves as a ligand for the LDLr 
and LRP-1 and, through its interaction with these receptors, participates in the 
transport of cholesterol and other lipids among various cells of the body, including 
macrophages.75,92 ApoE principally resides on VLDL, IDL, and large HDL, as well as 
on CM and their remnants.75
Considerable interest in understanding the role of apoE in lipoprotein metabolism 
came from the observation of Havel and Kane that apoE enriched VLDL accumulates 
in the plasma of patients with type III hyperlipoproteinemia, a genetic disorder 
characterized by elevated plasma cholesterol levels and accelerated coronary 
artery disease.93 An isoform of apoE (apoE2) that is defective in binding to the 
LDLr is associated with type III hyperlipoproteinemia.75,94 This affects about 1 in 
5000 individuals.95
Structure, expression and regulation
In humans, the three major isoforms of apoE, referred to as apoE2, E3, and E4,96 
are products of three alleles (ε2, ε3, ε4) at a single gene locus. Three homozygous 
phenotypes (apoE2/2, E3/3 and E4/4) and three heterozygous phenotypes 
(apoE3/2, E4/3, and E4/2) arise from the expression of any two of the three 
alleles.75 Population studies have shown that this allelic variation causes small 
but significant changes in plasma LDL levels.97 The most common phenotype is 
apoE3/3 and the most common allele is ε3. Therefore, apoE3 is considered to be 
the parent form of the protein, and apoE4 and E2 are variants.92,98 ApoE2 differs 
from apoE3 by having a cysteine at position 158 instead of an arginine. This amino 
acid substitution in the LDLr binding region of apoE reduces the LDLr binding 
ability of apoE2 to less than 2% relative to that of apoE3.95 Approximately 1% 
of the population are E2/2 homozygotes. The complexity of the pathogenesis of 
hyperlipoproteinemia is, however, illustrated by the fact that only about 2% of the 
E2/2 individuals develop hyperlipoproteinemia. The majority of individuals with 
this genotype have, in fact, lower than normal plasma cholesterol levels. Thus, 
other factors are necessary for the development of type III hyperlipoproteinemia 
associated with apoE2.99,100
The human apoE gene is 3.7 kilobytes in length, contains four exons and is found 
on chromosome 19.101,102 The promoter sequence TATAATT occurs approximately 









































Figure 3. Reverse cholesterol transport. See text for explanation. ABCA1 / G1, ATP-binding cassette 
transporter A1 / G1; SR-BI; scavenger receptor class B type I; apoE / A-I, apolipoprotein E / A-I; FC, free 
cholesterol; PL, phospholipid; LCAT, lecithin: cholesterol acyltransferase; HDL, high-density lipoprotein; 
LDL, low-density lipoprotein; VLDL, very low-density lipoprotein; LDLr, low-density lipoprotein receptor; 
CE, cholesteryl ester; TG, triglyceride; CETP, cholesteryl ester transfer protein. Modifi ed from Mahley 
RW.198
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messenger RNA (mRNA) is 1163 bp in length.104,105 The primary translation product 
is composed of 317 amino acids, with the 18 amino-terminal amino acids serving 
as a signal peptide. The mature apoE is secreted as a 299-amino acid protein with 
a Mr of 34,200.75
ApoE is primarily synthesized by hepatocytes in the liver, which probably accounts 
for two-thirds to three-fourths of the plasma apoE, although synthesis has been 
documented in virtually every tissue in both humans and mice.106,107 In addition, the 
second largest site of apoE synthesis is the brain, where it is solely responsible for 
the formation of lipoproteins in the brain.108 It is also present in high concentrations 
in interstitial fluid, where it appears to participate in cholesterol redistribution from 
cells with excess cholesterol to those requiring cholesterol.109,110 The participation 
of several cell types in the widespread production of apoE indicates the importance 
of apoE in lipid transport and possibly in roles unrelated to lipid transport.75,107
ApoE plays an essential role in systemic lipoprotein metabolism,63 as well as in lipid 
metabolism at the level of the individual cell.111 The various metabolic pathways 
involving apoE can be divided into three different categories:
1. Redistribution of lipids among cells of different organs.
a. Transport of dietary lipids from the intestine to the liver and 
peripheral tissues.
b. Transport of lipids from the liver to peripheral tissues.
c. Transport of lipids from peripheral tissues to the liver.
2. Redistribution of lipids among cells within an organ or tissue.
a. Macrophages or other cells capable of storing and releasing lipids 
to acceptors in the interstitial fluid (apoE-lipid complexes or HDL) 
play a key role in this redistribution.
3. Functions of apolipoprotein E unrelated to lipid transport.
a. ApoE produced by smooth muscle cells may be involved in 
modulating cell proliferation and differentiation.75
b. Regulation of hematopoietic stem cell proliferation.112
ApoE deficiency and atherosclerosis
ApoE deficiency causes severe hyperlipidemia and atherosclerosis in humans 
and in gene-targeted mice.113 Individuals deficient for apoE have type III 
hyperlipoproteinemia with elevated cholesterol but near normal triglyceride 
levels.95 Several groups created apoE-deficient mice by inactivating the apoE 
gene by targeting.114 ApoE-deficient mice have markedly increased total plasma 
cholesterol levels which are five times higher than those of normal littermates.95,114 
At 10 weeks of age, apoE-deficient mice have already developed spontaneous 
atherosclerotic lesions in the aorta and coronary and pulmonary arteries, 
demonstrating that a simple lack of apoE is sufficient to initiate atherogenesis.95
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Macrophage-derived apoE in atherogenesis
The anti-atherogenic role of macrophage apoE can be mainly attributed to its 
function in the removal of excess cholesterol from macrophage foam cells111 
as well as its anti-inflammatory,115 antiproliferative,116 and immunomodulatory 
properties.117,118 Macrophages isolated from the peritoneal cavity of mice and 
human blood monocytes produce large quantities of apoE.119–121 ApoE represents 
up to 8-10% of protein constitutively secreted from macrophages,122 and its 
synthesis and secretion can be highly induced via liver X receptor (LXR), upon 
loading of mouse peritoneal macrophages with cholesterol.119 LXR is a sterol-
responsive nuclear receptor that regulates the expression of genes involved 
in cholesterol metabolism and homeostasis, including apoE.123 In agreement, 
expression of macrophage apoE is transcriptionally modulated by cholesterol and 
cytokines.124,125 Interestingly, although the pathways stimulating apoE secretion 
and cholesterol efflux are disctinct,126,127 apoE, whether added to cells or during its 
secretion from cells, can itself mediate cholesterol efflux.
In the developing atherosclerotic lesion, macrophages are a significant source 
of apoE. Physiological concentrations of apoE in the arterial wall have been 
demonstrated to be atheroprotective,128 since it is able to modulate lipid and 
lipoprotein metabolism in arterial wall cells.129 At sites of atherosclerotic lesion 
development, apoE has predominantly been found on the surface of macrophages 
and in the matrix surrounding macrophages. ApoE expression in the vessel wall 
is important for modulating vessel wall cholesterol homeostasis.130–132 In fact, 
macrophage-specific expression of apoE in apoE-null mice protects against 
atherosclerotic lesion development even in the presence of high levels of 
circulating atherogenic lipoproteins.113 Macrophage-derived apoE has thus been 
shown to be anti-atherogenic and anti-inflammatory in several ways. Yet, both 
pro- and anti-atherogenic functions for macrophage apoE in atherosclerosis have 
been described.133–136
We133 and others136 have shown that mice transplanted with apoE KO bone 
marrow developed 4- to 10-fold larger atherosclerotic lesions as compared to WT 
transplanted animals. In contrast, a significant decrease in lesion development is 
also described.134,135
Chapters 3 and 4 contain more detailed information about the role of macrophage 
apoE in atherosclerosis.
Adipose triglyceride lipase (ATGL)
Triglyceride stores are the most important energy reserve in vertebrates. 
Dysfunctional lipolysis affects energy homeostasis and may contribute to the 
pathogenesis of diseases like obesity and insulin resistance. Upon fasting, TG in fat 
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are hydrolyzed to sustain energy levels within the body. Hydrolysis of TG leading 
to the release of FFA requires the enzymatic activity of lipases. The first step in TG 
hydrolysis, resulting in the generation of diacylglycerols (DG) and FFA is facilitated 
by adipose triglyceride lipase (ATGL).137,138 ATGL is mainly expressed in adipose 
tissue. Mutations in the gene for ATGL lead to neutral lipid storage disease (NLSD) 
in humans. NLSD is a rare, autosomal genetic disorder characterized by excessive 
accumulation of TG in all tissues of the body.139,140 Similarly, mice deficient for 
ATGL suffer from massive TG accumulation in organs and tissues including the 
heart, resulting in cardiac dysfunction and subsequent premature death.138 The 
hydrolyzed TG by ATGL can be further hydrolyzed to monoglycerides (MG) by 
hormone-sensitive lipase (HSL).141 The final conversion of a monoglyceride into 
FFA and glycerol is facilitated by monoglyceride lipase (MGL).142
Structure, expression and regulation
The murine ATGL gene is approximately 6kb in length, contains 9 exons, and is 
found on chromosome 7. The 2kb mRNA codes for a 486-amino-acid protein with 
a molecular mass of 54 kDa, whereas the human gene encodes a 504-amino-acid 
protein that shares 86% homology with the murine protein.137 Surprisingly, ATGL 
and classical lipases like LPL, HL, and endothelial lipase (EL) have no clear sequence 
similarity and differ with regard to catalytic mechanisms,143 since the N-terminal 
region of the ATGL gene contains a “patatin” domain. These proteins have been 
shown to have acyl-hydrolase activity on phospholipid, monoacylglycerol and 
diacylglycerols substrates.144
In mice and humans, ATGL is predominantly expressed in white and brown adipose 
tissue. In addition, progressively decreasing amounts of ATGL are found in the 
testis, cardiac muscle, and skeletal muscle.137,145–147 ATGL expression is highly 
increased during adipocyte differentiation,148 reaching maximal levels when the 
cells accumulate visible lipid droplets.137,149,150 Interestingly, ATGL is also expressed 
in macrophages and macrophage foam cells in atherosclerotic lesions.151 
ATGL mRNA content is strongly controlled by nutritional factors, being increased 
during fasting and decreased by re-feeding in adipose tissue145,147 and liver.146 
Insulin appears to be a potent regulator of ATGL, since it dose-dependently inhibits 
ATGL transcription in vitro, and enhances ATGL mRNA expression in murine models 
of insulin deficiency and insulin resistance.145,152,153
Unlike HSL, relatively little is known about the molecular pathways leading to the 
activation of ATGL activity. ATGL has been shown to reside in the cytoplasm and 
on lipid droplets (LD) in the basal state,137,154 and protein kinase A (PKA) activation 
only elicits minor translocation of ATGL to LD.154 In addition to possible regulation 
of activity by phosphorylation, ATGL activity is highly dependent on several 
biochemical events for efficient lipolysis. First by association with an activating 




Besides its important role in adipocytes, ATGL also has hydrolytic capacities 
regarding macrophage TG stores. Chandak et al. demonstrated that macrophages 
lacking ATGL fail to efficiently hydrolyze macrophage TG stores, which led to 
decreased cellular FFA concentrations and concomitant accumulation of lipid 
droplets.151 As a consequence, cellular ATP concentrations decreased. Importantly, 
both macrophage RCT (largely mediated via ABCA1 and ABCG1), as well as its 
phagocytosis capacities are ATP driven. Indeed, phagocytosis was shown to 
be decreased in vivo when ATGL deficient mice were challenged with bacterial 
particles.151 In addition, macrophages lacking ATGL were shown to favor an anti-
inflammatory M2-like phenotype,159 implying a possible role for macrophage ATGL 
in inflammation and atherosclerosis.
ATGL deficiency and atherosclerosis
ATGL deficiency in both mice and humans leads to massive TG accumulation 
in organs. However, not much is known about the specific role of ATGL in 
atherosclerosis. This is primarily the result of the fact that mice lacking ATGL 
die prematurely (50% dies at 16-20 weeks) from cardiac dysfunction.138 With 
such an acute phenotype, ATGL deficient mice are unable to develop sufficient 
atherosclerosis. However, to investigate the importance of macrophage-produced 
ATGL in the pathogenesis of atherosclerosis, the bone marrow transplantation 
technique can be used.
Bone marrow transplantation (BMT)
Monocyte-derived macrophages play a significant role in the pathogenesis of 
atherosclerosis. Through the expression of proteins such as apoE and several 
of the receptors involved in lipoprotein uptake including the LDLr, macrophages 
can impact the growth of the atherosclerotic plaque both by affecting systemic 
lipoprotein metabolism and locally by mediating cholesterol accumulation.160
Gene targeting studies in mice provide a powerful approach to examine the 
contribution of a given gene to atherogenesis. A number of the genes of interest 
in lipoprotein metabolism and atherosclerosis are expressed both by the liver and 
by macrophages. The expression of a gene by the liver may have different effects 
on the process of atherosclerosis as compared to its expression by macrophages. 
Bone marrow transplantation experiments using knock-out or knock-in mice have 
proven to be a useful approach to dissect out the contribution of macrophage gene 
expression to atherogenesis in vivo.161
The transport, repair, and defense functions of peripheral blood cells are well 
known. Their diversity in function is reflected by an extreme variation in shape 
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and size. Common to the different blood cells is a relatively short life-span: an 
average human produces daily about 1011 new blood cells. This process, termed 
hematopoiesis, is maintained from a small population of bone marrow stem cells.162
Transplantation of the hematopoietic system offers a unique opportunity to replace 
genes in cells from hematopoietic origin, including macrophages. In humans, bone 
marrow, mobilized peripheral blood stem cells, or cord blood can be used as stem 
cell source for transplantation. In mice, fetal liver cells163 and bone marrow164 are 
generally used as donor sources for transplantation of the hematopoietic system. 
In both cases, transplantation of the hematopoietic system will result in a gradual 
replacement of the cells of the recipient by cells from donor origin, including 
monocytes and tissue macrophages.165
The bone marrow transplantation procedure involves four different stages: 
- conditioning of the recipient
- isolation of the donor bone marrow
- transplantation of the donor bone marrow cells into the recipient
- repopulation of the recipients bone marrow by the donor cells
The primary purpose of conditioning of the recipient prior to infusion of donor bone 
marrow is to create space for the donor cells in the bone marrow by eradication 
of the endogenous bone marrow cells of the recipient and immunosuppression 
to prevent immunological reactions. The most active single conditioning agent 
in mammals to eradicate endogenous bone marrow is total body irradiation 
(TBI). The recovery time after lethal irradiation and bone marrow transplantation 
is 4-8 weeks.166–168 Without donor bone marrow cell transplantation after lethal 
total body irradiation, the recipient will eventually die within two weeks as 
peripheral hematopoietic cells die in the two weeks following TBI. In the second 
week after irradiation (without transplantation) depletion of thrombocytes and 
leukocytes causes haemorrhages and septicaemia, leading to the death of the 
animal. Recovery of the hematopoietic cells in the irradiated recipient can be 
obtained by bone marrow cell infusion. Bone marrow is isolated by either bone 
marrow puncture in large animals or flushing femurs and tibias with saline in small 
animals, including mice. Repopulation of the bone marrow starts at four days after 
administration.169–171
Following successful bone marrow transplantation, the bone marrow cell population 
is generally completely restored at the seventh day after the transplantation. 
The peripheral blood cell count is returned to normal values at 8 weeks after 
transplantation.54 Finally, a stable hematopoietic system is formed in which 
hematopoiesis is derived from small numbers of hematopoietic pluripotent stem 
cells of donor origin.172 This bone marrow transplantation technique provides a 
unique opportunity to create an animal model in which the effect of certain genes 
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in cells of hematopoietic origin, including macrophages, can be studied against a 
specified, for example hyperlipidemic or atherosclerotic, background.
Animal models in atherosclerosis
Atherosclerosis is a complex, multifactorial, chronic inflammatory disease. The 
environmental and genetic factors make it particularly difficult to study the function 
of specific genes on the pathogenesis of atherosclerosis in man. To overcome 
this, suitable animal models, which possess an identical genetic background and 
can be kept in controlled environmental conditions, are widely used to study the 
mechanisms affecting atherosclerotic lesion development.173 An animal model 
frequently used to study lipoprotein metabolism and atherogenesis is the mouse. 
With the development of genetic models of atherosclerosis, the mouse has become 
a very accessible model, especially since a very large genetic database about this 
species in relation to human biology has become available.174 However, mouse 
lipoprotein metabolism differs from that in humans in several respects, thereby 
influencing the development of atherosclerosis.
The predominant lipoprotein in mice is HDL, whereas LDL is particularly abundant 
in humans.175,176 Moreover, mice do not express CETP, which transfers CE from 
HDL to LDL and VLDL. Notably, compared to humans, mice are highly resistant to 
atherosclerosis (Table 2). Feeding mice a high cholesterol cholic acid containing 
diet, however, results in dramatic changes in their lipoprotein profiles, with the 
majority of cholesterol now in VLDL and LDL.177,178 Consequently, feeding this 
diet for several months will result in fatty streak formation in the C57BL/6J 
mouse strain.179 In addition to feeding high cholesterol diets, transgenesis and 
gene targeting are frequently used methods to alter the murine genome in order 
to study the function of specific genes regarding lipoprotein metabolism and 
atherogenesis.180–182 To overcome the natural lack of atherosclerosis susceptibility 
in mice, several mouse strains were developed with genetic alterations, resulting 
in increased susceptibility to atherosclerotic lesion development.
The LDLr KO mouse model is among the most widely used models for characterization 
of atherosclerotic lesion development. Due to the absence of LDL receptors, VLDL 
and LDL removal from the circulation is impaired,183 which subsequently results in 
Parameter Human Mouse
HDL 50 mg/dL 50 mg/dL
LDL 150 mg/dL 10 mg/dL
CETP Present Absent
Atherosclerosis Susceptible Resistant
Table 2. Differences in lipid metabolism and atherosclerosis between humans and mice.
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elevated serum cholesterol levels. Upon feeding a high-cholesterol diet, LDLr KO 
mice show strongly elevated serum cholesterol levels and thus rapid development 
of atherosclerosis.184
Another model to study atherosclerotic lesion development is the earlier mentioned 
apoE KO mouse model. Absence of apoE results in severe hypercholesterolemia. 
As a result, apoE KO mice spontaneously develop atherosclerosis, which can be 
strongly accelerated by a high-cholesterol diet.185 Although murine atherosclerotic 
plaques resemble human plaques in several manners, they are not prone to 
rupture. As a result, atherosclerotic mouse models do not usually develop MI due 
to advanced atherosclerotic lesion development. Therefore, in order to study the 
consequences of MI, specific animal models need to be used. The predominant 
models of MI/ischemia are the Langendorff perfusion system (ex vivo; isolated 
heart),186–189 and left anterior descending (LAD) occlusion (in vivo; Fig 4).190,191
In 1895, Langendorff for the first time described a method for perfusion of an 
isolated heart.192 The modernized Langendorff setup is an ex vivo model used to 
study cardiac physiology, acute global or regional ischemia reperfusion, or the 
efficacy of drug or cell therapy on the heart.187 The aorta is cannulated above 
the aortic valves, and perfused with a physiologic Krebs and Henseleit solution, 









Figure 4. Myocardial infarction. See text for explanation. LAD, left anterior descending coronary artery.
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arteries are filled with the perfusion fluid and the aortic valve is closed by the 
perfusion pressure. The venous effluent can then easily be collected via openings 
of the caval veins or the pulmonary artery. Global ischemia is caused by clamping 
the aortic flow, whereas regional ischemia can be induced by ligation of a coronary 
artery.
Unlike the Langendorff model, which studies the heart outside the systemic 
influences from the body, the LAD occlusion model provides insight into the 
systemic influences on the heart after MI.190,191 Occlusion of the LAD is generally 
performed through a left thoracotomy. After exposing the LAD, a suture is used to 
either temporarily occlude or permanently ligate the LAD or a branch of the LAD.186 
The use of an LAD occlusion model is most suitable for investigating the effects of 
MI over time, as these mice can be followed for several weeks after intervention 
without complicating factors such as anesthesia or artificial ventilation.
Thesis outline
In this thesis, the roles of several key genes in relation to reverse cholesterol 
transport and cardiovascular disease are described. Chapter 2 provides a 
comprehensive review of the importance of ABCA1 and ABCG1 in HDL metabolism, 
macrophage cholesterol efflux, and atherogenesis. Chapter 3 focuses on the 
combined deletion of macrophage ABCA1 and apoE in atherosclerosis susceptible 
LDLr KO mice. ABCA1/apoE dKO transplanted mice were shown to have elevated 
serum cholesterol levels as compared to single ABCA1 KO transplanted mice. 
Importantly, these dKO transplanted mice also suffered from enhanced systemic 
and hepatic inflammation. Together with an observed defect in cholesterol efflux, 
this led to augmented atherosclerotic lesion development. Chapter 4 delineates 
the combined effect of macrophage ABCG1 and apoE has been studied by means 
of bone marrow transplantation. Whereas single deletion of macrophage ABCG1 
or apoE led to a moderate increase in atherosclerotic lesion development, 
combined deletion induced a more dramatic increase in atherosclerosis. Moreover, 
gene- and protein expression data revealed independent roles for both genes in 
atherogenesis. Since differential effects of (macrophage) ABCG1 deficiency were 
observed in different laboratories, in chapter 5, the effect of ABCG1 deficiency 
in LDLr KO mice has been studied at different stages of atherosclerotic lesion 
development. In chapter 6, the role of macrophage ATGL with respect to 
atherosclerotic lesion development has been investigated. Despite the observed 
TG accumulation in ATGL deficient macrophages, LDLr KO mice transplanted with 
ATGL KO bone marrow showed attenuated atherosclerotic lesion formation as 
compared to controls. Decreased infiltration of less inflammatory macrophages 
into the arterial wall, and increased macrophage apoptosis most likely caused this 
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effect. In chapter 7, the importance of macrophage ABCA1 in atherosclerosis in 
the absence or presence of the spleen has been investigated. Although splenic 
alterations were observed upon macrophage ABCA1 deficiency, this had no 
effects on atherosclerotic lesion development. Chapter 8 describes the role of 
ABCA1 in case of acute myocardial infarction. ABCA1 deficiency was shown to 
attenuate cardiac ischemia after a myocardial infarction, despite its protective role 
in atherosclerosis. The presence of ABCA1 in isolated hearts did not contribute to 
the observed effects, indicating that the reduced myocardial infarction has been 
caused by secondary, ABCA1-mediated effects. In chapter 9, the results obtained 
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Abstract
Atherosclerosis has been characterized as a chronic inflammatory 
response to cholesterol deposition in arteries. Plasma high density 
lipoprotein (HDL) levels bear a strong independent inverse relationship 
with atherosclerotic cardiovascular disease. One central antiatherogenic 
role of HDL is believed to be its ability to remove excessive peripheral 
cholesterol back to the liver for subsequent catabolism and excretion, 
a physiologic process termed reverse cholesterol transport (RCT). 
Cholesterol efflux from macrophage foam cells, the initial step of RCT is 
the most relevant step with respect to atherosclerosis. The ATP-binding 
cassette (ABC) transporters ABCA1 and ABCG1 play crucial roles in the 
efflux of cellular cholesterol to HDL and its apolipoproteins. Moreover, 
ABCA1 and ABCG1 affect cellular inflammatory cytokine secretion by 
modulating cholesterol content in the plasma membrane and within 
intracellular compartments. In humans, ABCA1 mutations can cause a 
severe HDL-deficiency syndrome characterized by cholesterol deposition 
in tissue macrophages and prevalent atherosclerosis. Disrupting ABCA1 
or ABCG1 in mice promotes accumulation of excessive cholesterol in 
macrophages, and physiological manipulation of ABCA1 expression 
affects atherogenesis. 
Here we review recent advances in the role of ABCA1 and ABCG1 in 
HDL metabolism, macrophage cholesterol efflux, inflammation, and 
atherogenesis. Next, we summarize the structure, expression, and 
regulation of ABCA1 and ABCG1. Finally, we give an update on the 
progress and pitfalls of therapeutic approaches that target ABCA1 and 
ABCG1 to stimulate the flux of lipids through the RCT pathway.
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Introduction
Plasma levels of high density lipoprotein (HDL) are inversely proportional to 
the risk of atherosclerotic cardiovascular disease (CVD) in humans.1 The key 
mechanism underlying the atheroprotective properties of HDL is thought to be 
its role in reverse cholesterol transport (RCT), a physiologic process by which 
excess peripheral cholesterol is transported by HDL to the liver for excretion in the 
bile and feces.2 In addition, HDL can prevent oxidation of low density lipoprotein 
(LDL),3 act as an anticoagulant,4 and have anti-inflammatory properties,5 all of 
which may contribute to the antiatherogenic effects of HDL. This presumption 
leads to an assertion that raising HDL cholesterol (HDL-C) levels alone would 
improve RCT and protect against the development of atherosclerosis. However, 
high HDL-C concentration appears not to be always synonymous with an efficient 
RCT. Therefore, improving the HDL functionality may be more attractive to 
potentially stimulate RCT. The initial step of RCT is thought to be dependent upon 
extracellular lipid acceptors, including HDL and/or lipid-poor apolipoproteins. 
Studies have indicated that the ATP-binding cassette (ABC) transporter ABCA1 is 
required for the maintenance of normal plasma HDL-C levels, and is important for 
the first step of RCT, i.e., transfer of cholesterol to lipid-poor HDL apolipoproteins 
(e.g., apoA-I).6 ABCG1 is also of interest, since it participates in an intermediate 
RCT step, i.e. transfer of cholesterol to mature HDL particles (e.g., HDL2 and 
HDL3).
7 Moreover, ABCA1 and ABCG1 export lipids to either cell surface-bound or 
internalized apolipoproteins.8,9 Minor changes in cholesterol content in the plasma 
membrane or within intracellular vesicular compartments can significantly impact 
cell function via influencing cellular signaling events.10,11 Thus, the traditional role 
of ABCA1 and ABCG1 in lipid transport is mechanistically linked to their potential 
role in suppressing inflammation.
Here we review recent advances in the role of ABCA1 and ABCG1 in HDL 
metabolism, macrophage cholesterol efflux, inflammation, and atherogenesis. 
Next, we summarize the structure, expression, and regulation of ABCA1 and 
ABCG1. Finally, we attempt to integrate this information and discuss the progress 
and pitfalls of therapeutic approaches that target ABCA1 and ABCG1 to stimulate 
the flux of lipids through the RCT pathway.
ABCA1 and ABCG1 in HDL metabolism and 
consequences for atherosclerosis
ABCA1, HDL, and atherosclerosis
ABCA1, first known as ABC1, was cloned in 1994 by Luciani and colleagues,12 
as a homolog of yeast ced-7, and is a member of the large superfamily of ABC 
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transporters that use ATP as an energy source to transport lipids and other 
molecules across membranes.13 Understanding of the role of ABCA1 in HDL 
biogenesis came with the discovery that mutations in the ABCA1 gene result in the 
extreme HDL deficiency syndrome Tangier disease (TD). In 1999, the mutation 
in TD was mapped to chromosome 9q31 in the ABCA1 gene.14-17 Since then, an 
enormous amount of research has been set off to investigate the mechanism of 
action, regulation, and suitability of ABCA1 as a target to increase HDL formation 
therapeutically for the treatment and prevention of atherosclerosis.
The defective cholesterol and phospholipid efflux to apoA-I from fibroblasts 
derived from TD patients suggested that the removal of cellular lipids to apoA-I is 
a major predictor of plasma HDL-C levels.18,19 Although the structure and synthetic 
rates of apoA-I are normal in TD, the hypercatabolism of circulating apoA-I 
may result in the severe HDL deficiency syndrome in this disease.20 As a result, 
homozygous TD is associated with extremely low levels of apoA-I (<1% normal) 
and HDL-C (<5% normal). In accord, several recent genome-wide association 
studies have identified common variants in ABCA1 as a significant source of 
variation in plasma HDL-C levels across multiple ethnic groups,21-23 establishing 
ABCA1 as a major gene influencing HDL levels in humans. However, the impact 
of ABCA1 on atherosclerosis remains controversial. An early systematic survey 
of TD patients indicated homozygotes over the age of 30 display a 6-fold higher 
incidence of CVD than normolipidemic control subjects.24 Of note, the increased 
risk of atherosclerosis in TD patients does not appear to be as dramatic as one 
would expect in individuals with an almost complete absence of HDL. One possible 
explanation is that TD homozygotes in addition to having low HDL-C also have 
reduced levels of VLDL and LDL cholesterol (VLDL-C and LDL-C), and thus the 
atherogenic stimulus may be diminished. Comparison of the phenotypes of TD 
homozygotes with heterozygotes who have decreased HDL-C (≈40% normal) 
but normal VLDL-C or LDL-C levels confirmed that ABCA1 is a rate-limiting factor 
in HDL biosynthesis, while one functional ABCA1 allele is sufficient to maintain 
normal LDL levels. Moreover, heterozygotes do not display the excessive 
accumulation of lipid-laden tissue macrophages as observed in homozygotes,25 
implying that one functional ABCA1 allele is sufficient to prevent excessive 
cholesterol accumulation in macrophages. Interestingly, heterozygotes also 
showed significant increases in CVD incidence and carotid artery intima media 
thickness as compared to healthy controls.26 One study of the Copenhagen City 
Heart cohort revealed that genetic variations in ABCA1 affect CVD in the general 
population.27 However, a follow up study of the same cohort concluded that low 
HDL caused by loss-of-function mutations in ABCA1 does not contribute to the risk 
of CVD.28 It was also reported that both common and rare ABCA1 variations are 
associated with increased CVD despite normal HDL levels.27,29,30 Collectively, these 
studies support the idea that impaired ABCA1 function increases atherosclerosis 
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in humans, although not in all cases by mechanisms that reflect reduced plasma 
HDL-C levels. 
Studies in mice where the ABCA1 locus is deleted or human ABCA1 is 
overexpressed generally support the hypothesis that ABCA1 by maintaining 
circulating HDL-C levels and cellular cholesterol efflux significantly prevents 
atherosclerosis. Total-body ABCA1-deficient (ABCA1 KO) mice exhibit low 
plasma HDL-C levels and cholesterol accumulation in peripheral macrophages, a 
phenotype similar to that of TD patients.31 However, atherosclerotic lesions were 
not increased when ABCA1 KO mice were fed chow or a high-fat, high-cholesterol 
(HF/HC) diet.31 Upon cross-breeding of ABCA1 KO mice with hypercholesterolemic 
mouse models (apoE KO or LDLr KO mice), the accumulation of lipid-laden foam 
cells in peripheral tissues was especially pronounced.32 However, compared with 
the control mice, lesion size was not increased in either ABCA1 KO apoE KO or 
ABCA1 KO LDLr KO double knockout mice, which is probably caused by a less 



























































Figure 1. Schematic overview of the role of ABCA1 and ABCG1 in the reverse cholesterol transport (RCT). 
ApoA-I is secreted by liver and intestine and loaded with cholesterol (C) and phospholipids by ABCA1. The 
thus formed preβ-HDL picks up cholesterol and phospholipids from ABCA1 in macrophages and peripheral 
cells and is converted to α-HDL. These mature HDL particles can be further loaded with cholesterol at 
least in part by ABCG1 in macrophages and delivers in turn its cargo to SR-BI in the liver. Subsequently, 
cholesterol can be secreted into the bile either in the free form or after conversion as bile salt (BS). After 
transport via the bile into the intestine, cholesterol and bile salts are reabsorbed or excreted in the feces.
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knockout or knockdown of the ABCA1 locus to assess the respective role of liver, 
intestine, and macrophage ABCA1 in HDL metabolism and atherogenesis. Liver-
specific ABCA1 KO mice have a ≈80% reduction in HDL-C levels,33 and liver-
specific partial gene knockdown of ABCA1 significantly reduced HDL-C levels by 
≈40%.34 Subsequent studies reported that intestine-specific ABCA1 KO mice 
have a ≈30% reduction in HDL-C levels.35 Thus, the liver and intestine that 
synthesize apoA-I,36,37 are primarily responsible for lipidating newly secreted 
lipid-poor apoA-I via ABCA1-mediated lipid efflux. More recently, Brunham et al. 
elegantly showed the tissue-specific role of ABCA1 in influencing susceptibility 
to atherosclerosis.38 Their results indicated that physiologically global ABCA1 
overexpression reduced atherosclerosis. Deletion of hepatic ABCA1 significantly 
accelerated atherosclerosis, indicating that the liver is an important site at 
which ABCA1 plays an antiatherogenic role. Surprisingly, selective deletion of 
macrophage was not found to have a strong impact on lesion burden. Moreover, 
previous studies have shown that, independently of changes in plasma HDL-C 
levels, deletion of ABCA1 in bone marrow-derived hematopoietic cells increases 
atherosclerosis,32,39 whereas overexpression of bone marrow ABCA1 reduces 
atherosclerosis.40 Whether ABCA1 expression in other hematopoietic cells 
(e.g., dendritic cells, lymphocytes, and endothelial progenitor cells) prevents 
atherosclerosis via modulating immunologic responses, including the secretion of 
inflammatory cytokines and T cell proliferation, remains to be further investigated.
Together, these studies demonstrate that ABCA1 is a rate-limiting factor in HDL 
biosynthesis. In liver and intestine ABCA1 is essential for maintaining plasma 
HDL-C levels, while macrophage ABCA1 only has a minor effect on circulating 
HDL but is important as a mediator of cellular lipid efflux to exogenous lipid-
poor HDL apolipoproteins (Fig. 1). Physiological deletion or expression of ABCA1 
modulates susceptibility to atherosclerosis in mice, and hepatic ABCA1 may be an 
appropriate therapeutic target for raising HDL levels and reducing atherosclerosis 
in humans. 
ABCG1, HDL, and atherosclerosis
ABCG1, also known as ABC8 or human white gene, exhibits high homology with 
the Drosophila white gene, which acts as a regulator of tryptophan and guanine 
uptake in conjunction with the scarlet and brown genes.41,42 To date, no genetic 
variations in human ABCG1 have been identified that link it to any inheritable 
disease. Nevertheless, Mauldin et al. reported that ABCG1 expression and 
function are significantly reduced in patients with type 2 diabetes mellitus, 
potentially contributing to the formation of lipid-laden macrophages and 
accelerated atherosclerosis in these patients.43 Schou et al. demonstrated 
that a functional variant in the ABCG1 promoter, ABCG1 -376C>T located in 
a putative SP1 binding site, reproducibly predicts an increased incidence of 
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ischemic heart disease in the general population.44 In addition, Furuyama et al. 
reported that another ABCG1 -257T>G promoter polymorphism confers an 
appreciable increase in the risk of atherosclerotic disease severity in Japanese 
men.45 In the latter two studies, plasma HDL-C levels are relatively normal in 
subjects with ABCG1 mutations.44,45 However, Furuyama et al. suggested that 
ABCG1 may influence the lipid composition in HDL particles, affect the turnover 
of HDL metabolism and atherogenesis in humans.45 In an attempt to determine 
the function for human ABCG1, Klucken et al. treated human macrophages with 
antisense oligonucleotides to ABCG1, and this treatment resulted in decreased 
efflux of cholesterol and phospholipids to HDL3.
7 However, the exact cellular and 
physiological function of ABCG1 remained unclear.
Studies evaluating the physiological relevance of ABCG1 transport activity have 
relied mainly on mouse models where the endogenous ABCG1 locus is deleted 
or human ABCG1 is overexpressed. Kennedy et al. first reported that ABCG1 
KO animals did not display an overt dyslipidemia when maintained on a chow 
diet.46 However, these null animals accumulated massive both neutral lipids and 
phospholipids in hepatocytes and in macrophages within multiple tissues following 
administration of a HF/HC diet. Conversely, overexpression of human ABCG1 
protected murine tissues from dietary fat-induced lipid accumulation. Despite 
these observations, when administered a HF/HC diet, loss of total body ABCG1 
transport did not significantly accelerate atherosclerosis, and loss of macrophage 
ABCG1 in atherosclerotic mouse models (apoE KO or LDLr KO mice) has been 
variously reported to be either pro- or antiatherosclerotic.47-50 Moreover, total body 
human ABCG1 overexpression resulted in either no effect,51 or aggravation,52 of 
atherosclerosis. These results indicate that manipulating ABCG1 alone does not 
markedly impact atherosclerosis in mice.
ABCA1 converts lipid-poor/free apoA-I to partially lipidated “nascent” HDL, and 
these particles in turn may serve as substrates for ABCG1-mediated cholesterol 
export.53 This raises the interesting possibility that ABCA1 and ABCG1 may 
coordinate the removal of excessive cellular cholesterol. Recently, ABCA1 and 
ABCG1 double knockout (ABCA1/ABCG1 dKO) mice were generated by several 
independent groups to investigate the potential synergistic relationship between 
ABCA1 and ABCG1 in modulating macrophage cholesterol homeostasis and 
atherogenesis. Out et al. reported that combined ABCA1 and ABCG1 deficiency 
resulted in a completely abolished cholesterol mass efflux from macrophages to 
HDL.54 Similar studies by Yvan-Charvet et al. showed that ABCA1/ABCG1 dKO 
macrophages displayed a more than 2-fold decrease in the ability to promote 
cholesterol efflux to HDL or serum as compared to ABCA1 KO, ABCG1 KO and 
wild-type macrophages.55 In vivo studies using a macrophage-specific RCT assay 
also indicated that cholesterol efflux from ABCA1/ABCG1 dKO macrophages to 
plasma, liver, and feces was highly reduced as compared to animals that received 
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macrophages from single knockout or wild-type mice.56 Defective cholesterol 
efflux due to the combined deficiency of ABCA1 and ABCG1 was associated with 
markedly increased cholesterol content, primarily in the form of cholesteryl ester 
(CE), in resident macrophages of the peritoneal cavity, lung, liver, spleen, Peyer’s 
patches, and lymph nodes in chow-fed ABCA1/ABCG1 dKO mice.54 However, these 
mice did not show lipid accumulation in the arterial wall. This is most likely caused 
by the severe hypocholesterolemia in these mice, which is unable to provide the 
stimulus to attract macrophages to infiltrate into the arterial wall. Furthermore, 
Yvan-Charvet et al. showed that LDLr heterozygous mice receiving ABCA1/
ABCG1 dKO transplants had substantially greater atherosclerosis as compared 
to recipients receiving single knockout or wild-type bone marrow, following 
administration of a HF/HC bile salt diet (1.25% cholesterol, 7.5% cocoa butter 
and 0.5% cholic acid).55 Out et al. reported that reconstitution of LDLr KO mice 
with ABCA1/ABCG1 dKO bone marrow cells resulted in a prominent accumulation 
of lipids in the liver, lung and spleen as compared to recipients receiving single 
knockout or wild-type bone marrow, following a Western-type diet (0.15% 
cholesterol and 15% fat).57 However, in the context of LDLr KO recipients, loss of 
ABCG1 did not significantly worsen atherosclerosis beyond that caused by the loss 
of only ABCA1, which is possibly reflecting an unexpected decreased in plasma 
VLDL/LDL levels in the ABCA1/ABCG1 dKO transplanted mice. The study of Out et 
al. was interpreted as showing a disproportionate increase in atherosclerosis given 
the degree of VLDL/LDL lowering.
Taken together, these studies indicate that ABCG1 plays a critical role in 
lipid homeostasis by controlling tissue lipid levels and the efflux of cellular 
cholesterol to HDL (Fig. 1). Unlike ABCA1, ABCG1 does not have a rate-limiting 
role in maintaining plasma HDL-C levels. Likewise, loss of ABCG1 alone does 
not markedly accelerate atherosclerosis. In spite of having a varied effect on 
atherosclerosis, ABCG1 in concert with ABCA1 does make a major contribution to 
cellular cholesterol export and prevent macrophage foam cell formation. 
ABCA1 and ABCG1 in inflammation, independent of 
changes in circulating HDL levels
Atherosclerosis is a chronic inflammatory disease in which macrophages and 
endothelial cells (EC) play important roles. Macrophages are a primary cell 
type involved in innate immunity. Lipopolysaccharide (LPS), a major outer 
membrane constituent of Gram-negative bacteria, is a potent endotoxin that, 
through the activation of cellular immunity, induces a cytokine-mediated 
systemic inflammatory response in the host.58,59 A series of studies have 
shown that deficiency of ABCA1 and/or ABCG1 in macrophages leads to LPS 
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hypersensitivity,55,60,68,78 implying a potential role of these two transporters in 
suppressing macrophage inflammation. In addition to macrophages, aortic EC 
also express ABCA1 and ABCG1 and export cholesterol to HDL.61 EC in the artery 
wall become activated in many cases by oxidized lipids in early atherogenesis.62 
Activated EC secrete pro-inflammatory chemokines that recruit monocytes to the 
activated endothelium.63 Several studies have shown that incubation of EC with 
HDL reduces the endothelial inflammatory response.64-66 It is thus possible that 
ABCA1 and ABCG1 modulate inflammatory responses in vascular EC at least in 
part by facilitating cholesterol efflux to HDL in these cells.
Anti-inflammatory properties of ABCA1 
Francone et al. reported that LPS-induced septic shock was exacerbated in 
ABCA1/LDLr KO mice compared with LDLr KO mice,59 suggesting a potential 
role of ABCA1 in suppressing inflammation. Subsequent studies by Aiello et al. 
showed that macrophages from ABCA1 KO/LDLr KO mice were enriched in CE 
content (80-fold higher), and plasma HDL concentrations in these mice were 
extremely low.67 However, it is not clear whether the observed heightened 
response to LPS in macrophages from ABCA1 KO/LDLr KO mice is due to the 
massive cellular CE accumulation, the low plasma HDL-C levels, or some other 
alterations. Recently, macrophage-specific ABCA1 KO mice were generated 
by Zhu et al.,68 and it was demonstrated that macrophages lacking ABCA1 are 
hypersensitive to LPS stimulation, independently of low plasma HDL-C levels, 
requiring the expression of MyD88 which is an adaptor protein that mediates LPS 
signaling initiated by the Toll-like receptor 4 (TLR4). Koseki et al. showed that 
cultured ABCA1 KO macrophages secreted greater amounts of pro-inflammatory 
tumor necrosis factor-α (TNF-α) in response to LPS, and that this response was 
associated with increased levels of free cholesterol (FC) in lipid rafts on the cell 
surface.69 These data support the concept that ABCA1 modulates cell surface 
cholesterol levels and inhibits its partitioning into lipid rafts, which may explain 
the hypersensitivity to LPS in ABCA1 KO macrophages. Moreover, Sun et al. 
reported that FC accumulation in the endosomal compartment increased the 
inflammatory response in a TLR-dependent fashion, with TLR3 playing the major 
role.70 Combined, it is plausible that the anti-inflammatory properties of ABCA1 
are mediated by its ability to modulate cholesterol content both on the cell surface 
and within intracellular compartments (Fig. 2).  
However, recent work by Tang et al. suggested that not all of the anti-
inflammatory properties of ABCA1 are a consequence of its lipid transport 
activity.71 It was reported that the interaction of apoA-I and its mimetic peptides 
with ABCA1 promotes cholesterol removal and activates signaling molecules, such 
as Janus kinase 2 (JAK2), which optimize the lipid export activity of ABCA1.72,73 
JAK2 activation, however, also stimulates signaling pathways that activate 
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transcription factors called STATs.74 One of the STATs, STAT3, plays a major 
role in suppressing inflammatory cytokine production by macrophages.74,75 As 
a result, incubation of apoA-I with activated ABCA1-expressing macrophages 
































Figure 2. Protective effects of ABCA1 and ABCG1 on macrophage cholesterol efflux and inflammation. 
The ABC transporters ABCA1 and ABCG1 coordinate to facilitate macrophage cholesterol efflux to HDL 
and its apolipoproteins. ABCA1 transports phospholipids (PL) and cholesterol, while ABCG1 is largely a 
cholesterol transporter. Cholesterol efflux to apoA-I specifically requires ABCA1, whereas efflux to HDL 
requires ABCG1. Unlike ABCA1, ABCG1 has a specific role in promoting cellular efflux of oxysterols 
modified at the 7 position, such as 7-ketocholesterol- and 7β-hydroxycholesterol. Activation of LXR by 
oxysterols robustly induces the transcriptional expression of ABCA1 and ABCG1 in macrophages, leading 
to enhanced cholesterol efflux and resolution of the cholesterol overload in these cells. ABCA1 and ABCG1 
modulate the fluidity of the plasma membrane as well lipid raft formation. This, in turn, modulates the 
Toll-like receptor 4 (TLR4) expression and signaling upon activation via the LPS/MD-2 complex formed 
after binding of LPS to CD14. Subsequently, downstream signaling molecules such as Myd88 will control 
the activation of NF-κB and the inflammatory gene expression response. Activation of LXR can also 
modulate the inflammatory response through suppression of NF-κB, but this mechanism appears to 
be independent of ABCA1 or ABCG1 activity. Free cholesterol (FC) accumulation in the late endosome/
lysosome can also modulate the inflammatory response by spontaneous activation of TLRs, such as TRIF-
dependent TLR3, present in these intracellular compartments. By promoting cholesterol efflux from the 
late endosomal compartment, ABCA1 thus has a unique role in dampening inflammation. In addition, 
binding of apoA-I to ABCA1 stimulates the activation of signaling molecules, such as Janus kinase 
2 (JAK2). The activated JAK2 both enhances the interaction of apoA-I with ABCA1 and stimulates the 
transcription factor STAT3. The phosphorylated STAT3 is translocated to the nucleus where it suppresses 
LPS-mediated production of inflammatory cytokines, without inhibiting LPS-induced NF-κB activation.
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a STAT3-dependent process.75 This novel role of ABCA1 was further confirmed 
by results showing that apoA-I lost its anti-inflammatory activity in ABCA1 KO 
macrophages.75 The generation of mutant forms of ABCA1 that lack the ability to 
activate STAT3 but retain lipid export activity is worth exploiting, and is expected 
to provide important mechanistic insight into the anti-inflammatory properties of 
ABCA1 (Fig. 2).  
Anti-inflammatory properties of ABCG1 
Wojcik et al. reported that ABCG1 KO mice had increased pro-inflammatory 
cytokine levels in their lungs, leading to the recruitment of neutrophils, 
eosinophils, B cells, T cells, and dendritic cells.76 They also showed that 
macrophages are the primary cell type involved in the onset of both pulmonary 
lipidosis and inflammation in ABCG1 KO mice. Likewise, Yvan-Charvet et al. 
found that macrophages lacking either ABCG1, or both ABCA1 and ABCG1 
secreted significantly more cytokines and chemokines.55 Both ABCA1 and 
ABCG1 modulate cell surface cholesterol levels and inhibit its partitioning into 
lipid rafts. Given lipid rafts may provide platforms for innate immune receptors 
to respond to inflammatory signals,77 it follows that loss of ABCA1 and ABCG1 
by increasing raft content will increase signaling through these receptors. 
In agreement, basal and LPS-stimulated thioglycollate-elicited peritoneal 
macrophages showed increased inflammatory gene expression in the order 
ABCA1/ABCG1 dKO>ABCG1 KO>ABCA1 KO>wild-type, and TLR4 cell surface 
concentration was increased in ABCA1/ABCG1 dKO>ABCG1 KO>ABCA1 KO>wild-
type macrophages.78 Interestingly, replenishment or removal of cholesterol using 
cyclodextrin reduced the inflammatory response of ABCA1 KO and ABCG1 KO 
macrophages,78,79 supporting the hypothesis that the increased inflammatory 
response is attributable to cholesterol accumulation in the plasma membrane of 
ABCA1 KO and ABCG1 KO macrophages. ABCG1 appears to have a more potent 
role in modulating macrophage inflammation than ABCA1, which perhaps reflects 
a predominant role of this transporter in modulating cholesterol content in lipid 
rafts.80
Both apoptosis and necrosis was increased in ABCG1 KO alveolar macrophages,76 
which may also contribute to or dampen pulmonary inflammation. In agreement, 
Baldán et al. showed that ABCG1 KO peritoneal macrophages were more 
apoptotic.47 When FC accumulates in the macrophage, the ratio of FC to 
phospholipids is disturbed in the endoplasmic reticulum (ER) membrane.81 The 
"stiffening" of the ER membrane bilayer leads to ER protein dysfunction, ER 
stress, and the unfolded protein response, resulting in apoptosis of the cell.81 
Furthermore, oxysterols that are formed within macrophages as a consequence 
of cholesterol accumulation may cause cells to be more prone to apoptosis.82,83 
Unlike ABCA1, ABCG1 has a specific role in promoting cellular efflux of oxysterols 
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modified at the 7 position, such as 7-ketocholesterol- and 7β-hydroxycholesterol, 
to prevent macrophages from oxysterol-induced cell death.84,85 Thus, it is possible 
that ABCG1 KO macrophages are more prone to apoptosis due to the toxic effects 
of FC and oxysterol accumulation.
More recently, Whetzel et al. reported that reductions in ABCG1 expression in 
endothelium promote a pro-inflammatory endothelial phenotype.86 Aortic EC from 
ABCG1 KO mice displayed increased production of chemokines and increased 
surface expression of the adhesion molecules that promote monocyte adhesion 
and interactions. The regulation of monocyte-endothelial interactions by ABCG1 
appeared to be independent of HDL binding. Furthermore, the pro-inflammatory 
phenotype of ABCG1 KO EC was not mediated by NFκB, a key molecule involved in 
the regulation of the inflammatory response to both infection and tissue damage. 
Instead, the IL-6-IL-6 receptor axis was found to be induced in ABCG1 KO EC, 
and this pathway, through STAT3 signaling, regulates monocyte-endothelial 
interactions in ABCG1 KO mice. Thus, in addition to suppressing macrophage 
inflammation, ABCG1 may also be important for regulating the early inflammatory 
response in EC in the vessel wall. Further studies examining whether the effect 
of ABCG1 deficiency on the total cholesterol content and/or the intracellular 
distribution of cholesterol in EC as well as macrophages and the consequence for 
cellular signaling are needed to fully understand the anti-inflammatory properties 
of ABCG1.
Structure, expression and regulation of ABCA1 and 
ABCG1
The structure, expression, and regulation of ABCA1
ABCA1 is a 2261 amino acid integral membrane protein. It is a full transporter, 
comprising two halves of similar structure. Each half has a transmembrane 
domain containing six helices and a nucleotide binding domain (NBD) containing 
two conserved peptide motifs known as Walker A and Walker B, which are 
present in many proteins that use ATP in energizing their transport activity, and a 
Walker C signature unique to ABC transporters. ABCA1 is predicted to have an N 
terminus oriented into the cytosol and two large extracellular loops that are highly 
glycosylated and linked by one or more cysteine bonds.87,88
ABCA1 is expressed ubiquitously, but with the highest concentrations in the 
liver, brain, adrenal glands, and macrophage foam cells.89-91 Experiments 
using biotinylation,92 anti-FLAG antibody in FLAG-ABCA1 transfected cells,93 
green fluorescent protein (GFP)-ABCA1 transfected cells,94,95 and a polyclonal 
antibody,96 have suggested that ABCA1 localizes to the plasma membrane and 
to intracellular compartments (e.g., early and late endosomes and lysosomes). 
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Although still controversial, it is suggested that ABCA1 may form a channel in 
the plasma membrane that promotes flipping of lipids from the inner to outer 
membrane leaflet by an ATPase-dependent process.97 Some data support a direct 
efflux mechanism wherein ABCA1 first binds apoA-I, resulting in subsequent 
transfer of lipid to the bound apoA-I, which is then released from the cell, with 
the latter steps presumably still occurring within the context of the high affinity 
complex.98,99 Other more indirect models have also proposed that ABCA1 activity 
creates lipid raft membrane domains in the absence of apoA-I, and that these lipid 
domains may represent a larger capacity but lower affinity cellular binding site 
for apoA-I that is not closely associated with ABCA1.100,101 Subsequently, cellular 
phospholipids and cholesterol are transported simultaneously or phospholipid 
efflux precedes cholesterol efflux.102,103 These partially lipidated apolipoproteins 
can then acquire additional cholesterol by other processes and mature into larger 
spherical HDL particles (HDL2 and HDL3). The selective uptake of HDL by the liver 
is mediated by scavenger receptor class B type I (SR-BI), which has a high affinity 
for lipid-rich HDL particles, but low affinity for lipid-poor HDL apolipoproteins.104
In addition to mediating lipid efflux on the cell surface, ABCA1 may also be 
internalized along with apoA-I in vesicles to intracellular compartments where 
ABCA1 pumps lipids into the vesicles for association with apoA-I, and subsequent 
release of nascent HDL particles upon fusion with the plasma membrane 
(retroendocytosis).105,106 Smith et al. reported the uptake and resecretion of 
labeled apoA-I,107 and colocalization of GFP-ABCA1 and apoA-I in intracellular 
compartments.108 In agreement, Hassan et al. showed that cell binding of apoA-I 
specifically mediates the continuous endocytic recycling of ABCA1, and that this 
pathway plays a central role in the genesis of nascent HDL.109 Moreover, Chen 
et al. found impaired ABCA1 internalization in cells expressing a mutant form 
of ABCA1 (ABCA1delPEST), and the failure of the ABCA1-PEST mutant to reach 
late endosomes was associated with less ability to export endosome/lysosomal 
cholesterol to apoA-I, but not cell surface cholesterol.110 They also reported 
that trafficking of ABCA1, and possibly apoA-I, to the late endosome/lysosome 
compartment is responsible for a quantitatively significant percentage of total 
ABCA1-dependent cholesterol efflux.110 Thus, it is conceivable that internalization 
of ABCA1 is necessary for the mobilization of cellular cholesterol, at least during 
transit through the late endosome/lysosome compartment.
As expected for a transporter that mediates excess cellular cholesterol 
export, transcription of ABCA1 is markedly induced by overloading cells with 
cholesterol.89,90 ABCA1 expression is regulated at multiple levels, including the 
nuclear receptors liver X receptor (LXR) and retinoid X receptor (RXR) binding to 
the promoter region of the ABCA1 gene, with LXR being activated by elevated 
levels of oxysterols in cholesterol-loaded cells.111,112 Several additional modes of 
transcriptional regulation of ABCA1 by the transcription factors Sp1/3, upstream 
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stimulatory factor 1/2 (USF1/2), hepatocyte nuclear factor 1a (HNF-1a), cyclic 
AMP (cAMP), and Zinc finger protein 202 (ZNF202) have been reviewed.113 
Although much emphasis has been placed on the transcriptional regulation of 
ABCA1, new studies are beginning to reveal its post-transcriptional regulation. 
Under basal conditions in cultured cells, ABCA1 has a relatively rapid turnover 
rate, as evidenced by the fact that ABCA1 protein is highly unstable in absence 
of inducers (half-life of 1 to 2 hours).114-116 ABCA1 is stabilized by apoA-I binding 
to cells, through apoA-I-dependent inhibition of calpain-mediated proteolysis of 
ABCA1.115 Multiple constitutive and apoA-I-stimulated phosphorylation events 
have been described that both enhance,72,117-121 or inhibit,122 ABCA1 activity. In 
addition, Arakawa and Yokoyama showed that apoA-I itself stabilizes ABCA1 by 
retarding its degradation.123 In their study, A,N-acetyl-leucine-leucyl-norleucinal 
aldehyde (ALLN), but not lactacystin, blocked the turnover of ABCA1 in the 
absence of apoA-I, and these authors speculated that a non-proteasomal thiol 
protease was involved. In another study by Feng et al., the decrease in ABCA1 
protein in FC-loaded macrophages was blocked to similar degrees by ALLN 
and lactacystin, suggesting an important role for proteasomal degradation in 
this process.124 An important area of future investigation will be to determine 
the molecular mechanisms linking FC loading to proteasomal degradation 
of ABCA1, including the possibility that FC loading triggers ubiquitination of 
ABCA1. Moreover, Wang and Oram reported that unsaturated fatty acids (FAs) 
also accelerate the degradation of ABCA1 and thus decrease apoA-I-mediated 
efflux.116 Unsaturated FAs not only act on the transcriptional regulation of ABCA1 
(as antagonists of oxysterols in LXR activation), but also induce ABCA1 protein 
degradation (via a signaling pathway involving activation of phospholipase D2 and 
phosphorylation of ABCA1 serines).125
The structure, expression, and regulation of ABCG1
ABCG1 is a half-transporter containing only one 6-helix transmembrane domain 
and a single nucleotide binding fold. As an active transporter which needs two 
NBD and two transmembrane bundles, ABCG1 needs to form a homodimer or a 
heterodimer with another ABC transporter to become active.126,127
In general, high expression of ABCG1 mRNA was noted in spleen, lung, 
thymus, and brain, whereas expression in kidney, liver, and heart was low or 
undetectable.127,128 Subsequent studies using ABCG1-null/LacZ knock-in mice 
demonstrated that ABCG1 is predominantly expressed in macrophages, EC, 
and lymphocytes.46 The mammalian ABCG1 cDNA was originally identified from 
studies using degenerate PCR and RNA from either a murine macrophage cell 
line,127 a murine pre-B cell library,128 or a human Jurkat T-cell line,128 or after using 
exon-trapping and a human chromosome 21 cDNA library.129 Both the human 
and murine ABCG1 genes utilize multiple promoters and alternative splicing to 
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produce a diverse array of mRNAs that encode multiple putative protein isoforms 
that range from 64-79 kDa.130-132 It is not known if these isoforms, which vary 
only at the amino terminus upstream of the Walker A motif, form distinct dimers 
and/or have different functions in vivo. One interesting human isoform variation 
is predicted to arise due to alternative splicing in a section of the cytoplasmic 
domain of ABCG1 between the transmembrane regions and the ATP cassette. 
Splicing in this region leads to either the presence or absence of a 12 amino 
acid (AA) internal segment in the ABCG1 protein, termed as ABCG1(+12) and 
ABCG1(−12).128,133 The two ABCG1 isoforms are expressed at both RNA and 
protein levels in human macrophages, with ABCG1(−12) tending to be the more 
abundant.134 Of note, ABCG1(+12) is not expressed in mice,135 while mouse 
models are widely used to elucidate the function of ABCG1, further investigations 
into the importance of this human ABCG1 isoform are warranted. 
ABCG1 promotes cholesterol efflux from cells to mature HDL but not to lipid-
free apoA-I.7,136,137 In contrast to ABCA1-dependent lipid export, which requires 
apolipoprotein binding, ABCG1-dependent cholesterol efflux does not appear to 
directly bind HDL.138 Different models have been proposed to explain how ABCG1 
acts to increase the availability of plasma membrane cholesterol to its acceptors. 
One suggested that ABCG1 helps cholesterol molecules to overcome the energy 
barrier for entry into the hydrophilic water layer, perhaps by using ATP to 
promote protrusion of the cholesterol molecule into water, followed by a transient 
collision with an acceptor.138 A second model pointed to a function of ABCG1 as 
a phospholipid floppase, promoting changes in the organization of plasma 
membrane phospholipids and subsequent attraction of cholesterol to the outer 
leaflet for diffusional efflux.139 Although expression of ABCG1 does not increase 
cellular binding of HDL, it does increase the oxidation sensitivity of cellular 
cholesterol in the absence of HDL,100,137 suggesting that ABCG1 (like ABCA1) can 
modify plasma membrane cholesterol domains such that they are more accessible 
to cholesterol oxidase. Whether the cholesterol in the ABCG1 modified membrane 
domains is spatially different from those generated by ABCA1 remains to be 
investigated. 
ABCG1 predominantly localizes to the intracellular compartments in basal 
macrophages, and it can be redistributed to the plasma membrane after LXR 
activation.140 Thus, the LXR system performs a dual function of inducing ABCG1 
transcription and its translocation to the plasma membrane. However, one recent 
study by Larrede et al. demonstrated that stimulation of cholesterol efflux to 
HDL by LXR activation in human foam cells involves an ATP-dependent transport 
mechanism solely mediated by ABCA1 that it appears to be independent of 
ABCG1 expression.141 In addition to LXR activation, ABCG1 expression can also be 
induced by agonist of peroxisome proliferator-activated receptor gamma (PPARγ) 
paralleling with increased LXR.142 In agreement, Akiyama et al. showed that 
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hepatic expression of ABCG1 was reduced in mice following conditional disruption 
of hepatic PPARγ.143 Moreover, PPARγ agonists were reported to induce ABCG1 in 
LXR α/β-null macrophages and to exert antiatherogenic effects.144 These results 
suggest that the expression of macrophage ABCG1 could be increased by PPARγ 
agonists, which is associated with or independent of LXR activation. 
Like ABCA1, ABCG1 expression can also be post-transcriptionally regulated by 
diverse factors. Uehara et al. demonstrated that unsaturated FAs significantly 
suppress the stimulatory effects of oxysterols and retinoids on the mRNA and 
protein expression of ABCG1 as well as the activity of the wild-type human ABCG1 
promoter.145 In addition, lipoxygenases comprise a family of enzymes capable 
of mediating selective lipid oxidation. One of them, called 12/15-lipoxygenase 
(12/15LO) catalyzes the conversion of free FAs to produce eicosanoids.146 Nagelin 
et al. previously showed that 12/15LO activity in macrophages enhances the 
degradation of ABCG1 protein and thus reduced cholesterol efflux.147 Correlating 
with the increased turnover of ABCG1, the 12/15LO eicosanoid product 
12S-hydroxyeicosatetranoic acid (12SHETE) enhances the serine phosphorylation 
of ABCG1.147 More recently, the mechanism by which 12/15LO regulates ABCG1 
was further elucidated by the same group, and it was suggested that 12/15LO 
activates c-Jun NH2-terminal kinase 2 (JNK2) and p38 mitogen-activated protein 
kinase (MAPK) pathways to enhance the phosphorylation and degradation of 
ABCG1.148 Furthermore, Mauldin et al. demonstrated that ABCG1 expression 
was decreased in peritoneal macrophages isolated from Type 2 diabetic mice.149 
Similarly, down-regulation of ABCG1 was observed by using C57BL/6J peritoneal 
macrophages cultured in the presence of elevated glucose levels. These results 
suggest that ABCG1 expression in diabetic macrophages is regulated by chronic 
exposure to elevated glucose. Zhou et al. recently reported that the expression of 
ABCG1, but not ABCA1, was reduced in monocytes from Type 2 diabetic patients, 
which is partly related to the increased exposure to serum advanced glycation end 
(AGE) products.150 The effect of AGEs on ABCG1 expression is mediated by the 
receptor for AGE (RAGE) through a LXR-independent pathway. However, the exact 
mechanism remains unknown.151 
Therapeutic targeting ABCA1 and ABCG1
As described above ABCA1, but not ABCG1, is a rate-limiting factor in HDL 
biosynthesis. Both ABCA1 and ABCG1 play critical roles in lipid homeostasis by 
controlling tissue lipid levels and cellular cholesterol efflux. Cholesterol efflux to 
apoA-I specifically requires ABCA1, whereas efflux to HDL requires ABCG1. In 
addition, ABCA1 and ABCG1 have also anti-inflammatory properties which are 
independent of changes in plasma HDL-C levels. The beneficial effects of ABCA1 
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and ABCG1 have made them important new therapeutic targets for preventing 
atherosclerosis. The expression and activity of ABCA1 and ABCG1 is regulated 
transcriptionally and post-transcriptionally by multiple processes. Nowadays, 
various programs have been initiated by the pharmaceutical industry to target 
these two ABC transporters.
Target transcription of ABCA1 and ABCG1
Both ABCA1 and ABCG1 are strongly induced in human macrophages on LXR/
RXR activation, and ABCG1 appears to be a preferential target of LXR ligands 
in foam cells.141 Thus, upregulation of macrophage ABCA1 and ABCG1 by LXR 
agonists may constitute an effective pharmacological approach to attenuate 
foam cell formation, and thereby to prevent arterial lipid accumulation and lesion 
progression in dyslipidemic patients. In addition to ABCA1 and ABCG1, LXR 
agonists are also known to induce the transcription of other molecules involved 
in the RCT pathway, including apoE,152 which promotes cholesterol efflux from 
macrophages by both ABCA1-independent and -dependent mechanisms; liver 
and intestinal ABCG5 and ABCG8,153 which promote excretion of liver and dietary 
cholesterol into the bile; lipid transfer proteins, such as cholesteryl ester transfer 
protein (CETP),154 and phospholipid transfer protein (PLTP),155 which remodel 
extracellular HDL particles to regenerate lipid-free apolipoproteins. On the other 
hand, Joseph et al. reported that LXR is important for macrophage survival and 
regulation of the innate immune response, but this mechanism does not seem 
to be controlled by ABCA1 or ABCG1 activity.156 In agreement, Valledor et al. 
demonstrated that LXR and RXR coordinately regulate the network of genes that 
control programmed cell death, resulting in protection of macrophages from 
bacterial-induced apoptosis.157
Initial studies using two non-steroidal synthetic LXR agonists (TO901317 and 
GW3965) in mice suggested they were able to increase plasma HDL-C levels 
and reduce atherosclerosis.158-161 Recently, Verschuren et al. demonstrated 
that TO901317 strongly suppressed atherosclerotic lesion evolution and 
promoted lesion regression in apoE*3Leiden mice, a model for atherosclerosis 
with predictive value for the human situation.162 Remarkably, the effect of 
TO901317 on plaque regression occurred even in the presence of proatherogenic 
plasma cholesterol and triglyceride profiles. The ability of TO901317 to induce 
atherosclerosis regression is mechanistically linked to (1) enhanced cholesterol 
efflux from macrophages in the aortic lesions (via upregulation of ABCA1, ABCG1, 
and apoE); (2) suppressed endothelial monocyte adhesion (at least in part via 
upregulation of ABCG1); (3) reduced lesional macrophage content by apoptosis; 
and (4) increased expression of the chemokine receptor CCR7 in foam cells, which 
is essential for the emigration of mature dendritic cells to lymph nodes during 
regression. The exciting possibilities for LXR agonists as new therapeutics are, 
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however, counterbalanced by one significant side effect: the induction of liver 
de novo lipogenesis and elevation of plasma triglyceride levels.163-165 This liability 
is, at least in part, mediated by LXR-induced transcription of sterol regulatory 
element binding protein-1c (SREBP-1c), which induces some of the key enzymes 
involved in fatty acid synthesis, such as fatty acid synthase (FAS) and acetyl-
coenzyme A carboxylase (ACC).163,164
Clearly, a major challenge for LXR agonists is to achieve a favorable balance 
between the beneficial effects of induction of cholesterol exporters (e.g., 
ABCA1 and ABCG1) and the detrimental effects of induction of SREBP-1c. A 
few possible strategies have been proposed to minimize the side effects of LXR 
agonist treatment. Both LXR isoforms (i.e., LXRα and LXRβ) respond to the 
same natural and synthetic ligands, but they show different tissue distribution. 
LXRα predominates in tissues that synthesize triglycerides, such as the liver, 
whereas LXRβ has a ubiquitous tissue distribution.166,167 It is thus possible that 
LXR subtypes can control different genes due to their different tissue distribution. 
Interestingly, peritoneal macrophages from LXRβ knockout mice, but not LXRα 
knockout mice, show altered basal expression of ABCA1 mRNA,166 suggesting 
that LXRβ is the subtype more responsible for controlling ABCA1 transcription 
in macrophages. Furthermore, unlike LXRα-selective agonists, LXRβ-selective 
agonists may not induce hepatic lipogenesis.167,168 However, the crystal structures 
of LXRα and β are very similar in the ligand binding domains, and it may be a 
challenge to develop subtype-selective ligands.169,170 
Another approach is the identification of target gene-selective or tissue-
selective LXR agonists. Encouragingly, several natural or synthetic steroidal 
LXR agonists have been shown to selectively activate gene expression with 
minimal SREBP-1c gene activation in the liver and strongly induce ABCA1 
expression in macrophages.171,172 More recently, a novel synthetic steroidal 
LXR agonist ATI-829 was reported in mice to selectively activate LXR target 
gene expression in the intestine and macrophages rather than in the liver, 
without inducing hypertriglyceridemia and liver steatosis.173 Given the variety of 
factors that modulate atherosclerosis in mice, the development of LXR agonists 
that are LXRβ, gene, or tissue selective, which can raise circulating HDL-C and 
stimulate macrophage cholesterol efflux without causing liver and plasma 
triglyceride accumulation is critical for the development of LXR-based agonists as 
therapeutically useful agents.
Target post-transcription of ABCA1 and ABCG1
The possibility of targeting posttranscriptional regulation of ABCA1 and 
ABCG1 has received less attention. A series of studies have indicated that both 
ABCA1 and ABCG1 are highly unstable proteins, and that they may be post-
transcriptionally regulated in vivo by metabolic factors associated with common 
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disorders, such as diabetes. It is also likely that transcription of ABCA1 and ABCG1 
in highly cholesterol-loaded cells may already be maximally stimulated. Under 
these conditions, stimulating transcriptional process alone may have a limited 
contribution to enhance the overall activity of ABCA1 and ABCG1. 
ABCA1 is degraded by calpain,115 and it appears to be one of the major 
mechanisms for regulation of its cellular level, and helical apolipoproteins protect 
ABCA1 against this degradation.123 Helical apolipoproteins interact with ABCA1 
and generate new HDL by removing cellular lipid. ABCA1 is phosphorylated 
and stabilized by a mechanism involving protein kinase C that is presumably 
activated by diacylglycerol generated by replenishment reaction for the removal of 
sphingomyeline.120 To date, several synthetic amphipathic α-helical peptides have 
been produced. One of them, called D4-F because it contains 4 phenylalanines 
and only D-amino acids, can be absorbed orally into the blood stream with a 
low rate of turnover in mice.174 Administration of this peptide in drinking water 
has been shown to markedly reduce atherosclerosis in mouse models.174,175 
D-4F protects against atherosclerosis by several possible mechanisms including 
interactions with ABCA1. Another advantage of synthetic amphipathic α-helical 
peptides is that they may be relatively resistant to the oxidative damage which 
has been reported to impair the interaction of apoA-I with ABCA1.176 However, a 
disadvantage of these peptides is that they have non-specific detergent effects 
on membrane lipids and can accumulate in tissues and damage cells.177,178 Further 
investigation is needed to develop novel synthetic peptides that mimic amphiphilic 
helical segments of apolipoproteins to specifically remove cellular lipids via the 
ABCA1 pathway without having detergent-like effects. 
Other potential therapeutic targets
Another potential strategy under investigation is to increase the concentration of 
acceptors for ABCA1 and ABCG1. ABCA1 transports phospholipids to lipid-poor 
apoA-I to generate partially lipidated "nascent" HDL, called preβ-HDL. These 
preβ-HDL particles can acquire additional cholesterol by other processes and then 
convert into spherical larger HDL, called α-HDL. These mature HDL particles are 
effective substrates for ABCG1-mediated cholesterol transport.53,179,180 In this 
regard, intravenous infusion of apoA-I or apoA-I mimetic peptides are promising 
approaches. Infusion of recombinant apoA-IMilano/phospholipid complexes 
in apoE KO mice reduced the foamcell content of arterial lesions within 48h 
post infusion.181 A weekly infusion of recombinant apoA-IMilano/phospholipid 
complexes in humans for 5 weeks appeared to induce regression of coronary 
atherosclerosis in a small study.182 Currently, one intravenously administered 
apoA-I mimetic peptide, known as the RLT peptide (ETC-642, Esperion 
Therapeutics Inc., Ann Arbor, Michigan), is being studied in clinical trials.183 More 
recently, Sacks et al. developed a novel selective delipidation technique by which 
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large HDL in human or monkey plasma was converted into cholesterol-depleted 
HDL, resembling preβ-HDL and small spherical HDL3 that are active in removing 
excessive cholesterol from cells.184 Importantly, treatment with the delipidated 
plasma tended to reduce diet-induced aortic atherosclerosis in monkeys, 
suggesting that the selective HDL delipidation could be an attractive therapy for 
atherosclerosis. 
Conclusions
Studies of human disorders and mouse models show that the ABC cholesterol 
transporters ABCA1 and ABCG1 have a major impact on whole-body lipid 
homeostasis by a process termed RCT. ABCA1 and ABCG1 work synergistically to 
remove excess cholesterol from cells (particularly macrophages), and they also 
play important roles in suppressing inflammation through multiple mechanisms. 
In humans, ABCA1 mutations can cause a severe HDL-deficiency syndrome 
characterized by cholesterol deposition in tissue macrophages and prevalent 
atherosclerosis. Disrupting ABCA1 or ABCG1 in mice promotes accumulation of 
excessive cholesterol in macrophages, and physiological manipulation of ABCA1 
expression affects atherogenesis in mouse models. ABCA1 and ABCG1 have 
complex cellular and regulatory pathways that are far from being completely 
understood. At present, a number of approaches have been utilized to target 
ABCA1 and ABCG1 in efforts to raise circulating HDL levels and stimulate lipid flux 
through the RCT pathway. However, the efficacy and safety of these therapies 
remains an open question. As we learn more, there will undoubtedly be additional 
novel therapeutic targets that offer the best opportunity to treat atherosclerosis. 
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Objective: ABCA1 protects against atherosclerosis by facilitating 
cholesterol efflux from macrophage foam cells in the arterial wall to 
extracellular apolipoprotein (apo) A-I. In contrast to apoA-I, apoE is 
secreted by macrophages and can, like apoA-I, induce ABCA1-mediated 
cholesterol efflux. Yet, the combined effect of macrophage ABCA1 and 
apoE on lesion development is unexplored.
Methods: LDL receptor knockout (KO) mice were transplanted with bone 
marrow from ABCA1/apoE double KO (dKO) mice, their respective single 
knockouts, and wild-type (WT) controls and were challenged with a high-
fat/high-cholesterol diet for 9 weeks. 
Results: In vitro cholesterol efflux experiments showed no differences 
between ABCA1 KO and dKO macrophages. The serum non-HDL/
HDL ratio in dKO transplanted mice was 1.7-fold and 2.4-fold 
(p<0.01) increased compared to WT and ABCA1 KO transplanted 
mice, respectively. The atherosclerotic lesion area in dKO transplanted 
animals (650±94×103 µm2), however, was 1.9-fold (p<0.01) and 1.6-
fold (p<0.01) increased compared to single knockouts (ABCA1 KO: 
341±20×103 µm2; apoE KO: 402±78×103 µm2, respectively) and 
3.1-fold increased (p<0.001) compared to WT (211±20×103 µm2). 
When normalized for serum cholesterol exposure, macrophage ABCA1 
and apoE independently protected against atherosclerotic lesion 
development (p<0.001). Moreover, hepatic expression levels of TNFα 
and IL-6 were highly induced in dKO transplanted animals (3.0-fold; 
p<0.05, and 4.3-fold; p<0.001, respectively). In agreement, serum 
IL-6 levels were also enhanced in ABCA1 KO transplanted mice (p<0.05) 
and even further enhanced in dKO transplanted animals (3.1-fold as 
compared to ABCA1 KO transplanted animals; p<0.05).
Conclusions: Combined deletion of macrophage ABCA1 and apoE 
results in a defect in cholesterol efflux and, compared to ABCA1 
KO transplanted mice, elevated serum total cholesterol levels. 
Importantly, these mice also suffer from enhanced systemic and 




Accumulation of cholesterol in macrophages leads to the formation of foam cells, a 
crucial event in the development of atherosclerotic lesions. Because macrophages 
are incapable of limiting the uptake of lipoproteins, these cells rely on reverse 
cholesterol transport (RCT) for maintaining cellular cholesterol homeostasis.1,2 
We have shown that apolipoprotein (apo) E as well as the ATP-binding cassette 
(ABC) transporters A1 and G1 are key players in the efflux of cholesterol from 
macrophages, the first step in RCT and protection against atherosclerosis.3-5 
ABCA1 facilitates cholesterol efflux to lipid-poor apolipoproteins like apoA-I,6 
resulting in the formation of lipidated HDL. Subsequently, ABCG1 mediates the 
efflux of cellular cholesterol to these mature HDL particles.7,8 In addition, ABCA1 
can modulate the secretion of apoE.9 Secreted apoE by macrophages facilitates 
cellular cholesterol efflux10 both in the presence and absence of extracellular 
cholesterol acceptors.11 Although both pro- and anti-atherogenic functions for 
macrophage apoE have been described,12-15 we recently showed that macrophage 
apoE protects against atherosclerotic lesion development, independent of 
ABCG1,5 in LDL receptor knockout (LDLr KO) mice. Moreover, very recently, 
Zanotti et al. showed that expression of apoE only in macrophages is sufficient 
to promote RCT, emphasizing the pivotal anti-atherogenic role for macrophage 
apoE.16 Importantly, macrophage apoE-mediated cholesterol efflux was shown 
to be independent of ABCA1 in apoE expressing J774 macrophages,17 suggesting 
that the atheroprotective effects of macrophage ABCA1 are independent of apoE 
production by macrophages. However, in primary human monocyte-derived 
macrophages and THP-1 cells it was shown that apoE secretion from macrophages 
is promoted by ABCA1.9
To investigate the possible interaction between ABCA1 and apoE in promoting 
macrophage cholesterol efflux and their combined roles in atherogenesis, we 
generated mice deficient for both ABCA1 and apoE and performed a bone marrow 
transplantation (BMT) experiment in LDLr KO mice. Our results evidently show 
that transplantation of LDLr KO mice with either ABCA1 KO or apoE KO bone 
marrow resulted in a moderate increase in atherosclerotic lesion development, 
while combined deletion of ABCA1 and apoE in bone marrow-derived cells led to a 
more dramatic increase in atherosclerosis.
Methods
Animals and bone marrow transplantation
ABCA1 KO18 and apoE KO (The Jackson Laboratory, Bar Harbor, ME, USA) mice (both more than 7 times 
backcrossed onto a C57BL/6J background) were mated to generate F1 heterozygotes. Heterozygote 
F1 animals were crossbred to obtain ABCA1 KO/apoE WT (ABCA1 KO), ABCA1 WT/apoE KO (apoE KO), 
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ABCA1 KO/apoE KO (dKO), and ABCA1 WT/apoE WT (WT)mice, which were used as donors for the bone 
marrow transplantation. These donor mice were anaesthetized subcutaneously with a mix of 70 mg/kg 
body weight xylazine, 1.8 mg/kg bodyweight atropine and 350 mg/kg body weight ketamine. Animals 
were subsequently sacrificed by cervical dislocation. Bone marrow cells were then isolated from the 
femurs and tibias from these mice. Homozygous C57BL/6J LDL receptor knockout (LDLr KO) mice were 
obtained from The Jackson Laboratory as mating pairs and bred at the Gorlaeus Laboratories, Leiden, 
The Netherlands. Bone marrow transplantations to male LDLr KO mice were performed as described.19 
Briefly, irradiated recipients (≥11 per group) received 5×106 bone marrow cells by intravenous injection 
into the tail vein. After a recovery period of 8 weeks, the animals were challenged with a high-fat/high-
cholesterol (HF/HC; 1.25% cholesterol, 21% fat (Abdiets, Woerden, the Netherlands)) diet for 9 weeks to 
induce atherosclerotic lesion development. At 17 weeks after transplantation, mice were anaesthetized 
subcutaneously with a mix of 70 mg/kg body weight xylazine, 1.8 mg/kg bodyweight atropine and 
350 mg/kg body weight ketamine. Animals were subsequently sacrificed by cervical dislocation. The 
hematologic chimerism of the transplanted LDLr KO mice was confirmed in genomic DNA from bone 
marrow by PCR analysis (Fig. 1). Animal experiments were approved by the Ethics Committee for Animal 
Experiments of Leiden University (permit number 08015) and performed at the Gorlaeus Laboratories of 
the Leiden/Amsterdam Center for Drug Research in accordance with the National Laws and the Directive 
2010/63/EU of the European Parliament.
Histological analysis of the aortic root, aortic arch, and spleen
To analyze the development of atherosclerosis at the aortic root and aortic arch, transplanted LDLr KO 
mice were euthanized after 9 weeks of feeding the HF/HC diet. The arterial tree was perfused in situ with 
PBS (100 mm Hg) for 10 min via a cannula in the left ventricular apex. The heart plus aortic root and the 
aortic arch were excised and stored in 3.7% neutral-buffered formalin (Formal-fixx; Shandon Scientific 
Ltd, Runcorn, UK). Serial sections (10 µm) of the aortic root were cut using a Leica CM3050S cryostat. 
The atherosclerotic lesion areas in oil red-O-stained cryostat sections of the aortic root and whole aortic 
arches were quantified using the Leica image analysis system, consisting of a Leica DMRE microscope 
coupled to a video camera and Leica Qwin Imaging software (Leica Ltd, Cambridge, UK). Mean lesion 
area (in µm2) was calculated from 10 consecutive oil red-O-stained sections of the aortic root, starting at 
the appearance of the tricuspid valves. Sections were stained immunohistochemically for the presence of 
macrophages using a rat MoMa-2 antibody, dilution 1:50 (Serotec Ltd, Oxford, UK). Goat anti-rat coupled 
to horse radish peroxidase (HRP) (1:100) (Dako, Glostrup, Denmark) was used as a secondary antibody 
and Nova red substrate (Vector Laboratories, Burlingame, CA, USA) was used for visualization of HRP. 
Collagen content of the plaques was determined after Masson Trichrome staining (Sigma Diagnostics, 
St Louis, MO, USA). Relative plaque area in the aortic arch was quantified en face calculating the ratio of 
atherosclerotic lesions to the surface of the entire aortic arch. In addition, 7 µm cryosections of formalin-
fixed spleen from the transplanted LDLr KO mice were prepared and stained for lipid accumulation using 
oil red-O and counterstained with hematoxylin.
Figure 1. Successful disruption of 
macrophage ABCA1 and apoE by 
bone marrow transplantation. RT-
PCR on genomic DNA of bone marrow 
isolated from ABCA1 and/or apoE KO 
transplanted LDLr KO mice and their WT 
transplanted controls at 17 weeks after 
transplantation.
 Targeted allele (245 bp) 
 Wild-type allele (155 bp)
ABCA1 KO apoE KOWT dKO
ABCA1 PCR
apoE PCR
 Wild-type allele (750 bp)









Eight weeks after bone marrow transplantation, 100 µL of blood was drawn from each individual 
mouse by tail bleeding after an overnight fasting period. Upon sacrifice, 17 weeks after bone marrow 
transplantation, blood was collected by retro-orbital venous plexus puncture after an overnight fasting 
period. Lipid analyses were performed as described.19 Lipoprotein profiles from all mice were determined 
by fractionation of 50 µL samples of serum, pooled from 2 mice per genotype, using a Superose 6 
column (3.2×300 mm, Smart-System; Pharmacia, Uppsala, Sweden). Total cholesterol (TC) content of 
the effluent was determined as described,19 and calculated as a percentage of serum TC. Splenic free 
cholesterol (FC), cholesteryl ester (CE), and triglyceride (TG) content were determined as described19 
after extraction according to Bligh and Dyer,20 and dissolving the lipids in 2% Triton X-100. ApoE Western 
blot analysis of pooled VLDL and LDL fractions was performed by running equal amounts of total 
cholesterol per lipoprotein (VLDL: 3.8 mg, LDL: 4.6 mg) on a 15% SDS-PAGE gel. ApoE was detected 
using a rabbit-anti-mouse apoE polyclonal antibody (SB Rabbit 67-AH). As a secondary antibody a goat-
anti-rabbit IgG-HRP (Jackson ImmunoResearch, Suffolk, UK) was used.
Cellular cholesterol efflux
For isolation of bone marrow-derived macrophages (BMDM), femurs and tibias were lavaged with PBS. 
Bone marrow cells were plated in DMEM / 20% FCS / 1% penicillin / 1% streptomycin and differentiated 
into macrophages by addition of 30% L929 cell-conditioned media (as a source of M-CSF) for 7 days. 
Subsequently, BMDM were incubated with 0.5 µCi/mL 3H-cholesterol in DMEM / 0.2% fatty acid free 
BSA and 30 µg/mL non-labeled cholesterol for 24h at 37°C in 24 well tissue culture plates (Greiner Bio-
One). Cholesterol efflux was determined after incubating the cells in DMEM / 0.2% fatty acid free BSA 
in the absence or presence of 10 µg/mL apoA-I (Calbiochem, La Jolla, CA, USA) or 50 µg/mL human 
HDL, isolated according to Redgrave et al.21 Radioactivity in the medium and the cells was determined by 
scintillation counting after 24h of incubation. Cholesterol efflux is expressed as the percentage of total cell 
3H-cholesterol present in the medium after 24h. Basal efflux to BSA (in the absence of apoA-I and HDL) 
has been subtracted from the data shown.
mRNA expression analysis by real time PCR
Total RNA from BMDM was isolated using the guanidinium thiocyanate (GTC) method22 and reverse 
transcribed using a RevertAid M-MuLV enzyme (Fermentas, Burlington, Canada). Relative mRNA 
expression was measured from the following genes: scavenger receptor class B type I (SR-BI), LDL 
receptor-related protein 1 (LRP1), 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG-CoA reductase), 
microsomal triglyceride transfer protein (MTP), ATP-binding cassette transporter sub-family G member 
1 (ABCG1), apolipoprotein (apo) B and E, lipoprotein lipase (LPL), fatty acid synthase (FAS), interleukin 
6 (IL-6), tumor necrosis factor α (TNFα), and diacylglycerol acyltransferase-1 (DGAT-1). The mRNA 
expression levels were assessed by real time PCR (ABI PRISM 7500; Applied Biosystems, Foster City, CA, 
USA) using SYBR Green technology (Applied Biosystems). Housekeeping genes RPS13, 36B4, and HPRT 
were used as a control. Primer sequences are available upon request.
Determination of serum cytokine concentrations
Murine IL-6 and IFNγ serum levels were assayed using an instant ELISA kit (eBioscience, Hatfield, UK) 
according to the manufacturer's protocol. Murine IL-10 and TNFα serum levels were assayed using an 
instant ELISA kit (BD Biosciences, Erembodegem, Belgium) according to the manufacturer's protocol.
Statistical analysis
Statistically significant differences among the means of the different populations were tested using 
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analysis of variance (ANOVA) and when specifically indicated the unpaired Student's t-test (GraphPad 
InStat and Prism software). The Student-Newman-Keuls multiple comparison test was performed after 
ANOVA. Two-way ANOVA was used to check possible interactions. The probability level (alpha) for 
statistical significance was set at 0.05. Results are expressed as an average ± SEM.
Results
Shift toward a more pro-atherogenic lipoprotein profile in ABCA1/apoE 
dKO transplanted LDLr KO mice
Cholesterol levels were measured at 8 weeks (chow diet) and at 17 weeks (HF/
HC diet, containing 1.25% cholesterol and 21% fat) after BMT (Table 1). On 
chow diet, free cholesterol (FC) levels were moderately increased in apoE KO 
transplanted mice (15%, p<0.01). However, no effect of ABCA1 and/or apoE 
deletion in bone marrow-derived cells was observed on serum total cholesterol 
(TC) levels. After 9 weeks of feeding the HF/HC diet, serum cholesterol levels of 
the control mice and the apoE KO transplanted mice increased ≈3-fold. However, 
in agreement with previous studies,3,23 deletion of ABCA1 in bone marrow cells 
resulted in an attenuated 1.7-fold increase in plasma TC levels upon feeding an 
atherogenic diet compared to WT controls (p<0.001). Importantly, although 
ABCA1/apoE dKO transplanted mice still exhibited an attenuated rise in TC levels 
compared to WT controls (2.4-fold; p<0.01), these levels were significantly higher 
compared to levels of ABCA1 KO transplanted mice (1.4-fold; p<0.05).
The distribution of TC among serum lipoproteins was analyzed by liquid 
chromatography (Fig. 2). The observed decrease in cholesterol levels of ABCA1 
Figure 2. Lipoprotein profiles from ABCA1 and/or apoE KO transplanted LDLr KO mice and their WT 
transplanted controls. Fifty mL samples of serum, pooled from 2 mice per genotype, collected after 9 
weeks of HF/HC feeding, were subjected to FPLC fractionation. Distribution of serum FC and TC over the 
fractions (25 mL) was determined enzymatically. Values represent the means of n≥5 samples per group. 
1 sample corresponds to pooled serum of 2 mice.
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KO transplanted mice upon feeding the HF/HC diet was mainly caused by a 54% 
decrease in cholesterol associated with VLDL and LDL (non-HDL-C; p<0.001; 
Table 1). However, HDL-C levels in these mice were only reduced by 32%, which 
resulted in a decreased non-HDL/HDL ratio (Table 1). In contrast, the non-
HDL/HDL ratio of apoE KO transplanted mice was increased compared to WT 
controls (1.7-fold; Table 1), since HDL-C was reduced by 34% (p<0.05; Table 
1), whereas non-HDL-C levels remained stably high. In agreement with ABCA1 
KO transplanted mice, non-HDL-C of apoE/ABCA1 dKO transplanted animals 
was reduced compared to WT controls (30%; p<0.05; Table 1). However, also a 
dramatic 52% reduction was observed in HDL-C levels of these mice (p<0.001; 
Table 1), which resulted in an increased non-HDL/HDL ratio (2.4-fold; p<0.01 
compared to ABCA1 KO; Table 1), suggesting a more pro-atherogenic index.
No differences in serum VLDL/LDL apoE concentrations after HF/HC diet 
feeding
ApoE is essential for clearance of lipoproteins from the circulation via the LDLr or 
LDL receptor-related protein-1 (LRP1). To investigate if normalization of the HF/
HC diet-induced increase in VLDL/LDL is the consequence of a lower apoE content 
on these particles, apoE was determined in the lipoprotein fractions by Western 
blotting and normalized for cholesterol in the fractions (Fig. 3).
No apparent differences were observed in the apoE content of VLDL and 
LDL between the different groups of mice, indicating that disruption of apoE 
production by bone marrow-derived cells does not impair the availability of apoE 
on the particles for clearance. No apoE was visible in the HDL fraction of the 
different groups.
Data represent mean ± SEM of n≥10 mice. *p<0.05, **p<0.01, ***p<0.001 compared to WT; #p<0.05, 
##p<0.01 compared to ABCA1 KO; n.d. = not determined.


















WT 8 Chow 81±2 31±15 n.d n.d n.d
17 HF/HC 267±14 1021±75 929±89 92±11 10±1
ABCA1 KO 8 Chow 75±5 294±15 n.d n.d n.d
17 HF/HC 148±13*** 493±41*** 430±56*** 63±5** 7±1
apoE KO 8 Chow 93±3** 323±14 n.d n.d n.d
17 HF/HC 303±17 1030±84 969±67 61±5* 17±3##
dKO 8 Chow 83±3 294±13 n.d. n.d n.d
17 HF/HC 216±18*## 691±66**# 647±106* 44±7*** 17±4##
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Increased lipoprotein lipase mRNA expression in liver
In order to further investigate the possible mechanisms regarding the observed 
differences in serum TC levels, we quantifi ed mRNA expression levels of key liver 
enzymes in fatty acid and triglyceride synthesis (FAS and DGAT-1, respectively), 
cholesterol effl ux (ABCG1) and synthesis (HMG-CoA reductase), apolipoproteins 
(apo) B and E, and genes involved in lipoprotein assembly (MTP) and uptake (SR-
BI, LRP1), but found no differences. However, hepatic lipoprotein lipase (LPL) 
expression was 1.9-fold increased in ABCA1 KO transplanted animals as compared 
to dKO transplanted animals (p<0.05). LPL is essential for the lipolysis of 
lipoproteins. Induction of LPL leads to rapid clearance of VLDL and chylomicrons. 
Therefore, the observed attenuation of LPL expression in the dKO transplanted 
mice might have contributed to the increased TC levels as compared to ABCA1 KO 
transplanted animals.
Enlarged, cholesteryl ester enriched spleens in ABCA1/apoE dKO 
transplanted mice
Upon sacrifi ce (17 weeks after BMT; 9 weeks HF/HC diet feeding), spleens from 
all mice were examined. While both single KO transplanted groups showed 
no differences in spleen weight compared to WT controls, spleens from dKO 
transplanted animals were enlarged by 39% (p<0.001; Fig. 4). To further 
investigate this, spleen sections were stained with oil red-O to visualize lipid 
accumulation. No apparent staining was visible in spleens from WT controls and 
Figure 3. ApoE protein content in VLDL and LDL fractions from ABCA1 and/or apoE KO transplanted LDLr 
KO mice and their WT transplanted controls. Western blots showing apoE protein expression in VLDL (A) 
and LDL (B) isolated from ABCA1 KO and/or apoE KO transplanted LDLr KO animals and WT transplanted 
controls after feeding the HF/HC diet for 9 weeks. Samples were adjusted for cholesterol content. The 
density of the bands was determined using quantifi cation software (Image J). n≥5 samples per group 
(pooled). WT values were set at 100%.
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apoE KO transplanted mice, while spleens from ABCA1 KO transplanted mice 
stained mildly for lipids (Fig. 4). In contrast, mice transplanted with ABCA1/apoE 
dKO bone marrow exhibited a heavily lipidated spleen, predominantly in the red 
pulp, explaining the large increase in size. To further investigate the splenic lipid 
composition, we isolated the lipid content and measured FC, CE and TG levels. In 
agreement with the lipid accumulation visualized by oil red-O staining, spleens 
Figure 4. Increased CE content in enlarged spleens from ABCA1/apoE dKO transplanted LDLr KO mice. 
Representative cross sections of spleens from the bone marrow transplanted LDLr KO mice stained with 
oil red-O for the detection of neutral lipids and counterstained with hematoxylin (magnifi cation 50x; 
upper panels). Spleen weight to bodyweight ratio is increased in ABCA1/apoE dKO transplanted LDLr KO 
mice (A). Values represent the means of n≥11 mice ± SEM per group. Quantifi cation of cholesteryl ester 
(CE) and free cholesterol (FC) content of spleens (B and C, respectively). Values represent the means of 
n≥5 mice ± SEM per group. **p<0.01, ***p<0.001 as compared to WT transplanted controls.
Figure 5. Analysis of atherosclerosis in the aortic arch of bone marrow transplanted LDLr KO mice after 9 
weeks of HF/HC diet feeding. Relative plaque area in the aortic arch was quantifi ed en face calculating the 
ratio of atherosclerotic lesions to the surface of the entire aortic arch (left panel). Representative pictures 
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from dKO transplanted mice revealed a 3.0-fold (p<0.01; Fig. 4B) increase in CE 
levels. FC and TG content of these spleens were not signifi cantly different. No lipid 
accumulation was observed in other tissues.
Increased atherosclerosis in ABCA1/apoE dKO transplanted LDLr KO mice
After feeding the HF/HC diet for 9 weeks, lesion development in the aortic 
root and the aortic arch of the transplanted animals was analyzed. En face 
quantifi cation of the aortic arch lesions revealed a 2.5-fold increased lesion 
area in single KO transplanted mice compared to WT controls (p<0.01; WT: 
9±2%, ABCA1 KO: 23±3%, apoE KO: 22±1%) and a striking 3.8-fold increase 
in dKO transplanted animals (p<0.01; dKO: 34±5%; Fig. 5). In agreement, 
quantifi cation of the lesion sizes in oil red-O-stained sections of the aortic root 
showed that single deletion of macrophage ABCA1 or apoE led to a 1.6- or 1.9-
fold increase in the mean atherosclerotic lesion size, respectively, compared to 
lesions in WT transplanted animals (341±20×103 µm2 in mice reconstituted with 
ABCA1 KO bone marrow and 402±78×103 µm2 in animals transplanted with apoE 
KO bone marrow, compared to 211±20×103 µm2 in mice reconstituted with WT 
Figure 6. Analysis of atherosclerosis in the aortic root of bone marrow transplanted LDLr KO mice after 9 
weeks of HF/HC diet feeding. Quantifi cation of atherosclerotic lesion sizes in the aortic root and TC levels 
in bone marrow transplanted LDLr KO mice after 9 weeks of HF/HC diet feeding (A). Lesion size divided 
by TC levels show cholesterol independent effects on lesion development (B). Representative cross-
sections, stained with oil red-O (magnifi cation 50×; lower panels). Values are the means of 10 aortic root 
sections of individual mice (n≥11 mice ± SEM per group. **p<0.01, ***p<0.001 as compared to WT 
transplanted controls, #p<0.05 as compared to ABCA1 KO transplanted animals. 
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bone marrow; Fig. 6A). This however failed to reach statistical significance by 
ANOVA. As the current study consisted of four groups, ANOVA is the appropriate 
test to check for significant differences. Previous studies,3,12,13 however, used two 
groups (WT vs. KO), which only required a t-test. When the same t-test is used, 
both ABCA1 KO and apoE KO transplanted animals showed a significant increase 
in atherosclerotic lesion size compared to mice reconstituted with WT bone 
marrow (p<0.001 and p=0.042, respectively). Combined deletion of both ABCA1 
and apoE in bone marrow-derived cells in LDLr KO mice induced a significant 3.1-
fold (p<0.001; ANOVA) increase in the mean atherosclerotic lesion size compared 
to WT transplanted animals (650±94×103 µm2 compared to 211±20×103 µm2). 
In addition, the lesion size in the dKO transplanted animals was also significantly 
larger compared to mice transplanted with single ABCA1 KO or apoE KO bone 
marrow (1.9- and 1.6-fold, respectively; p<0.01; ANOVA).
No differences in macrophage content in the aortic root plaques were observed 
(WT: 143±19×103 µm2, ABCA1 KO: 136±19×103 µm2, apoE KO: 198±27×103 
µm2, dKO: 139±21×103 µm2). As expected, the collagen content was 
significantly increased in plaques from dKO transplanted mice, indicating more 
advanced lesions (p<0.01 to single KO transplanted mice and WT controls (WT: 
3.3±1.2×103 µm2, ABCA1 KO: 6.8±1.8×103 µm2, apoE KO: 3.6±0.8×103 µm2, 
dKO: 26±9.3×103 µm2).
Interestingly, although single deletion of macrophage ABCA1 or apoE showed a 
comparable increase in atherosclerotic lesion development, TC levels between 
these groups were dramatically different (Fig. 6A). In humans, TC levels are 
correlated with atherosclerosis and are therefore a widely accepted risk factor 
for atherosclerotic disease.24 To adjust for cholesterol exposure, we divided 
the atherosclerotic lesion size by TC concentrations (Fig. 6B). As a result, the 
corrected atherosclerotic lesion size of ABCA1 transplanted mice was 3.1-fold 
increased compared to WT controls, underscoring the important anti-atherogenic 
role for macrophage ABCA1 in atherosclerotic lesion development. Furthermore, 
since TC levels did not differ between apoE KO transplanted mice and WT 
controls, the corrected lesion size also showed a similar anti-atherogenic role 
for macrophage apoE. Importantly, dKO transplanted mice displayed a 4.3-fold 
increased lesion development compared to WT controls after TC adjustment.
To examine the relative contribution of both genes to atherosclerotic lesion 
development, independent of effects on TC levels, two-way ANOVA was used 
on the corrected atherosclerosis data to analyze possible interactions between 
macrophage ABCA1 and apoE expression. The regular P value was used to 
express the significance of the effect of apoE deletion on ABCA1 and vice versa, 
whereas the interaction P value shows the independent effects of both genes on 
atherosclerotic lesion development. This test showed highly independent effects 
of ABCA1 or apoE deletion in bone marrow-derived cells on atherosclerotic 
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lesion formation (Fig. 6B). The apoE gene accounted for 10% of the variation 
(p=0.0008), whereas the ABCA1 gene contributed 59% to the total variation 
(p<0.0001). In agreement, no interaction (p=0.37) was observed, suggesting 
that single deletion of ABCA1 or apoE induces atherosclerosis, independent 
of cholesterol levels. Moreover, atherosclerotic lesion development in dKO 
transplanted mice is an additive, independent effect of the single deletions of 
ABCA1 and apoE.
In vitro cellular cholesterol efflux
Combined deletion of macrophage ABCA1 
and apoE resulted in a significant increase in 
atherosclerotic lesion development. Moreover, 
spleens of these mice were significantly 
enlarged and enriched in CE content. To 
determine whether these effects were 
caused by a defect in the ability to transport 
cholesterol out of the cells to exogenous 
lipid acceptors, an in vitro cholesterol 
efflux assay to BSA, apoA-I, and HDL was 
performed. In line with previous results,5 
deletion of macrophage apoE resulted in an 
impaired cholesterol efflux to BSA (41%, 
p<0.001; Fig. 7A) emphasizing its ability 
to promote the efflux of cellular cholesterol 
in the absence of extracellular acceptors. 
Similarly, a 35% decreased cholesterol 
efflux to BSA was observed with ABCA1 
KO and dKO cells (p<0.001). As expected, 
cholesterol efflux to apoA-I was completely 
inhibited when macrophages lacking ABCA1 
were used (p<0.001; Fig. 7B). ABCA1 KO 
macrophages also exhibited a 47% decreased 
efflux capacity to HDL (p<0.001; Fig. 7C). In 
agreement with previous data,5,12 deficiency 
of apoE in macrophages resulted in a small 
but significant decrease in cholesterol efflux 
to both apoA-I (16%, p<0.001), and HDL 
(21%; p<0.001). However, surprisingly, 
no additional effect of apoE deficiency was 
observed on cholesterol efflux to HDL in the 
absence of macrophage ABCA1, suggesting 
Figure 7. In vitro cellular cholesterol 
efflux. Cholesterol efflux from bone 
marrow-derived macrophages (BMDM) to 
BSA (A), apoA-I (10 mg/mL; B) and HDL 
(50 mg/mL; C) was determined after 24h. 
Data are expressed as the percentage of 
radioactivity released into the medium. 
Values represent the means of n≥3 
mice ± SEM per group. ***p<0.001 as 






























































































that efflux induced by endogenously produced apoE requires ABCA1 expression. It 
also indicates that the enlarged lipidated spleen and the enhanced atherosclerotic 
lesion development specifically observed in dKO transplanted mice cannot be 
explained by additional effects on the cholesterol efflux mechanisms.
Increased expression of hepatic and systemic pro-inflammatory 
cytokines
In order to further investigate the possible mechanisms regarding the increased 
atherosclerotic lesion development in ABCA1/apoE dKO transplanted mice, we 
quantified mRNA expression levels of the inflammatory molecules TNFα and IL-6 
in the liver. Surprisingly, we found highly increased TNFα (3.0-fold; p<0.05; 
Fig. 8A) and IL-6 (4.3-fold; p<0.001; Fig. 8B) expression levels, indicating an 
enhanced inflammatory status of these animals. In addition, we analyzed both 
pro- and anti-inflammatory cytokines in the circulation, including TNFα, IFNγ, 
IL-6 and IL-10. Whereas TNFα, IFNγ, and IL-10 concentrations were too low to be 
detected in the serum of these animals, a major increase in the secretion of the 
pro-inflammatory cytokine IL-6 in ABCA1 KO transplanted animals was observed 
(p<0.05; Fig. 8C), which was even further enhanced in dKO transplanted animals 
(3.1-fold as compared to ABCA1 KO transplanted animals; p<0.05). Serum IL-6 is 
generally considered a systemic inflammatory marker. As a result, the observed 
elevated IL-6 levels indicate an intensified inflammatory environment which, 
at least partly, contributed to the observed increase in atherosclerotic lesion 
development.
Figure 8. Hepatic gene expression levels and circulating IL-6 levels. mRNA expression of TNFα (A), and 
IL-6 (B) in liver from bone marrow transplanted LDLr KO mice. Gene expression analysis was performed 
by RT-PCR. Values are relative to the average expression of housekeeping genes and expressed as 
fold induction compared to WT transplanted controls. Values are mean ± SEM, n≥3 mice per group as 
compared to WT. Increased circulating IL-6 levels in LDLr KO mice transplanted with ABCA1/apoE 
dKO bone marrow (C). Serum from the transplanted LDLr KO mice was collected at 17 weeks after 
transplantation including 9 weeks of WTD feeding. Values are mean ± SEM, n≥8 mice per group. 
*p<0.05, **p<0.01, ***p<0.001 as compared to WT transplanted controls. #p<0.05 as compared to 
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Discussion
Although the functions of macrophage ABCA1 and apoE in the development of 
atherosclerosis have been studied extensively,3-5,12-15 their potential combined 
role in atherosclerotic lesion development is still unexplored. In the present 
study, we show that macrophage ABCA1 and apoE independently protect against 
atherosclerotic lesion formation, when normalized for serum cholesterol exposure.
ABCA1 is known to facilitate cholesterol efflux to lipid-poor apolipoproteins.6 As 
a result, cholesterol efflux to apoA-I was completely abolished upon deletion of 
ABCA1 in macrophages. Macrophages do not produce apoA-I, but, apoE secreted 
by macrophages10 is able to induce efflux of cholesterol both in the presence 
and absence of extracellular cholesterol acceptors (e.g. apoA-I or HDL),11 which 
is confirmed in this study. Interestingly, no added effect on cholesterol efflux 
was observed in dKO macrophages compared to ABCA1 deficient macrophages, 
indicating that endogenously produced apoE requires ABCA1 to facilitate 
cholesterol efflux.
Nonetheless, spleens of ABCA1/apoE dKO transplanted mice were enlarged 
due to severe CE accumulation. In agreement with the current study, several 
publications have shown increased lesion development in ABCA1 KO transplanted 
mice, despite a clear reduction in serum cholesterol levels.3,23,25 Interestingly, TC 
levels in serum were markedly increased upon combined deletion of macrophage 
ABCA1 and apoE as compared to single deletion of ABCA1 in macrophages. This 
thus leads to ABCA1 deficiency - a defect in cholesterol efflux - combined with 
elevated serum total cholesterol levels. Therefore, the observed enlargement and 
CE accumulation of spleens from dKO transplanted mice are most likely the result 
of enhanced lipid uptake due to the increased TC pressure from the circulation. In 
agreement with this hypothesis, less lipid accumulation and no changes in spleen 
size were observed in single KO transplanted animals.
In the current study, transplanted LDLr KO mice were fed a HF/HC diet for 9 
weeks to induce increased serum cholesterol levels. A minimum serum cholesterol 
concentration of >300 mg/dL is required for the development of experimental 
atherosclerosis in LDLr KO mice.26 Single deletion of macrophage ABCA1 or 
apoE led to a comparable increase of atherosclerotic lesion development. 
However, circulating TC levels were over 2-fold higher in apoE KO transplanted 
animals compared to ABCA1 KO transplanted mice. Accordingly, although the 
absolute lesion size did not differ between both genotypes, the lesions adjusted 
for serum total cholesterol exposure showed the high relative importance of 
ABCA1 deficiency for determining atherosclerosis susceptibility. Strikingly, 
despite the fact that single macrophage apoE deficiency did not alter serum TC 
concentrations, dKO transplanted mice had significantly higher TC levels than 
chapter 384
single macrophage ABCA1 KO transplanted animals.
We previously found that circulating apoE levels can be influenced by macrophage 
ABCA1 deficiency.3 In addition, ABCA1 was shown to promote macrophage apoE 
secretion in primary human monocyte-derived macrophages and THP-1 cells.9 
However, in the present study, the amount of apoE on VLDL and LDL particles 
was not reduced upon transplantation of apoE or ABCA1 deficient bone marrow 
into LDLr KO mice, indicating no direct quantitative effects of macrophage ABCA1 
deficiency on apoE availability.
To get insight into the mechanisms behind the altered TC levels, key genes 
involved in lipoprotein metabolism were analysed in liver. Of all genes analysed 
only LPL was found to be differentially expressed in liver. Therefore, it is tempting 
to speculate that the lower serum TC levels in ABCA1 KO transplanted animals 
might be the result of the observed increase in hepatic LPL expression levels. 
LPL is essential for the lipolysis of lipoproteins. Induction of LPL leads to rapid 
clearance of VLDL and chylomicrons.27 Therefore, the observed attenuation of LPL 
expression in the dKO transplanted mice as compared to ABCA1 KO transplanted 
animals might have contributed to the increased TC levels.
Besides the general significance of serum TC levels, the distribution over the 
different lipoproteins in the circulation can vary greatly, thereby changing its 
impact on atherosclerotic lesion development. Non-HDL is considered to have 
a pro-atherogenic function, whereas HDL - involved in RCT  acts as an anti-
atherogenic lipoprotein.2,28,29 Serum lipoprotein distribution analysis revealed 
that dKO transplanted mice not only showed an increase in the pro-atherogenic 
non-HDL cholesterol levels, but also exhibited a decrease in anti-atherogenic 
HDL cholesterol which will probably also have contributed to the enhanced lesion 
development in the dKO transplanted animals.
Two-way ANOVA analysis showed that the effects of ABCA1 and apoE on lesion 
development, when normalized for serum TC levels, were independent of each 
other. This is surprising since apoE can induce cholesterol efflux via ABCA1 and 
our in vitro studies using the single and dKO macrophages clearly showed that 
ABCA1 is required to induce efflux via endogenously produced apoE.
Importantly, ABCA1/apoE dKO transplanted mice exhibited a large induction of 
the pro-inflammatory cytokines IL-6 and TNFα in the liver. In addition, serum 
IL-6 levels were also highly increased in these animals, indicating an enhanced 
inflammatory status of these animals. The pro-inflammatory cytokine IL-6 is 
reported to promote endothelial dysfunction, smooth muscle cell proliferation and 
migration as well as recruitment and activation of inflammatory cells.30 Moreover, 
it induces the formation of macrophage-derived foam cells; a key feature of early 
and advanced atherosclerotic lesion formation.31
In conclusion, LDLr KO mice transplanted with either ABCA1 or apoE KO 
bone marrow exhibited a distinct increase in atherosclerosis compared to WT 
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transplanted animals. Importantly, combined deletion of macrophage ABCA1 
and apoE results in a defect in cholesterol efflux and, compared to ABCA1 
KO transplanted mice, elevated serum total cholesterol levels, and enhanced 
systemic and hepatic inflammation, together resulting in the observed augmented 
atherosclerotic lesion development.
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Objective: ATP-binding cassette transporter G1 (ABCG1) and 
apolipoprotein E (apoE) play a role in macrophage cholesterol efflux and 
consequently the development of atherosclerosis. A possible interaction 
between ABCG1 and apoE in cholesterol efflux was postulated, but the 
potential combined action of these proteins on atherosclerotic lesion 
formation is unclear.
Methods: LDL receptor knockout (KO) mice were transplanted with bone 
marrow from ABCG1/apoE double KO (dKO) mice, their respective single 
knockouts, and wild-type (WT) controls and challenged with a high-fat/
high-cholesterol diet for 6 weeks to induce atherosclerosis.
Results: No differences were found in serum lipid levels. The mean 
atherosclerotic lesion area in dKO transplanted animals (187±18×103 
μm2) was 1.4-fold (p<0.01) increased compared to single knockouts 
(ABCG1 KO: 138±5×103 μm2; apoE KO: 131±7×103 μm2) and 1.9-
fold (p<0.001) as compared to WT controls (97±15×103 μm2). In vitro 
cholesterol efflux experiments established that combined deletion of 
ABCG1 and apoE leads to a larger attenuation of macrophage cholesterol 
efflux to HDL as compared to single knockouts.
Conclusions: Single deletion of macrophage ABCG1 or apoE does 
lead to a moderate non-significant increase in atherosclerotic lesion 
development as tested by ANOVA, while combined deletion of ABCG1 and 
apoE induces a more dramatic and significant increase in atherosclerosis. 
Our results indicate an additive, independent effect for both macrophage 
ABCG1 and apoE in the prevention of atherosclerosis.
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Introduction
Reverse cholesterol transport (RCT) is a pathway by which excess cholesterol is 
transported from macrophages in the vessel wall to the liver for excretion, thereby 
preventing atherosclerosis.1,2 We have shown that the ATP-binding cassette 
(ABC) transporters A1 and G1 are key players in the efflux of cholesterol from 
macrophages, the first step in RCT and the protection against atherosclerosis.3-6 
ABCA1 was shown to facilitate cholesterol efflux to lipid-poor apolipoproteins,7 
while ABCG1 mediates the efflux of cellular cholesterol to mature high-density 
lipoproteins (HDL).8,9
In addition to ABCA1 and ABCG1, apoE secretion by macrophages facilitates 
cellular cholesterol efflux.10 Interestingly, apoE enhances cholesterol efflux both 
in the presence and absence of extracellular cholesterol acceptors.11 Yet, both 
pro- and anti-atherogenic functions for macrophage apoE in atherosclerosis 
have been described.12-15 We12 and others13 showed that mice transplanted with 
apoE KO bone marrow developed 4- to 10-fold larger atherosclerotic lesions as 
compared to WT transplanted animals. In contrast, a significant decrease in lesion 
development is also described.14,15
Von Eckardstein et al. observed that apoE secretion from macrophages is 
promoted by ABCA1 and ABCG1.16 Whereas ABCA1 is well known for its anti-
atherogenic function, the putative role of macrophage ABCG1, like macrophage 
apoE, is under debate. Recently, we showed that specific deletion of ABCG1 in 
bone marrow-derived cells in LDL receptor knockout (LDLr KO) mice resulted in 
increased atherosclerosis after feeding a Western-type diet.17 In contrast to our 
findings, Baldán et al. and Ranalletta et al. unexpectedly showed a decrease 
in lesion size in LDLr KO mice transplanted with ABCG1 KO bone marrow upon 
feeding a high-fat/high-cholesterol diet. Despite a comparable setup of the latter 
studies, Baldán et al. proposed accelerated apoptosis of ABCG1 KO macrophages 
to explain the decrease in the atherosclerosis.18 Ranalletta et al., however, 
observed a compensatory upregulation of apoE secretion by ABCG1 deficient 
macrophages. This latter study thus suggests a protective role for macrophage 
apoE in the absence of macrophage ABCG1.19
To investigate the possible interaction between ABCG1 and apoE in macrophage 
cholesterol efflux and their combined roles in atherogenesis, we generated 
mice deficient for both ABCG1 and apoE and performed a bone marrow 
transplantation (BMT) experiment in LDLr KO mice. Our results evidently show 
that transplantation of LDLr KO mice with either ABCG1 KO or apoE KO bone 
marrow resulted in a moderate increase in atherosclerotic lesion development, 
while combined deletion of ABCG1 and apoE in bone marrow-derived cells led to 
an additional more dramatic increase in atherosclerosis. These results indicate an 
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additive, independent protective effect for both ABCG1 and apoE in macrophage 
cholesterol efflux and atherosclerotic lesion development.
Methods
Animals and bone marrow transplantation
ABCG1 KO (Deltagen Inc., San Carlos, CA, USA) and apoE KO (The Jackson Laboratory, Bar Harbor, 
ME, USA) mice (both more than seven times backcrossed onto a C57BL/6J background) were mated 
to generate F1 heterozygotes. Genotyping for ABCG1 and apoE was performed according to the 
protocol from Deltagen and The Jackson Laboratory, respectively. Heterozygote F1 animals were 
crossbred to obtain the ABCG1 KO/apoE WT (ABCG1 KO), ABCG1 WT/apoE KO (apoE KO), ABCG1 KO/
apoE KO (dKO), and ABCG1 WT/apoE WT (WT) mice, which were used as donors for the bone marrow 
transplantation. Homozygous LDL receptor knockout (LDLr KO) mice were obtained from The Jackson 
Laboratory as mating pairs and bred at the Gorlaeus Laboratories, Leiden, The Netherlands. Bone marrow 
transplantations to male LDLr KO mice were performed as described.17 Briefly, irradiated recipients 
received 5×106 bone marrow cells by intravenous injection into the tail vein. After a recovery period 
of 8 weeks, the animals were challenged with a high-fat/high-cholesterol (HF/HC; 1.25% cholesterol, 
21% fat) diet for 6 weeks to induce atherosclerotic lesion development. This diet has previously been 
used in experiments concerning the role of macrophage ABCG1.18 During the experiment, serum lipid 
analysis was performed as described previously.17 Upon sacrifice, at 14 weeks after transplantation, the 
hematologic chimerism of the transplanted LDLr KO mice was determined in genomic DNA from bone 
marrow by PCR analysis as described above (Fig. 1). Animal experiments were approved by the Ethics 
Committee for Animal Experiments of Leiden University and performed at the Gorlaeus Laboratories of 
the Leiden/Amsterdam Center for Drug Research in accordance with the National Laws.
Histological analysis of the aortic root and other organs
To analyze the development of atherosclerosis at the aortic root, transplanted LDLr KO mice were 
euthanized after 6 weeks of feeding the HF/HC diet. Mean lesion area in the aortic root was calculated 
as described.17 Sections were stained immunohistochemically for the presence of macrophages using 
a rat MoMa-2 antibody, dilution 1:50 (Serotec Ltd., Oxford, UK). Masson Trichrome-staining (Sigma 
Diagnostics, USA) was used to determine the collagen content of the plaque. Terminal deoxynucleotidyl 
transferase-mediated dUTP nick end-labeling (TUNEL) staining of lesions was performed to determine 
the rate of apoptosis of macrophages in the atherosclerotic lesions using the In Situ Cell Death Detection 
Kit (Roche Diagnostics). In addition, 7 μm cryosections of formalin-fixed lung, liver, and spleen from the 
transplanted LDLr KO mice were prepared and stained for lipid accumulation using oil red-O.
 Targeted allele  
 Wild-type allele 
ABCG1 KO apoE KOWT dKO
ABCG1 PCR apoE PCR
ABCG1 KO apoE KOWT dKO
Figure 1. Verification of success of bone marrow transplantation. To verify whether reconstitution with 
donor hematopoietic cells was successful, PCR amplification of both ABCG1 (left) and apoE (right) wild-
type and targeted alleles was performed using genomic DNA isolated from bone marrow at 14 weeks after 
transplantation.
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In vitro studies using bone marrow-derived macrophages
Cellular cholesterol efflux from acetylated LDL-loaded bone marrow-derived macrophages, stimulated 
with 22-hydroxycholesterol (10 μmol/L) and 9-cis retinoic acid (1 μmol/L) was performed as described.6 
Cholesterol efflux is expressed as the percentage of total cell cholesterol present in the medium after 24h. 
Total RNA was isolated from the bone marrow-derived macrophages using the guanidinium thiocyanate 
(GTC) method.20 The resulting cDNA was used in the real time PCR assay to perform gene expression 
analysis21 (Table 1). Protein expression was measured by Western blot analysis as described.6
Statistical analysis
Statistically significant differences among the means of the different populations were tested using 
analysis of variance (ANOVA) and the unpaired Student's t-test (GraphPad InStat and Prism software). 
The Student-Newman-Keuls multiple comparison test was performed after ANOVA. Two-way ANOVA was 
used to check possible interactions. The probability level (alpha) for statistical significance was set at 
0.05. Results are expressed as an average ± SEM.
Results
Effect of macrophage ABCG1 and apoE disruption on plasma lipid levels in 
LDLr KO mice
Cholesterol levels were measured at 8 weeks (chow diet) and at 14 weeks (HF/
HC diet, containing 1.25% cholesterol and 21% fat) after BMT (Table 2). On a 
chow diet, no effect of ABCG1 or ABCG1/apoE deletion in bone marrow-derived 
Table 1. Sequences of the PCR primers used for the bone marrow-derived macrophage real-time PCR.
Table 2. Serum lipid levels were measured at 8 weeks (chow diet) and 14 weeks (HF/HC diet) after 
transplantation.
Data represent mean ± SEM of ≥12 mice. Non-HDL indicates the total of VLDL and LDL concentrations. 

















WT 8 Chow 86±3 285±8 n.d. n.d. 114±11 146±10
14 HF/HC 228±23 1018±104 92±12 755±65 89±15 864±73
ABCG1 KO 8 Chow 80±3 269±5 n.d. n.d. 100±7 154±7
14 HF/HC 239±19 1031±77 99±8 717±42 76±6 1064±114
apoE KO 8 Chow 74±3 243±8* n.d. n.d. 101±9 140±6
14 HF/HC 197±15 881±71 120±11 731±27 60±10 865±107
dKO 8 Chow 85±4 273±11 n.d. n.d. 96±7 173±6
14 HF/HC 219±12 960±58 129±12 724±26 63±8 1128±97
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cells was observed on serum total cholesterol (TC) and free cholesterol (FC) 
levels. Deletion of apoE in bone marrow-derived cells, however, resulted in a 14% 
decrease of TC (p<0.05, compared to WT), whereas FC levels were not affected.
After 6 weeks of feeding the HF/HC diet, the serum TC levels in both the control 
and the experimental groups increased ≈3-fold, but no significant differences 
were observed between the groups. Also no significant differences were visible 
in triglyceride (TG) and phospholipid (PL) levels both before and after feeding the 
HF/HC diet (Table 2).
The distribution of TC among serum lipoproteins was analyzed by liquid 
chromatography. The lipoprotein profiles of the different groups showed no 
significant differences on both chow diet and the HF/HC diet (Fig. 2). After the 
switch to the HF/HC diet, non-HDL cholesterol (VLDL and LDL cholesterol) 
increased ≈6-fold in all groups, while there was no significant change of HDL 
cholesterol. Thus, no significant effect of transplantation of ABCG1 KO and apoE 
KO bone marrow to LDLr KO mice on the cholesterol distribution among the 
different lipoproteins was observed.
Increased atherosclerosis in ABCG1/apoE dKO transplanted LDLr KO 
mice
After feeding the HF/HC diet for 6 weeks, lipid accumulation in different organs 
and lesion development in the aortic root (Fig. 3) of the transplanted animals were 
analyzed. dKO transplanted mice and, in agreement with our previous study,17 
ABCG1 KO transplanted animals showed accumulation of large amounts of lipids 
in the lungs as compared to WT transplanted mice. No differences between the 
groups were seen in oil red-O-stained sections of the spleen and liver (Fig. 4).
Figure 2. Distribution of serum cholesterol over the different lipoprotein fractions on (A) chow diet and 
after 6 weeks on (B) the HF/HC diet. Values are the means of ≥6 samples for each group. No significant 











































Quantifi cation of the lesion sizes in oil red-O-stained sections of the aortic root 
showed that single deletion of macrophage ABCG1 or apoE led to a 1.4-fold 
increase in the mean atherosclerotic lesion size as compared to lesions in WT 
transplanted animals, which however failed to reach statistical signifi cance by 
ANOVA (138±5×103 μm2 in mice reconstituted with ABCG1 KO bone marrow 
and 131±7×103 μm2 in animals transplanted with apoE KO bone marrow, 
compared to 97±15×103 μm2 in mice reconstituted with WT bone marrow) (Fig. 
3). As the current study consisted of four groups, ANOVA is the appropriate 
test to check for signifi cant differences. Previous studies,12,13,17-19 however, used 




































Figure 3. Analysis of atherosclerosis in cross-sections at the aortic root after 6 weeks on the HF/HC 
diet. Left: representative cross-sections, stained with oil red-O, Masson Trichrome, and MoMa-2 for 
detection of lipids, collagen, and macrophages, respectively (magnifi cation 50×). Right: quantifi cation 
of atherosclerotic lesion sizes. Values are the means of 10 aortic root sections of individual mice (≥12 
animals per group). *p<0.01, **p<0.001.




Figure 4. Oil red-O-stained cryostat sections of lung, liver, and spleen of LDLr KO mice transplanted with 
bone marrow of WT, ABCG1 KO, apoE KO, and dKO mice after 6 weeks on HF/HC diet (magnifi cation 50×). 
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two groups (WT vs. KO), which only required a t-test. When the same t-test is 
used, both ABCG1 KO and apoE KO transplanted animals showed a signifi cant 
increase in atherosclerotic lesion size as compared to mice reconstituted with 
WT bone marrow (p=0.016 and p=0.046, respectively). Combined deletion of 
both ABCG1 and apoE in bone marrow-derived cells in LDLr KO mice induced a 
signifi cant 1.9-fold (p<0.001; ANOVA) increase in the mean atherosclerotic lesion 
size as compared to WT transplanted animals (187±18×103 μm2 compared to 
97±15×103 μm2). In addition, the lesion size in the dKO transplanted animals 
was also signifi cantly larger as compared to mice transplanted with single ABCG1 
KO or apoE KO bone marrow (both 1.4-fold; p<0.01; ANOVA). Two-way ANOVA 
was used to check possible interactions between macrophage ABCG1 and apoE 
in atherosclerotic lesion development. The p-value for was used to express the 
signifi cance of the effect of apoE deletion on ABCG1 and vice versa, whereas 
the interaction p-value was considered to explore the independent effects of 


























































































































Figure 5. mRNA (A) and protein expression (B) of ABCG1, apoE and ABCA1 in bone marrow-derived 
macrophages of transplanted animals. Gene expression analysis was performed by RT-PCR. Values are 
relative to the average expression of the housekeeping gene GAPDH and expressed as fold induction 
compared to WT transplanted animals. Western blots (C) were used for protein quantifi cation. Values 
are mean ± SEM, n≥3 mice per group for mRNA expression. n=4 mice per group (pooled) for protein 
expression. *p<0.001.
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independent effects of ABCG1 (p=0.0004) or apoE (p=0.0019) deletion in bone 
marrow-derived cells on atherosclerotic lesion formation. Moreover, no interaction 
(p=0.55) was observed, suggesting that the effect of combined deletion of ABCG1 
and apoE on atherosclerotic lesion development is an additive, independent effect 
of the single deletions of ABCG1 and apoE.
Masson Trichrome staining showed no collagen accumulation in the plaques which 
is indicative for early lesions. In agreement, MoMa-2-stained sections showed 
that the lesions fully consisted of macrophages. No difference was observed 
between lesions of the different groups of 
mice. Furthermore, TUNEL-staining revealed 
no differences in apoptosis (WT: 4.4±1.0%, 
ABCG1 KO: 3.2±0.3%, apoE KO: 5.0±0.5% 
and dKO: 5.7±1.5%, n=9 per group). Deletion 
of ABCG1 or apoE in bone marrow-derived 
cells thus did not affect the composition of the 
lesions.
In vitro cellular cholesterol effl ux 
and mRNA and protein expression in 
macrophages lacking ABCG1 and apoE
Combined deletion of macrophage ABCG1 
and apoE resulted in a signifi cant increase 
in atherosclerotic lesion development. 
To determine whether the enhanced 
atherosclerosis susceptibility of animals 
transplanted with ABCG1 KO, apoE KO, or 
dKO bone marrow was due to a (combined) 
defect in the transport of cholesterol out 
of the cells to exogenous lipid acceptors, a 
cholesterol effl ux assay to apoA-I and HDL 
was performed. To investigate if deletion of 
ABCG1 and/or apoE in macrophages leads to 
compensatory upregulation of other cholesterol 
effl ux mechanisms, we also determined the 
expression of apoE, ABCG1 and ABCA1 in 
bone marrow-derived macrophages from the 
different groups of transplanted animals.
Deletion of macrophage apoE resulted in a 
complete absence of apoE mRNA (p<0.001) 
and protein expression (Fig. 5). In addition, 
cells of ABCG1 KO transplanted animals 
Figure 6. In vitro cholesterol mass effl ux 
from BMDM to 0,1% BSA (A), 10µg/
mL apoA-I (B), and 10 µg/mL HDL (C) 
for 24h. n≥3 mice per group. *p<0.01, 
**p<0.001, #p<0.001 compared to 
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revealed a major decrease of ABCG1 mRNA (p<0.01) and protein expression. 
Remarkably, in contrast to apoE, ABCG1 mRNA was not completely absent. The 
observed low level of ABCG1 mRNA expression measured in the bone marrow-
derived macrophages of mice transplanted with single ABCG1 KO bone marrow is 
probably just due to technical variations. This is also strengthened by the fact that 
in cells from mice transplanted with dKO bone marrow no residual apoE or ABCG1 
mRNA and protein expression was observed (Fig. 5). Alternatively, although 
unlikely, during the culture period of the bone marrow-derived cells a positive 
selection of low numbers of ABCG1 positive cells, that could not be detected by 
the PCR on the genomic bone marrow, might have occurred.
ApoE KO transplanted animals showed a significant decrease of ABCG1 mRNA 
(p<0.001), whereas ABCG1 protein expression was not affected. In agreement, 
apoE mRNA and protein expressions were not affected upon deletion of ABCG1.
No differences between the groups were observed in ABCA1 mRNA and protein 
levels. Moreover, both single and combined deletion of ABCG1 and apoE on 
macrophages resulted in a slight decrease on apoA-I-mediated cholesterol 
efflux as compared to WT macrophages (Fig. 6B). However, no differences were 
observed between single KO and dKO transplanted macrophages.
ApoE is known to facilitate cholesterol efflux in the absence of extracellular 
cholesterol acceptors.11 In agreement, cholesterol efflux to BSA is highly 
decreased in apoE deficient macrophages compared to WT macrophages 
(p<0.001; Fig. 6A). Macrophages of both ABCG1 KO and apoE KO mice did 
show a significant decrease (p<0.01) in HDL-mediated efflux (22% and 33%, 
respectively, compared to WT; Fig. 6C). Furthermore, a striking 61% decrease 
(p<0.001) in HDL-mediated efflux was observed upon combined deletion of 
ABCG1 and apoE in macrophages. Two-way ANOVA analysis showed clear 
independent effects of ABCG1 (p=0.0032) and of apoE (p=0.0004). Moreover, 
no interaction (p=0.65) between 
both genes was observed, suggesting 
independent roles for ABCG1 and 
apoE in cellular cholesterol efflux to 
HDL.
Interestingly, a clear inverse 
relationship is apparent when the 
HDL-mediated cholesterol efflux 
percentages of the different groups 
are plotted against the atherosclerotic 
plaque size measured at the aortic 
root (R2=0.94, p=0.0298; Fig. 7), 
suggesting that HDL efflux is an 
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Figure 7. Lower panels: HDL-mediated cholesterol 
efflux plotted against atherosclerotic plaque size 
resulted in a clear inverse correlation. n≥3 mice 
per group for cholesterol efflux towards HDL, n≥12 
mice per group for atherosclerotic lesion size.
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Discussion
Both ABCG1 and apoE have been implicated in cholesterol efflux and the 
development of atherosclerosis.22,23 The importance of macrophage apoE 
secretion for the pro- or anti-atherogenic effect of macrophage ABCG1, however, 
was still poorly understood. In the current study, we, for the first time provide 
evidence for an additive, independent role of ABCG1 and apoE in macrophage 
cholesterol efflux and atherosclerosis.
ABCG1 exports cellular cholesterol to mature HDL.23 As a result, ABCG1 
deletion results in a decreased cholesterol efflux from macrophages to HDL. In 
contrast, apoE facilitates cholesterol efflux both in the presence and absence of 
extracellular sterol acceptors (e.g. HDL or apoA-I),11 which is underlined by this 
study. Cholesterol efflux to BSA was highly impaired in macrophages lacking 
apoE. Furthermore, apoE KO macrophages showed a clear, significant reduction in 
cholesterol efflux from macrophages to HDL. Macrophages lacking apoE showed a 
significant reduction in ABCG1 mRNA expression. We cannot completely exclude 
that this might have partially contributed to observed reduced efflux to HDL. 
However, reduced ABCG1 expression was not observed on protein level. Moreover, 
upon combined deletion of ABCG1 and apoE on macrophages, a larger attenuation 
of cholesterol efflux to HDL was observed, indicating that both ABCG1 and apoE 
stimulate cholesterol efflux to HDL. Two-way ANOVA analysis indicated that the 
effects of ABCG1 and apoE on HDL-mediated efflux were independent of each 
other, in accordance with the independent additive role of macrophage ABCG1 and 
apoE in the protection against atherosclerosis.
Despite the clear role of ABCG1 in HDL-induced macrophage cholesterol efflux, 
the effect of single ABCG1 deletion on atherosclerotic lesion development 
has been under debate.24 In a previous study using a mild Western-type diet, 
we showed that macrophage ABCG1 deficiency led to a 1.4-fold increase in 
atherosclerosis in hyperlipidemic LDLr KO mice compared to WT transplanted 
mice.17 In contrast to this finding, Baldán et al. found a decrease in atherosclerotic 
lesion development upon disruption of macrophage ABCG1 in LDLr KO mice fed 
a more extreme HF/HC diet, containing 21% fat and 1.25% cholesterol.18 This 
diet induced a rise in plasma cholesterol levels to >1000 mg/dL. The observed 
decrease in lesion size in ABCG1 KO transplanted animals was, at least partly, 
attributed to accelerated apoptosis of macrophages in the absence of ABCG1. 
Despite the use of a similar HF/HC diet in the current study and corresponding 
plasma cholesterol levels (>1000 mg/dL), again a 1.4-fold increase in 
atherosclerotic lesion development was observed in the ABCG1 KO transplanted 
animals, suggesting that differences in the diet cannot fully explain the differential 
outcome of the studies. Furthermore, we observed no differences in apoptosis 
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in lesions of the ABCG1 KO transplanted animals. In agreement with the current 
study and our earlier observations, we5 and others25 also recently showed a 
distinct atheroprotective role for ABCG1 by transplanting ABCA1/ABCG1 dKO bone 
marrow into LDLr deficient mice.
In addition to the observed moderate increase in atherosclerotic lesion 
development upon disruption of macrophage ABCG1, transplantation of apoE KO 
bone marrow to LDLr KO mice also led to a slight increase in atherosclerotic lesion 
development, compared to WT transplanted animals. This is in agreement with 
previous studies from our group12 and Fazio et al.13 that showed a 4- or 10-fold 
increase, respectively, in atherosclerotic lesion development in C57BL/6J mice 
upon disruption of macrophage apoE.
Most importantly, we show for the first time that transplantation of bone marrow 
deficient for both ABCG1 and apoE into LDLr KO mice resulted in an additive, 
independent increase in atherosclerotic lesion development, compared to single 
ABCG1 KO or apoE KO transplanted mice. Despite a significant decrease of ABCG1 
mRNA in apoE KO macrophages, no compensatory upregulations of apoE and 
ABCG1 protein expression were observed in bone marrow-derived macrophages 
from single ABCG1 KO and apoE KO transplanted animals, respectively, indicating 
independent cholesterol efflux pathways for both ABCG1 and apoE.
The observed significant increase in lesion size in the dKO transplanted animals 
is thus likely a specific effect of the combined deletion of these two macrophage 
cholesterol efflux genes. Indeed, in the in vitro cholesterol efflux studies also the 
largest significant reduction in cholesterol efflux to HDL was observed in dKO 
macrophages. Furthermore, a clear significant inverse relation between HDL-
mediated efflux and the size of atherosclerotic plaques was apparent.
In conclusion, a moderate increase in atherosclerotic lesion development is 
observed in LDLr KO mice transplanted with either ABCG1 KO or apoE KO bone 
marrow compared to WT transplanted animals, while combined deletion of ABCG1 
and apoE in bone marrow leads to a more dramatic increase in atherosclerosis. 
These results indicate an additive, independent effect for both ABCG1 and apoE in 
macrophage cholesterol efflux and atherosclerotic lesion development.
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Objective: As ABCG1 plays a role in cholesterol efflux, macrophage 
ABCG1 expression has been suggested to protect against 
atherosclerosis. However, we and others observed varying effects of 
ABCG1 deficiency on atherosclerotic lesion size. The objective of this 
study was to define the effect of ABCG1 deficiency during atherosclerotic 
lesion progression in LDL receptor knockout (LDLr KO) mice.
Methods: ABCG1/LDLr dKO and LDLr KO littermates were fed a 
Western-type diet for 10 and 12 weeks in order to study the effect of 
ABCG1 deficiency in the exponential phase of atherosclerotic lesion 
formation. 
Results: At 10 weeks of diet feeding, a significant 1.5-fold increase 
in early atherosclerotic lesion size (130±12x103 μm2) was observed 
in ABCG1/LDLr KO mice compared to LDLr KO mice (88±11x103 μm2; 
p<0.05). Interestingly, in more advanced lesions, induced by 12 weeks 
of WTD feeding, ABCG1/LDLr dKO mice showed a significant 1.7-fold 
decrease in atherosclerotic lesion size (160±20x103 μm2 vs 273±19x103 
μm2 in control mice; p<0.01), indicating that in the ABCG1/LDLr dKO 
mice progression of lesion formation is retarded as compared to LDLr KO 
mice. In addition, correlation analysis performed on published studies 
and the current study showed a high correlation when the fold increase/
decrease in atherosclerotic lesion size of ABCG1 KO mice compared 
to ABCG1 WT mice is plotted against the atherosclerotic lesion size of 
ABCG1 WT mice.
Conclusions: It appears that the effect of ABCG1 deficiency on lesion 
development in LDLr KO mice depends on the stage of atherogenesis, 
whereby the absence of ABCG1 leads to increased lesions at sizes 
<167x103 μm2 while in more advanced stages of atherosclerosis 




Reverse cholesterol transport (RCT), defined as the transport of excess cholesterol 
from peripheral tissues back to the liver for biliary excretion, plays an important 
protective role in the development of atherosclerosis.1,2 Previously, the ATP-
binding cassette (ABC) transporter A1 has been reported to play an important role 
in the prevention of atherosclerosis by facilitating cholesterol and phospholipid 
efflux from macrophages to lipid-poor or lipid-free apolipoprotein A-I (apoA-I).3-6 
Similar to ABCA1, ABCG1 has been implicated in macrophage lipid homeostasis by 
actively effluxing cellular cholesterol to mature HDL.7,8 As cholesterol efflux from 
macrophages is an important protective mechanism to prevent excessive cellular 
lipid accumulation, macrophage ABCG1 expression was expected to protect 
against atherosclerosis. However, independent groups have shown that ABCG1 
might be pro-atherogenic as well as anti-atherogenic. 
Previously, we reported that both total body and macrophage ABCG1 deficiency 
led either to a significantly increased susceptibility to atherosclerotic lesion 
development,9,10 or to no change in lesion size.11,12 In contrast, the group of 
Edwards et al.13,14 and Tall et al.15 reported decreased atherosclerosis in LDL 
receptor knockout (LDLr KO) mice transplanted with ABCG1 KO bone marrow 
cells, which was explained by accelerated apoptosis of ABCG1 KO macrophages 
or compensatory upregulation of ABCA1 expression and apoE secretion in 
macrophages lacking ABCG1. Thus, the role of macrophage ABCG1 in the 
development of atherosclerosis still remains uncertain.
The aim of this study was to assess the effect of ABCG1 deficiency on different 
stages of atherosclerotic lesion development and especially during the exponential 
phase of lesion formation in order to unravel the mechanism by which ABCG1 
deficiency affects atherogenesis. Upon atherogenic diet feeding, total body ABCG1 
KO mice develop only modest atherosclerotic lesions. Therefore, we generated 
ABCG1/LDLr double knockout (ABCG1/LDLr dKO) mice to perform this lesion 
stage dependent study. 
Methods
Animals
ABCG1 heterozygous mice, obtained from Deltagen Inc., San Carlos, CA, USA were cross-bred with 
single LDLr KO mice to generated ABCG1/LDLr dKO mice on a C57BL/6J background (8 generations). 
Genotyping for ABCG1 and LDLr was performed according to the protocol from Deltagen and The Jackson 
Laboratory, respectively. Male ABCG1/LDLr dKO and LDLr KO mice were maintained on sterilized regular 
chow diet containing 4.3% (w/w) fat and no cholesterol (RM3, Special Diet Services, Witham, UK) and 
water ad libitum. At 10 weeks of age, the diet was switched to a high-fat, high-cholesterol Western-
type diet (WTD), containing 15% (w/w) cocoa butter and 0.25% (w/w) cholesterol (Diet W; Abdiets, 
Woerden, The Netherlands) to induce atherosclerotic lesion development. After 10 and 12 weeks of diet 
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feeding, mice were sacrificed after an overnight fasting period. Animal experiments were performed at 
the Gorlaeus Laboratories of the Leiden/Amsterdam Center for Drug Research in accordance with the 
National Laws. All experimental protocols were approved by the Ethics Committee for Animal Experiments 
of Leiden University. 
Serum lipid analyses
Serum concentrations of free cholesterol were determined by enzymatic colorimetric assays with 0.048 
U/mL cholesterol oxidase (Sigma) and 0.065 U/mL peroxidase (Roche Diagnostics, Mannheim, Germany) 
in reaction buffer (1.0 KPi buffer, pH=7.7 containing 0.01 M phenol, 1 mM 4-amino-antipyrine, 1% 
polyoxyethylene-9-laurylether, and 7.5% methanol). For the determination of total cholesterol, 0.03 U/
mL cholesteryl esterase (Seikagaku, Tokyo, Japan) was added to the reaction solution. Absorbance was 
read at 490 nm. Precipath (standardized serum; Roche Diagnostics) was used as internal standard. The 
distribution of cholesterol over the different lipoproteins in serum was determined by fractionation of 25 µl 
of serum of each mouse using a Superose 6 column (3.2 x 300 mm, Smart-System; Pharmacia, Uppsala, 
Sweden). Total cholesterol content of the effluent was determined as described above.
ApoE western blot
The circulating apoE levels were measured by analyzing 0.1μl of  serum on a 10% SDS-page gel. ApoE 
was detected using a rabbit-anti-mouse apoE polyclonal antibody (Abcam) as primary antibody and goat-
anti-rabbit IgG (Jackson ImmunoResearch) as a secondary antibody. 
Histological analysis of the aortic root and other organs
To analyze lipid accumulation in the different tissues, mice were sacrificed after 10 and 12 weeks of 
WTD feeding. After in situ perfusion, organs were excised and stored in 3.7% neutral-buffered formalin 
(Formal-fixx; Shandon Scientific Ltd, UK). Atherosclerotic lesion development was quantified in oil red-
O-stained cryosections of the aortic root of LDLr KO and ABCG1/LDLr dKO mice using the Leica image 
analysis system, consisting of a Leica DMRE microscope coupled to a video camera and Leica Qwin 
Imaging software (Leica Ltd., Cambridge, UK). Mean lesion area (in µm2) was calculated from ten 
sections at 20 μm intervals, starting at the appearance of the tricuspid valves. Sections were stained 
immunohistochemically for the presence of macrophages using a rat MoMa-2 antibody, dilution 1:50 
(Serotec Ltd., Oxford, UK). The percentage area of the lesion that is composed of macrophages was 
calculated as a ratio of the macrophage-stained area and the lesion area of one heart section per mouse 
of 7-8 mice in total. Masson Trichrome-staining (Sigma Diagnostics, USA) was used to determine the 
collagen content of the plaque. Apoptotic macrophages in atherosclerotic lesions were identified by 
terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) staining using the 
In Situ Cell Death Detection Kit (Roche Diagnostics, Mannheim, Germany). The percentage area of the 
lesion that is composed of necrotic core was calculated as a ratio of the necrotic-stained area (TUNEL-
staining positive and lack of nuclei) and the lesion area of one heart section per mouse of 7-8 mice in 
total. Corresponding sections of atherosclerotic lesions were stained immunohistochemically with a 
primary antibody specific for murine ABCA1 (Santa Cruz, Santa Cruz, CA, USA). In addition, seven μm 
cryosections of formalin-fixed lung and spleen from LDLr KO and ABCG1/LDLr dKO mice were prepared 
and stained for lipid accumulation using oil red-O staining. Hematoxylin (Sigma) was used to stain the 
nuclei in the different organs.
Cellular cholesterol efflux
Bone marrow cells, isolated from LDLr KO and ABCG1/LDLr dKO mice, were cultured for 7 days in 
complete RPMI medium supplemented with 20% fetal calf serum (FCS) and 30% L929 cell-conditioned 
medium, as the source of macrophage colony-stimulating factor (M-CSF), to generate bone marrow-
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derived macrophages. Bone marrow-derived macrophages were subsequently incubated with 0.5 µCi/mL 
3H-cholesterol in DMEM / 0.2% bovine serum albumin (BSA) for 24 hours at 37°C in 24 well tissue culture 
plates (Greiner Bio-One). To determine cholesterol loading, cells were washed 3 times with washing 
buffer (50 mmol/L Tris containing 0.9% NaCl, 1 mmol/L EDTA, and 5 mmol/L CaCl2, pH 7.4), lysed in 
0.1 mol/L NaOH, and the radioactivity was determined by liquid scintillation counting. Cholesterol effl ux 
was studied by incubation of the cells with DMEM / 0.2% BSA alone or supplemented with either 10 μg/
mL apoA-I (Calbiochem) or 50 µg/mL human HDL (density 1.063 to 1.21 g/mL), isolated according to 
Redgrave et al.15 Radioactivity in the medium and the cells was determined by scintillation counting after 
24 hours of incubation. The cholesterol effl ux percentages are calculated as the amount of radioactivity in 
the medium compared to the total amount of radioactivity measured in the medium plus the cells. Basal 
effl ux to BSA (in the absence of added acceptors) has been subtracted from the data shown.
Statistical analysis
Statistical analyses were performed using GraphPad Instat software. The probability level (alpha) for 
statistical signifi cance was set at 0.05. Results are expressed as an average ± SEM.
Results
Effect of ABCG1 defi ciency on serum lipid levels and lipid homeostasis in 
tissues
On regular chow diet, containing 4.3% fat and no added cholesterol, no signifi cant 
difference in total serum cholesterol levels were observed between LDLr KO and 
ABCG1/LDLr dKO mice (Table 1). Fractionation of serum lipoproteins, however, 
showed a moderate shift of HDL cholesterol to the LDL and VLDL fraction in 
Figure 1. Blood samples were drawn after an overnight fasting period while feeding a regular chow diet 
(A) and after 12 weeks on WTD (B). Serum samples from individual mice were loaded onto a Superose 
6 column, and fractions were collected. The distribution of cholesterol over the different lipoproteins is 
shown. Values represent the mean ± SEM of 8 mice per group. A representative immunoblot of apoE in 
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ABCG1/LDLr dKO mice (HDL: 75±4 compared to 90±3 mg/dL for LDLr KO mice, 
p<0.05; VLDL: 36±3 compared to 19±3 mg/dL, p<0.001; and LDL: 123±5 
compared to 108±4 mg/dL for LDLr KO mice; p<0.05; Table 1, Fig. 1A). To induce 
atherosclerotic lesion development, ABCG1/LDLr dKO and control mice were fed 
a WTD for 10 and 12 weeks, which induced approximately a 5-fold increase in 
serum cholesterol concentrations in both LDLr KO and ABCG1/LDLr dKO mice. 
Both after 10 weeks and 12 weeks on the WTD, total serum cholesterol levels 
did not differ between the groups. Lipoprotein profiles of mice fed the WTD for 
10 and 12 weeks were essentially identical. Therefore, the representative 12 
weeks WTD profile of ABCG1/LDLr dKO and control mice on WTD is shown in 
Figure 1B. A moderate increase in VLDL (~25%) and LDL (~23%) cholesterol 
levels was observed in ABCG1/LDLr dKO mice compared to control animals, which 
only reached significance for LDL after 12 weeks WTD feeding (p<0.01; Table 1). 
This increase in VLDL and LDL was associated with a moderate non-significant 
decrease in HDL (~16%) levels in ABCG1/LDLr dKO. Furthermore, during 
the course of the experiment, the weight gain curve did not show significant 
differences between ABCG1/LDLr dKO and LDLr KO mice both after 10 or 12 
weeks on WTD (data not shown).
ABCG1 deficiency has been shown to coincide with increased secretion of apoE 
by macrophages and elevated serum apoE levels.16 Immunoblotting for apoE was 
performed to analyse the association of ABCG1 deficiency with serum apoE levels 
of the LDLr KO mice fed WTD for 10 and 12 weeks. No significant effect of ABCG1 
deficiency was observed on serum apoE levels between the ABCG1/LDLr dKO and 
LDLr KO mice fed WTD (Fig. 1B). In addition, ABCG1 deficiency in macrophages 
has been shown to be correlated with an induction of ABCA1 expresssion.15 
However, immunohistochemical staining of aortic root cryosections showed no 
apparent increase in ABCA1 expression in macrophages located in atherosclerotic 
lesions of ABCG1/LDLr dKO mice, neither after 10 nor 12 weeks WTD feeding 
(data not shown).













LDLr KO 0 Chow 96±4 230±12 19±3 108±4 90±3
10 WTD 289±32 1030±36 361±82 369±42 58±4
12 WTD 289±16 1010±82 441±53 374±24 65±6
ABCG1/LDLr dKO 0 Chow 91±4 233±9 36±3*** 123±5* 75±4*
10 WTD 292±23 1206±107 492±81 451±33 58±6
12 WTD 332±20 1047±111 536±57 467±19** 54±5
Table 1. Serum lipid levels in ABCG1/LDLr dKO and LDLr KO control mice on chow and WTD.
Data represent the means ± SEM of 8 mice. *p<0.05, **p<0.01, ***p<0.001.
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with control mice. Both after 10 and 12 weeks of diet feeding, ABCG1 defi ciency 
resulted in accumulation of large amounts of lipids in the subpleural regions of the 
lungs (Fig. 2). In addition, spleens of ABCG1/LDLr dKO showed lipid accumulation 
in the red pulp regions, while no accumulation was observed in spleens of control 
mice (Fig. 3).
Effect of ABCG1 disruption on atherosclerotic lesion formation
To defi ne the role of ABCG1 in the exponential phase of atherogenesis, 
atherosclerotic lesion development was analyzed in the aortic root of LDLr KO and 
ABCG1/LDLr dKO mice after 10 and 12 weeks of WTD feeding. Representative 
photomicrographs of the aortic root of control mice and mice defi cient for ABCG1 









Oil red-O (10x) Oil red-O (40x)
Figure 2. Representative photomicrographs of oil red-O-stained lung sections of LDLr KO and ABCG1/
LDLr dKO mice after 10 weeks of WTD feeding at different magnifi cations (10x and 40x).
Figure 3. Representative photomicrographs of oil red-O-stained spleen sections of LDLr KO and ABCG1/
LDLr dKO mice after 10 weeks of WTD feeding at different magnifi cations (10x and 40x).
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increase in atherosclerotic lesion size was observed in the aortic root of ABCG1/
LDLr dKO mice (130±12x103 μm2 (n=8) compared to 88±11x103 μm2 (n=7 for 
LDLr KO mice; p<0.05). In vitro studies using bone marrow-derived macrophages 
of LDLr KO and ABCG1/LDLr dKO mice showed that disruption of ABCG1 results in 
a 15% decrease in cholesterol effl ux to HDL (p<0.001), whereas the cholesterol 
effl ux to apoA-I was unaffected (Fig. 4B). Additional 2 weeks of WTD feeding 
resulted in rapid progression of atherosclerotic lesion development in control 
mice (3.1-fold; Fig. 4C). Interestingly, atherogenesis in the ABCG1-defi cient mice 
LDLr KO ABCG1/LDLr dKO
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Figure 4. Atherosclerotic lesion formation was determined in the aortic root at the level of the tricuspid 
valves of LDLr KO and ABCG1/LDLr dKO mice fed a WTD for 10 and 12 weeks (separated by the dotted 
line). Mean lesion area of each individual mouse is shown (A). Representative photomicrographs of oil 
red-O-stained lesions are shown (magnifi cation 50x). Cholesterol effl ux to HDL is impaired in ABCG1-
defi cient macrophages. ApoA-I (10 µg/mL) and HDL (50 µg/mL) induced cellular cholesterol effl ux from 
3H-cholesterol-labeled bone marrow-derived macrophages of LDLr KO and ABCG1/LDLr dKO mice (B). 
Basal effl ux to BSA (in the absence of added acceptors) has been subtracted from the data shown. Values 
represent the mean ± SEM of 4 animals. Progression of atherosclerotic lesions LDLr KO and ABCG1/LDLr 
dKO mice from 10 to 12 weeks WTD feeding (C). Values represent the mean ± SEM of 7 to 9 mice. 
*p<0.05, ***p<0.001.
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appeared to be attenuated from 10 till 12 weeks and only a 1.2-fold increase in 
lesion size is noticed over this period. As a result, ABCG1-deficient mice showed 
a 1.7-fold smaller atherosclerotic lesions as compared to control mice after 12 
weeks WTD feeding (160±20x103 μm2 (n=8) compared to 273±19x103 μm2 
(n=9); p<0.01, respectively; Fig. 4A). 
Disruption of ABCG1 in LDLr KO mice also affected the composition of 
atherosclerotic lesions. Immunostaining for macrophages showed less staining in 
atherosclerotic lesions of ABCG1/LDLr dKO mice fed WTD for 10 weeks (65±2% 
of atherosclerotic area compared with 81±4% in control mice; p<0.01; Fig. 5A). 
The lower macrophage content, coincided with an almost significantly larger 
percentual necrotic core area after 10 weeks on WTD (22±5% of atherosclerotic 
area compared with 8±3% in control mice; p=0.06). Additional 2 weeks of WTD 
feeding resulted in an increase in absolute macrophage area and necrotic core 
area (Fig. 5A). However, no significant differences could be observed between 
lesions of LDLr KO and ABCG1/LDLr dKO mice. Furthermore, Masson Trichrome-
staining showed no significant differences in collagen accumulation in the 
atherosclerotic plaques between the ABCG1-deficient mice and control mice after 
10 weeks and 12 weeks of WTD feeding (data not shown).





















































































































10 wks WTD 12 wks WTD
Figure 5. Quantification of lesion macrophages and necrotic core in LDLr KO and ABCG1/LDLr dKO mice 
after 10 and 12 weeks of WTD feeding. The macrophage lesion area, necrotic core area and apoptotic 
macrophages were histochemically quantified and expressed as % area of the lesions that is composed of 
macrophages or necrotic core and/or expressed as absolute area (µm2). *p<0.05 and **p<0.01.
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is associated with increased susceptibility to apoptosis in response to the altered 
cellular lipid homeostasis,13 we examined the apoptotic macrophage content 
of the lesions by TUNEL staining. Lesions of ABCG1-deficient mice fed the WTD 
for 10 weeks showed no differences in TUNEL-positive macrophages compared 
with lesions of control mice (Fig. 5B). After 12 weeks of WTD feeding, a 2.5-
fold increase in TUNEL-positive macrophages was observed in lesions of ABCG1/
LDLr dKO mice compared with LDLr KO animals (p<0.05, n=7-8). The decrease 
in atherosclerotic lesion size observed in ABCG1/LDLr dKO mice fed WTD for 12 
weeks, might therefore be a result of increased susceptibility to apoptosis of 
ABCG1-deficient macrophages inside the lesions.
Overall, these findings indicate that the effect of ABCG1 deficiency on 
atherosclerotic lesion development depends on the stage of atherogenesis. 
ABCG1 expression protects against early atherosclerotic lesion development, by 
facilitating cholesterol efflux from macrophages to HDL. In the more advanced 
lesions, however, accumulation of cholesterol due to impaired cholesterol 
efflux from ABCG1-deficient macrophages, eventually, will lead to increased 
macrophage apoptosis and a reduced further progression of atherogenesis.
Discussion
Several pathways are involved in the efflux of cholesterol from macrophages, 
including aqueous diffusion, SR-BI mediated cholesterol efflux, efflux dependent 
on macrophage apoE secretion, and active cholesterol efflux mediated by 
ABCA1.17-19 Also ABCG1 has been implicated in cellular lipid homeostasis by its 
property to actively efflux cholesterol to mature HDL.8,20 Studies using genetically 
engineered mice have established the physiological importance of ABCG1. 
Targeted disruption of ABCG1 in mice resulted in age-related progressive 
pulmonary lipidosis when fed a regular chow diet.21-23 In addition, overexpression 
of ABCG1 protected against diet-induced lipid deposition within multiple tissues.8 
These findings imply a critical role for ABCG1 in maintaining normal lipid 
metabolism in the lung, thereby preventing inflammatory responses triggered by 
massive cholesterol and/or cholesterol metabolite accumulation. 
Although the critical role of ABCG1 in lung lipid homeostasis is clearly established, 
contradictory findings on the role of macrophage ABCG1 in the development of 
atherosclerosis have been reported by different groups/laboratories.9-14,16,24-26
Transgenic mice overexpressing human ABCG1 showed either no effect,25 or 
increased atherosclerosis.26 In contrast, Westerterp et al.27 recently reported 
an atheroprotective role of vascular ABCG1, which is likely related to its role in 
the preservation of endothelial NO synthase activity. Furthermore, independent 
studies using ABCG1-deficient mice or LDLr KO mice transplanted with bone 
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marrow cells of ABCG1-deficient mice, have shown that macrophage ABCG1 
might be proatherogenic,9,10,12 as well as antiatherogenic.13-15 In the present study, 
we show that ABCG1 deletion in LDLr KO mice can both induce and attenuate 
atherosclerotic lesion development. ABCG1 deficiency led to a significant 48% 
increase in atherosclerotic lesion size after only 10 wks Western-type diet feeding, 
while a significant 32% decrease in lesion size was observed after 12 wks WTD 
feeding. These data imply that the effect of ABCG1 deficiency on atherosclerotic 
lesion development in LDLr KO mice depends on the stage of atherogenesis. 
The reduced atherosclerosis in LDLr KO mice transplanted with ABCG1 KO 
bone marrow was suggested to be a result of compensatory induction of apoE 
secretion and ABCA1 expression in ABCG1-deficient macrophages.16 In this study, 
however, both at 10 weeks and 12 weeks of WTD feeding, ABCG1/LDLr dKO 
mice showed no compensatory increase in serum apoE levels, although ABCG1/
LDLr dKO mice did exhibit a decrease in atherosclerotic lesion development at 
12 weeks of WTD feeding. These findings are in agreement with our previous 
studies showing that apoE mRNA and protein expressions were not affected upon 
deletion of ABCG1.10,12 In addition, no apparent increase in ABCA1 expression 
was observed in ABCG1-deficient macrophages in atherosclerotic lesions of 
LDLr KO. Furthermore, accelerated apoptosis was proposed as a mechanism 
for the reduced atherosclerosis susceptibility of LDLr KO mice lacking ABCG1 
in macrophages.13,14 In agreement, in the present study, the more advanced 
atherosclerotic lesions of ABCG1/LDLr dKO mice fed WTD for 12 weeks 
were decreased in size and showed a significant increase in TUNEL-positive 
macrophages as compared to control mice. Macrophage apoptosis is an important 



































































Figure 6. Data from bone marrow transplantation studies in LDLr KO mice and total body studies by 
different groups, the present study, and unpublished studies are included (experimental details 
represented in Table 2). In early atherosclerotic lesions (lesions <167x103 μm2), ABCG1 deficiency causes 
an increase in atherosclerotic lesion development (ratio>1.0), while at atherosclerotic lesion sizes above 
167x103 μm2, enhanced apoptosis and/or compensatory mechanisms lead to retarded lesion progression. 
The numbers given in the graph represent the reference numbers of the different studies.
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feature of atherosclerotic plaque development and occurs during all stages of 
atherosclerosis with increasing frequencies as the plaque develops.28 Research 
directed at understanding the functional consequences of macrophage death in 
atherosclerosis has revealed opposing roles for apoptosis in atherosclerotic plaque 
progression. Under normal physiologic conditions, apoptotic cells are rapidly 
cleared by phagocytes, a process called efferocytosis. In early atherosclerotic 
lesions, macrophage apoptosis, followed by efferocytosis limits lesion cellularity 
and suppresses plaque progression.29,30 In advanced lesions, efferocytosis is 
defective and under these conditions macrophage apoptosis thus promotes the 
development of the necrotic core.31,32 
We show that lesions of ABCG1/LDLr dKO mice fed WTD for 10 weeks exhibited 
an increase in necrotic core in the absence of an increase in TUNEL-positive 
macrophages. In addition, in atherosclerotic lesions induced by 12 weeks WTD 
feeding, ABCG1 deficiency did not affect necrotic core size, despite a significant 
increase in macrophage apoptosis. These findings suggest that analysis 
of macrophage apoptosis is a snapshot and that there may be additional 
determinants of the lesional necrotic core area. Necrosis can be either secondary 
to apoptosis (secondary necrosis) or a primary process.33 In particular, necrotic 
cores are formed by multiple processes, including accumulation of both 
intracellular and extracellular lipid.34,35 Several studies have reported that ABCG1 
KO macrophages are indeed more susceptible to oxLDL-induced apoptosis as 
compared to ABCG1-expressing cells.13,14,36 Efflux of 7-ketocholesterol, the main 
oxysterol present in oxLDL, is completely dependent on expression of ABCG1 
and not on the expression of ABCA1.36 Therefore, ABCG1-deficient macrophages 
show increased accumulation of 7-ketocholesterol upon oxLDL loading, which is 
cytotoxic to the cell and induces accelerated apoptosis,14,36 indicating that ABCG1 
is essential for the prevention of oxLDL-induced apoptosis.
Our findings suggest that in addition to accelerated apoptosis, ABCG1 deficiency 
also leads to increased necrotic core formation. Under normal physiological 
conditions, necrotic core formation becomes more prominent in advanced lesions. 
In absence of ABCG1, however, necrotic core formation is already evident in early 
atherosclerotic lesions.
The current study indicates that the effect of ABCG1 deficiency on atherosclerotic 
lesion size depends on the stage of lesion development. To investigate the 
differential effects found on atherosclerosis susceptibility upon disruption 
of ABCG1, correlation analysis was performed on published studies of the 
independent groups, the current study, and one other unpublished study of 
our group. Experimental details of these studies are represented in Table 2. 
Although different diets and protocols were used in the individual studies, a 
high correlation (R=0.92) can be found when the fold increase/decrease in 
atherosclerotic lesion size of ABCG1 KO mice compared to ABCG1 WT mice is 
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plotted against the atherosclerotic lesion size of ABCG1 WT mice (Fig. 6). Based 
on this clear correlation, we propose that the effect of ABCG1 deficiency on lesion 
development depends on the stage of atherogenesis. In early atherosclerotic 
lesions (lesions <167x103 μm2), ABCG1 deficiency causes an increase in 
atherosclerotic lesion development (ratio>1.0), most likely as a direct result of 
the impaired cholesterol efflux to HDL in ABCG1-deficient macrophages. This 
indicates that ABCG1 expression is protective in early atherosclerotic lesion 
development. Interestingly, at atherosclerotic lesion sizes above 167x103 μm2, 
the role of ABCG1 in atherogenesis switches from anti-atherosclerotic to pro-
atherosclerotic. In more advanced lesions, the persistent impaired cholesterol 
efflux from ABCG1-deficient macrophages is likely to induce accumulation of 
(oxy)sterols, which leads to enhanced apoptosis/compensatory mechanisms and, 
subsequently, decreased atherosclerotic lesion size (ratio<1.0). Previously, we10 
also have reported a highly significant correlation when the fold increase/decrease 
in atherosclerotic lesion size of ABCG1 KO as compared with ABCG1 WT is plotted 
against total serum cholesterol whereby at about 900 mg/dL serum cholesterol a 
switch from ABCG1’s protective function to lesion formation was noticed. When 
recent published studies of the independent groups, the current study, and two 
other unpublished studies of our group are included, again a high correlation 
between the fold increase/decrease in atherosclerotic lesion size and total serum 
cholesterol is observed with a switch at 1000 mg/dL serum cholesterol from an 
atheroprotective function of ABCG1 to a proatherogenic function (p=0.0075; 
R=0.73). Therefore, under normal physiological levels of cholesterol, the role 
of ABCG1 in atherogenesis is likely to be protective. Furthermore, since higher 
serum cholesterol levels are associated with a more rapid development of 
atherosclerotic lesions, this correlation is probably also a direct effect of the stage 
of atherosclerotic lesion development. 
In conclusion, our results indicate that the effect of ABCG1 on lesion development 
depends on the stage atherogenesis, whereby the absence of ABCG1 leads 
to increased lesions at sizes <167x103 μm2 while in more advanced stages of 
atherosclerosis enhanced apoptosis and/or compensatory mechanisms lead to 
retarded lesion progression.
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Objective: The consequences of macrophage triglyceride (TG) 
accumulation on atherosclerosis have not been studied in detail so far. 
Adipose triglyceride lipase (ATGL) is the rate-limiting enzyme for the 
initial step in TG hydrolysis. Because ATGL knockout (KO) mice exhibit 
massive TG accumulation in macrophages, we used ATGL KO mice to 
study the effects of macrophage TG accumulation on atherogenesis.
Methods: Low-density lipoprotein receptor (LDLr) KO mice were 
transplanted with bone marrow from ATGL KO or wild-type (WT) mice 
and challenged with a Western-type diet for 9 weeks. 
Results: Despite TG accumulation in ATGL KO macrophages, 
atherosclerosis in ATGL KO transplanted mice was 43% reduced 
associated with decreased plasma monocyte chemoattractant protein-1 
(MCP-1) and macrophage interleukin-6 concentrations. This coincided 
with a reduced amount of macrophages, possibly because of a 39% 
increase in intraplaque apoptosis and a decreased migratory capacity of 
ATGL KO macrophages. The reduced number of white blood cells might 
be due to a 36% decreased Lin- Sca-1+ cKit+ hematopoietic stem cell 
population.
Conclusions: We conclude that the attenuation of atherogenesis in ATGL 
KO transplanted mice is due to decreased infiltration of less inflammatory 
macrophages into the arterial wall and increased macrophage apoptosis.
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Introduction
In most mammalian cells, excess neutral lipids form lipid droplets as storage 
organelles. Macrophage-derived foam cells are a hallmark of atherogenesis. 
Generally, foam cells in early atherosclerotic lesions accumulate cholesteryl esters 
(CE), whereas advanced lesions have increased concentrations of free cholesterol 
(FC), leading to macrophage apoptosis and an increased risk for plaque rupture.1-4 
Macrophages may also transform into triglyceride (TG)-rich foam cells on 
incubation with very-low-density lipoproteins.5-7 
However, the (patho)physiological consequences of TG accumulation in 
macrophages on atherogenesis have not been studied in detail so far. Unesterified 
fatty acids (NEFA) in macrophages are taken up from the plasma after hydrolysis 
of TG-rich lipoproteins by lipoprotein lipase or by absorption of albumin-bound 
fatty acids (FA). Inside the cells, FA are esterified within TG and CE, which are less 
harmful to the cells than NEFA,8,9 or routed to mitochondrial FA β-oxidation. Thus, 
CE and TG accumulation within lipid droplets might be seen as a buffer to detoxify 
excess NEFA and FC. 
Both FA and FC are released from lipid droplets by intracellular lipases. 
Adipose triglyceride lipase (ATGL) (also named patatin-like phospholipase 
domaincontaining protein-2, PNPLA2, desnutrin, and phospholipase A2ζ) plays a 
critical role in cellular lipid homeostasis because it specifically catalyzes the initial 
step in TG hydrolysis.10-12 Mice lacking ATGL exhibit massive TG accumulation in 
many tissues and cells as a consequence of defective TG hydrolysis and die from 
heart failure at an early age.13 
The importance of ATGL in macrophage TG metabolism and whether its activity 
contributes to atherogenesis in mice has not been investigated so far. Consistent 
with the hypothesis that lipase-mediated modulation of FA concentrations affects 
atherogenesis, it was reported that atherosclerosis susceptibility is increased in 
mice with high expression levels of lipoprotein lipase in macrophages and reduced 
in mice that lack lipoprotein lipase.14-16
The present study was designed to address the role of ATGL in macrophages and 
to examine the consequences of macrophage TG accumulation for atherogenesis. 
We used bone marrow transfer to investigate mechanisms by which the absence 
of macrophage ATGL may modulate atherosclerotic susceptibility. Evidence 
is provided that ATGL deficiency in macrophages and the concomitant TG 
accumulation resulted in reduced atherosclerosis in low-density lipoprotein 
receptor (LDLr) knockout (KO) mice. Downregulation of ATGL in macrophages 
might thus be an interesting and prospective strategy to attenuate early 
atherogenesis. 
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Methods
Animals and bone marrow transplantation
Female ATGL KO mice and wild-type (WT) littermates (on a C57BL/6J background) were housed and 
bred at the Medical University of Graz, Austria. Bone marrow of these mice was transplanted into female 
homozygous LDL receptor knockout (LDLr KO) mice (The Jackson Laboratory, Bar Harbor, ME,USA) as 
described previously.17 Briefly, irradiated recipients received 5x106 bone marrow cells by intravenous 
injection into the tail vein. The recipient mice were housed in sterilized filter-top cages and given 
unlimited access to food and water. They were maintained for 8 weeks on a sterilized regular chow, 
containing 4.3% (w/w) fat with no added cholesterol (RM3; Special Diet Services, Witham, UK). After 
a recovery period of 8 weeks, the animals were challenged with a Western-type diet (WTD; 0.25% 
cholesterol and 15% cocoa butter; Special Diet Services, Witham, Essex, UK) for 9 weeks to induce 
atherosclerotic lesion development. Seventeen weeks after transplantation, the hematologic chimerism 
of the transplanted LDLr KO mice was determined in genomic DNA from bone marrow by PCR analysis 
(ATGL-fwd: 5’-AGAGAGAGAAGCTGAAGCCTGG-3’; ATGL-rev: 5’-GCCAGCGAATGAGATGTTCC-3’; 
ATGL-neo: 5’-CTGCGTGCAATCCATCTTGT-3’). These experiments were performed at the Gorlaeus 
Laboratories of the Leiden/Amsterdam Center for Drug Research in accordance with the National Laws. All 
experimental protocols were approved by the Austrian Federal Ministry of Science and Research, Division 
of Genetic Engineering and Animal Experiments, Austria, and the Leiden University, the Netherlands.
Peritoneal and bone marrow-derived macrophage isolation and culturing
Peritoneal macrophages were obtained 3 days after i.p. injection of 3 ml 3% thioglycollate. Macrophages 
were cultured for 2h in DMEM / 10% LPDS / 1% penicillin / 1% streptomycin and subsequently used for 
measuring lipid parameters. To achieve foam cell formation of WT cells, macrophages were incubated 
with acetylated (ac)LDL for 24h in 24 well tissue culture plates (Greiner Bio-One). LDL was isolated from 
human plasma by density gradient ultracentrifugation and LDL was acetylated as described.18 For isolation 
of bone marrow-derived macrophages (BMDM), femurs and tibias were lavaged with phosphate-buffered 
saline (PBS). Bone marrow cells were plated in DMEM / 20% FCS / 1% penicillin / 1% streptomycin and 
differentiated into macrophages by addition of 30% L929 cell-conditioned media (as a source of M-CSF) 
for 7 days. Macrophages were incubated for 24h in the absence or presence of 50 µg/mL β-VLDL isolated 
according to Van Eck et al.19 and subsequently lysed for mRNA extraction or fixed and stained with oil 
red-O to visualize neutral lipid accumulation.
Electron microscopy
Cells were plated on a Melinex Film (Groepl, Tulln, Austria). Cells were fixed in 0.06 M phosphate buffer 
(pH 7.2) containing 2.5% glutardialdehyde for 90 min. Thereafter, cells were rinsed twice in 0.06 M 
phosphate buffer for 10 min and post-fixed in 1% osmium tetroxide in the same buffer for 1h. Then the 
cells were rinsed 4 times for 10 min in 0.06 M phosphate buffer and dehydrated in 50%, 70%, 90%, and 
100% cold acetone for 20 min each. Thereafter, cells were infiltrated by 2:1, 1:1, 1:2 mixtures of 100% 
aceton and agar 100 epoxy resin (Groepl) and pure agar 100 epoxy resin for 4h. The cells were then 
placed in agar 100 epoxy resin at RT for 8h, transferred into embedding molds and polymerized at 60°C 
for 48h. Sections (75 nm) were cut with a Reichert Ultracut S Ultramicrotome and stained with lead citrate 
(5 min) and uranyl acetate (15 min). Images were taken on a Zeiss transmission electron microscope 
equipped with a plate camera system.
Lipid analyses
Eight weeks after bone marrow transplantation, 100 μL of blood was drawn from each individual 
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mouse by tail vein bleeding after an overnight fasting period. Upon sacrifice, 17 weeks after bone 
marrow transplantation, blood was collected by retro-orbital venous plexus puncture after an overnight 
fasting period. Lipid analyses were performed as described.20 NEFA concentrations were assayed 
enzymatically (Diasys, Holzheim, Germany) according to the manufacturer’s protocol. Lipoprotein 
profiles were determined by fractionation of 50 μL of pooled serum from two mice by fast protein liquid 
chromatography (FPLC) using a Superose 6 column (3.2 × 300 mm, Smart-System; Pharmacia, Uppsala, 
Sweden). Total cholesterol (TC) and TG content of the effluent was determined as described.20
Histological analysis of the aortic root
To analyze the development of atherosclerosis at the aortic root, transplanted LDLr KO mice were 
euthanized after 9 weeks of WTD feeding. The arterial tree was perfused in situ with PBS (100 mm Hg) 
for 10 min via a cannula in the left ventricular apex. The heart plus aortic root and descending aorta were 
excised and stored in 3.7% neutral-buffered formalin (Formal-fixx; Shandon Scientific Ltd, Runcorn, UK). 
Serial sections (7 μm) of the aortic root were cut using a Leica CM3050S cryostat. The atherosclerotic 
lesion areas in oil red-O-stained cryostat sections of the aortic root were quantified using the Leica 
image analysis system, consisting of a Leica DMRE microscope coupled to a video camera and Leica 
Qwin Imaging software (Leica Ltd, Cambridge, UK). Mean lesion area (in μm2) was calculated from 10 
consecutive oil red-O-stained sections, starting at the appearance of the tricuspid valves. Sections were 
stained immunohistochemically for the presence of macrophages using a rat MoMa-2 antibody, dilution 
1:50 (Serotec Ltd, Oxford, UK). Goat anti-rat coupled to horse radish peroxidase (HRP) (1:100) (Dako, 
Glostrup, Denmark) was used as a secondary antibody and Nova red substrate (Vector Laboratories, 
Burlingame, CA, USA) was used for HRP visualization. Collagen content of the lesions was determined 
after Masson Trichrome staining (Sigma diagnostics, St Louis, MO, USA). Terminal deoxynucleotidyl 
transferase-mediated dUTP nick end-labeling (TUNEL) staining of lesions was performed to determine 
the rate of apoptosis of macrophages in the atherosclerotic lesions using the In Situ Cell Death Detection 
Kit (Roche Diagnostics, Mannheim, Germany). TUNEL-positive nuclei were visualized with Nova Red 
(Vector Laboratories), and sections were counterstained with 0.3% methylgreen. All quantifications were 
performed blinded by computer-aided morphometric analysis using the Leica image analysis system.
Western blotting analysis
Control and acLDL-loaded peritoneal macrophages were washed twice with Ripa buffer (50 mM 
Tris-HCl pH 8, 150 mM NaCl, 1% Triton X-100, 50% sodium deoxycholate) in the presence of 1 µg 
protease inhibitor cocktail (Sigma, Vienna, Austria). Forty µg of protein were separated on a 12.5% 
SDS polyacrylamide gel by electrophoresis and blotted onto nitrocellulose protran BA85 membranes 
(Whatman, Vienna, Austria). The blot was blocked with 5% BSA plus 0.1% Tween-20 and incubated 
with an anti-rabbit PARP antibody (1:800) (Cell Signaling, Vienna, Austria) and a monoclonal anti-
mouse β-actin (1:1000) (SantaCruz, Heidelberg, Germany). The blot was incubated overnight at 4°C. 
The horseradish peroxidase-conjugated goat anti-rabbit (1:5000) (Santa Cruz) and rabbit anti-mouse 
antibodies (1:1000) (Dako, Glostrup, Denmark) were visualized by enhanced chemiluminescence 
detection (ECL Plus, Amersham Biosciences, Piscataway, NJ, USA).
Cellular cholesterol efflux
BMDM were incubated with 0.5 µCi/mL 3H-cholesterol in DMEM / 0.2% fatty acid-free BSA and 30 µg/mL 
non-labeled cholesterol for 24h at 37°C in 24 well tissue culture plates (Greiner Bio-One). Cholesterol 
efflux was determined after incubating the cells in DMEM / 0.2% fatty acid-free BSA in the absence 
or presence of 10 µg/mL human apoAI (Calbiochem, La Jolla, CA, USA) or 50 µg/mL human HDL, 
isolated according to Redgrave et al.21 Radioactivity in the medium and in the cells was determined by 
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scintillation counting after 24h of incubation. Cholesterol efflux is expressed as the percentage of total 
cell 3H-cholesterol present in the medium after 24h. Basal efflux to BSA (in the absence of acceptors) has 
been subtracted from the data shown.
mRNA expression analysis by real time PCR
Total RNA from BMDM was isolated using the guanidinium thiocyanate (GTC) method22 and reverse 
transcribed using a RevertAid M-MuLV enzyme (Fermentas, Burlington, Canada). Relative mRNA 
expression was measured from the following genes: Scavenger receptor A (SR-A), scavenger receptor 
class B type 1 (SR-BI), CD36 receptor (CD36), LDLr, acyl-CoA:cholesterol acyltransferase 1 (ACAT-
1), ATP-binding cassette sub-family A member 1 (ABCA1), ABCG1, apolipoprotein E (apoE), hormone 
sensitive lipase (HSL), lipoprotein lipase (LPL), lysosomal acid lipase (LAL) and diacylglycerol 
acyltransferase 1 (DGAT1). The mRNA expression levels were assessed by real time PCR (ABI PRISM 
7500; Applied Biosystems, Foster City, CA, USA) using SYBR Green technology (Applied Biosystems). 
Housekeeping genes were used as a control. Primer sequences are available upon request.
Determination of cytokine concentrations
Murine monocyte chemoattractant protein 1 (MCP-1) serum levels were assayed using an MCP-1 instant 
ELISA kit (eBioscience, Hatfield, UK) according to the manufacturer’s protocol. IL-6 concentrations (R&D 
Systems Europe Ltd, Abingdon, UK) were determined in supernatants of peritoneal macrophages cultured 
in 6-well plates in 300 µL DMEM / 10% LPDS for 24h in the absence or presence of LPS (10 ng/mL).
White blood cell content andturnover analyses
White blood cell (WBC) repopulation and content was analyzed using an automated Sysmex XT-2000iV 
Veterinary Haematology analyzer (Sysmex Corporation, Kobe, Japan). To determine the life span of WBC 
in the circulation, blood cells were biotinylated by tail vein injection of 3 mg EZ-Link Sulfo-NHS-biotin 
(Pierce, Rockford, IL, USA) dissolved in 0.2 mL PBS. After 2.5h circulation, 20 µL of blood was collected in 
ethylene diaminetetraacetic acid (EDTA)-coated tubes (Sarstedt, Numbrecht, Germany) by tail bleeding 
for 100% biotinylated WBC determination. Twenty µL blood was drawn at set timepoints for turnover 
analysis. Blood samples were washed twice with erythrocyte lysis buffer to eliminate all red blood 
cells and WBC were subsequently labeled with phycoerythrin-conjugated streptavidin (1:500 in PBS) 
(Molecular Probes; Eugene, OR, USA) and analyzed by flow cytometry (FACS Canto II; BD Biosciences, 
Mountain View, CA, USA). WBC survival was determined by assessment of the number of biotinylated 
(streptavidin-labeled) WBC relative to the starting level, which was 100% biotinylated.
Flow cytometry
Using sterile procedures, bone marrow cells were obtained by flushing femoral and tibial bones from 
donor mice with PBS. Subsequently, erythrocytes were lysed and the cells were analyzed on a FACS Canto 
II (BD Biosciences, Mountain View, CA). As a control, total bone marrow cells were gated for the life-gate, 
based on forward scatter/side scatter characteristics. The Lin-, Sca-1+, cKit+ (LSK) population within the 
bone marrow was assessed by flow cytometry. Bone marrow cells were stained with FITC-labeled anti-
CD3, anti-CD4, anti-CD8, anti-CD11b, anti-CD19, anti-GR-1, anti-NK1.1, and anti-TER119 (all obtained 
from eBioscience, Vienna, Austria). These markers are further designated as Lin-. The LSK population is 
assigned as the Lin- population, double positive for PE-labeled anti-LY6A/E (Sca-1) and APC-labeled anti-
CD117 (c-Kit) (both obtained from eBioscience).
Cell migration
Cell migration assays were performed using 24-well transwell plates (5 μm pore size; Corning, Vienna, 
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Austria). Two million peritoneal macrophages were added into the upper wells. The lower chambers were 
fi lled with DMEM / 10% LPDS and 50 ng/mL MCP-1. After 4h at 37°C, macrophages were analyzed by 
FACS (BD Biosciences, San Jose, CA, USA) after staining with anti-F4/80 antibody (eBioscience, Vienna, 
Austria).
Statistical analysis
Statistically signifi cant differences among the means of different populations were tested using the 
unpaired Student’s t-test (GraphPad InStat and GraphPad Prism software). The probability level (alpha) 
for statistical signifi cance was set at 0.05. Results are expressed as an average ± SEM.
Results
Increased lipid accumulation in ATGL KO macrophages
First, we determined the presence of ATGL in bone marrow-derived macrophages 
(BMDM) and foam cells by real-time polymerase chain reaction. ATGL was highly 
expressed in both BMDM and β-very low-density lipoprotein-loaded macrophage 
foam cells (ATGL cycle threshold: 22.1±0.31 and 22.5±0.51 respectively; β-actin 
cycle threshold: 17.0±0.55 and 17.0±0.23 respectively). No signifi cant difference 
in ATGL expression was found between non-loaded BMDM and β-very low-density 
lipoprotein-loaded foam cells, indicating that ATGL expression was not regulated 
by lipid loading. 
Next, we visualized lipid droplets in peritoneal macrophages of WT and ATGL 
KO mice by electron microscopy. For comparison, acetylated low-density 
lipoprotein (ac-LDL)-laden macrophage foam cells were included. As expected, 
Figure 1. ATGL defi ciency induces lipid droplet accumulation in macrophages. Electron micrographs 
(scale bar, 2 μ m) and lipid parameters of isolated peritoneal macrophages (A). BMDM from transplanted 
mice (B). Images show representative oil red-O-stained BMDM. Magnifi cation 50×. ***p<0.001.
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ac-LDL-laden macrophage 
foam cells showed extensive 
lipid droplet accumulation and 
a drastic increase in cellular CE 
concentrations (Fig. 1A). ATGL KO 
BMDM accumulated lipid droplets 
even in the absence of exogenous 
lipid loading, whereas this was 
not observed in the majority of 
the WT macrophages (Fig. 1A). 
Lipid droplet formation in the 
ATGL KO macrophages was the consequence of a 3-fold (p<0.001) increase in 
cellular TG concentrations compared with WT macrophages (Fig. 1A). FC and CE 
concentrations were comparable in macrophages from both groups. 
To investigate the consequences of macrophage ATGL defi ciency on 
atherosclerotic lesion formation, we performed a transplantation of ATGL KO 
and WT bone marrow into LDLr KO mice. Successful hematologic chimerism 
of transplanted LDLr KO mice was confi rmed by polymerase chain reaction 
analysis of genomic DNA from bone marrow isolated 17 weeks after BMT (Fig. 
2). As expected, BMDM from LDLr KO mice transplanted with WT bone marrow 
(WT→LDLr KO mice) exhibited no lipid accumulation. In contrast, BMDM from 
ATGL KO→LDLr KO mice accumulated cytoplasmic lipid droplets (Fig. 1B), 
indicative of the reduced TG hydrolytic capacity and TG accumulation in ATGL KO 
macrophages. 
Serum lipid levels are comparable in ATGL KO→LDLr KO and WT→LDLr KO 
mice
After BMT, mice were fi rst fed a chow diet for 8 weeks followed by WTD feeding 
for another 9 weeks. Lipid parameters in WT→LDLr KO and ATGL KO→LDLr KO 
mice were measured at the end of each diet regimen. No signifi cant differences 
in plasma TG and NEFA concentrations were observed (Table 1). WTD feeding 









Figure 2. Successful disruption of ATGL by bone 
marrow transplantation. RT-PCR on genomic DNA of 














WT 8 Chow 63±2 31±9 131±9 n.d.
17 WTD 274±16 1516±96 104±10 1.07±0.03
ATGL KO 8 Chow 78±5* 357±22 161±16 n.d.
17 WTD 315±15 1711±87 133±18 1.06±0.03
Table 1. Plasma lipid parameters of overnight fasted ATGL KO→LDLr KO and WT→LDLr KO mice. After 
BMT, mice were fi rst fed chow diet for 8 weeks (wks) followed by WTD feeding for another 9 weeks. The 
data represents mean ± SEM of  ≥ 9 mice.
n.d. not determined; *p<0.05.
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resulted in a general ≈5-fold increase in cholesterol levels in both groups. The 
distribution of total cholesterol (TC) and TG within serum lipoproteins was 
analyzed by fast protein liquid chromatography. Lipoprotein profi les of ATGL 
KO→LDLr KO and WT→LDLr KO mice were similar on both chow diet (data not 
shown) and WTD (Fig. 3). WTD feeding led to ≈6-fold increased non-high-density 
lipoprotein cholesterol (very low-density lipoprotein and low-density lipoprotein 
cholesterol) in both groups, whereas no signifi cant changes in high-density 














































ATGL KO→LDLr KO 
WT→LDLr KO 
ATGL KO→LDLr KO 
Figure 3. Unchanged lipoprotein profi les in ATGL KO→LDLr KO mice. Fifty µl pools of 2 mice per genotype 
after 9 weeks of WTD feeding were subjected to FPLC. Distribution of serum TC and TG concentrations in 
25 µl fractions was determined enzymatically. Values represent the means of n≥5 samples per group.
ATGL KO→ 
LDLr KO





































































































Figure 4. Decreased lesion formation and increased apoptosis in aortic root sections of ATGL KO→LDLr 
KO mice. Representative slides were stained with oil red-O, MoMa-2, Masson trichrome, and terminal 
deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) for the detection of lipids, macrophages, 
collagen, and apoptosis, respectively. Arrows indicate apoptotic nuclei. Oil red-O and lesion composition 
data represent the means of 10 or 5 aortic root sections of n≥9 or n≥5 animals ± SEM, respectively. 
Magnifi cation  5× (apoptosis:  40×). *p<0.05; ***p<0.001.
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lipoprotein cholesterol concentrations were observed. In addition, lipoprotein-
associated TG distribution was similar in both groups. 
Decreased atherosclerosis in ATGL KO→LDLr KO mice
Visual inspection of oil red-O-stained aortic root sections showed a clear 
difference in lesion formation between WT→LDLr KO and ATGL KO→LDLr KO 
animals (Fig. 4). Quantitative analysis of lesion areas revealed a 43% reduction in 
the mean atherosclerotic lesion size in ATGL KO→LDLr KO mice compared with WT 
controls (373±37×103 μm2 and 652±40×103 μm2, respectively; p<0.001). 
Masson Trichrome staining, which was used to identify collagen in the lesion, 
showed no differences between WT→LDLr KO and ATGL KO→LDLr KO mice 
(68±15×103 μm2 and 37±16×103 μm2, respectively; Fig. 4). To visualize 
macrophages inside the lesions, sections were stained with the monocyte/
macrophage-specific MoMa-2 antibody (Fig. 4). In agreement with the observed 
attenuation in lesion size, quantification of the macrophage area revealed a 37% 
decrease in macrophage content between lesions of WT→LDLr KO (238±36×103 
μm2) and ATGL KO→LDLr KO mice (151±17×103 μm2; p<0.001; Fig. 4). Next, we 



































































































































Figure 5. Reduced WBC and MCP-1 concentration in ATGL KO→LDLr KO mice. Macrophage migration 
assays were performed using transwell plates (A). Values represent the means of n=3 ± SEM. WBC (B), 
neutrophils (C), monocytes (D), and lymphocytes (E) in plasma were determined with a hematology 
analyzer. MCP-1 concentrations were determined by ELISA (F). Values represent the means of n≥9 ± 
SEM. *p<0.05; **p<0.01.  
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by ATGL deficiency. As shown in Fig. 5A, ATGL KO macrophages had a 56% 
(p<0.05) reduced migration rate compared with WT macrophages. In addition, 
terminal deoxynucleotidyl transferase dUTP nick-end labeling staining showed a 
marked 39% increase in intraplaque apoptosis in ATGL KO→LDLr KO compared 
with WT→LDLr KO animals (11.7±1.5% and 7.1±1.4%, respectively; p<0.05; 
Fig. 4). 
To further investigate the observed increase in intraplaque apoptosis, we 
measured poly(ADP-ribose) polymerase (PARP) protein expression in ATGL 
KO macrophages. During apoptosis, full-length PARP (116 kDa) is cleaved by 
caspase-3, and possibly other caspases, into an 89-kDa fragment.23 In agreement 
with the observed increase in intraplaque apoptosis, a clear shift toward 
cleaved PARP was detectable in ATGL KO 
macrophages, which is not the case in WT 
macrophages (Fig. 6). This finding indicates 
that macrophages deficient for ATGL are 
more prone to apoptosis. 
Cellular cholesterol efflux and mRNA 
levels of genes implicated in lipid 
homeostasis in ATGL KO macrophages
To study the effect of ATGL deficiency on 
the cholesterol transport from macrophages 
to exogenous lipid acceptors, we measured 
cholesterol efflux to apolipoprotein A-I 
and high-density lipoprotein. Cholesterol 
efflux toward apolipoprotein A-I and high-
density lipoprotein was comparable in BMDM 
isolated from both genotypes (Fig. 7). 














































Figure 6. Decreased IL-6 production in ATGL KO macrophages. A, PARP protein expression in peritoneal 
macrophages of ATGL KO and WT mice. B, IL-6 concentrations were determined by ELISA in supernatants 






















ATGL KO→LDLr KO 
Figure 7. Decreased IL-6 production in 
ATGL KO macrophages. PARP protein 
expression in peritoneal macrophages 
of ATGL KO and WT mice (A). IL-6 
concentrations were determined by 
ELISA in supernatants of peritoneal 
macrophages (B). Values represent 
the means of n≥3 ± SEM. *p<0.05; 
**p<0.01.
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chain reaction to investigate whether lack of ATGL in macrophages resulted in 
compensatory upregulation of genes involved in TG hydrolysis (HSL, LPL, LAL) 
and biosynthesis (DGAT-1) or cholesterol uptake (SR-A, SR-BI, CD36, LDLr), 
esterification (ACAT-1), and efflux (ABCA1, ABCG1, SR-BI, apoE). We found a 
1.6-fold upregulation of CD36 (p<0.05) but no significant differences in mRNA 
expression of other genes (data not shown), indicating that ATGL deficiency does 
not affect macrophage cholesterol homeostasis, TG synthesis, and expression of 
other lipases. 
Attenuated production of the proinflammatory cytokine interleukin-6 in 
ATGL KO macrophages
Because inflammation is a critical process in atherogenesis, we measured 
interleukin-6 (IL-6) concentrations in the supernatant of peritoneal macrophages 
cultured in the absence or presence of lipopolysaccharide (Fig. 6B). Basal and 
lipopolysaccharide-stimulated IL-6 concentrations were significantly lower in 
ATGL KO macrophages compared with WT macrophages (30% (p<0.05) and 20% 
(p<0.01), respectively). 
Reduced circulating number of WBC and plasma MCP-1 levels in ATGL 
KO→LDLr KO mice challenged with WTD
On a regular chow diet, no differences in WBC counts were observed. After 9 
weeks of WTD feeding, the amount of circulating WBC, however, was 39% lower in 
ATGL KO→LDLr KO mice (2.35±0.24×109/L) compared with WT→LDLr KO animals 
(3.87±0.33×109/L; p<0.01; Fig. 5B). Challenging the mice with WTD is thus 
essential for the observed reduction in WBC counts on disruption of ATGL in bone 
marrow-derived cells. This decrease was caused by a 49% decrease in neutrophils 

































Figure 8. Decreased LSK population in ATGL KO→LDLr KO mice. Dot plots show representative examples 
of the LSK population within the bone marrow (Lin- cells, double positive for anti-LY6A/E (Sca-1) and 
anti-CD117 (c-Kit)). The right panel shows the percentage of LSK cells within the Lin- population. Values 
represent the means of n =5 ± SEM. *p<0.05.
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decrease in monocytes (WT, 0.34±0.05×109/L; ATGL KO, 0.15±0.04×109/L; 
p<0.05; Fig. 5D). We also observed a significant 29% reduction in lymphocytes 
(WT, 2.20±0.20×109/L; ATGL KO, 1.56±0.16×109/L; p<0.05; Fig. 5E). In 
addition, monocyte chemoattractant protein-1 (MCP-1) concentrations were 66% 
lower in ATGL KO→LDLr KO mice (74±19 pg/mL) compared with WT→LDLr KO 
mice (220±35 pg/mL; p<0.01; Fig. 5F). 
Unchanged WBC half-life in the circulation and decreased LSK population 
in bone marrow of ATGL KO→LDLr KO mice
To further investigate the apparent decrease in WBC in ATGL KO→LDLr KO 
mice, circulating WBC were biotinylated to measure their half-life. WBC of ATGL 
KO→LDLr KO mice had a half-life of 96±2.2 hours compared with 99±3.9 hours 
for WT→LDLr KO animals. These data indicate that the WBC half-life cannot 
account for the observed decrease in the total number of WBC in ATGL KO→LDLr 
KO mice. 
Therefore, next, we measured the LSK population representing hematopoietic 
stem and multipotential progenitor cells in the bone marrow. Hematopoietic stem 
and multipotential progenitor cells are capable of extensive self-renewal and are 
responsible for the production of WBC.24-26 No differences were observed in the 
Lin− population between groups. However, ATGL KO→LDLr KO mice exhibited a 
significant 36% decrease in LSK cells within the Lin− population as compared with 
WT→LDLr KO mice (p<0.05; Fig. 8), indicating a decreased WBC production from 
the bone marrow. 
Discussion
ATGL is expressed at high levels in macrophages and foam cells, raising 
the possibility that it might affect atherosclerosis. Similar to other tissues, 
the absence of ATGL in macrophages resulted in increased intracellular TG 
concentrations. Generally, macrophage-derived foam cells are filled with CE, 
which are hydrolyzed by the action of a neutral CE hydrolase resulting in the 
release of FC. ATGL KO macrophages, however, accumulated TG even in the 
absence of exogenous lipid loading, resulting in a cell morphology resembling 
macrophage foam cells.27 CE and FC concentrations were unchanged compared 
with control cells. Therefore, ATGL KO macrophages represent a perfect tool 
to elucidate the in vivo consequences of TG accumulation in macrophages 
on atherosclerosis. Thus, we created mice chimeric for macrophage ATGL 
expression by transplanting LDLr KO mice with bone marrow from ATGL KO and 
WT littermates. BMT results in the replacement of tissue macrophages, including 
those of the arterial wall that are involved in fatty streak formation.28
In contrast to total body ATGL KO mice,13 no differences were found in plasma 
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TG, TC, or NEFA concentrations between ATGL KO→LDLr KO and WT→LDLr KO 
mice after feeding the WTD. Thus, lack of ATGL in bone marrow-derived cells 
has no significant influence on serum lipid levels. In line with biochemical data 
determined in peritoneal ATGL KO macrophages, distinct neutral lipid loading 
was observed in BMDM of ATGL KO→LDLr KO and WT→LDLr KO mice. Despite 
increased macrophage TG concentrations, atherosclerotic lesion formation in the 
aortic root was highly attenuated in ATGL KO→LDLr KO mice. The integrity of the 
fibrous cap overlying lipid-rich cores fundamentally determines the stability of 
an atherosclerotic lesion.29 Quantification of the collagen content in the lesions 
revealed no differences between the groups, indicating that the plaque stability 
was unchanged. However, the observed reduction in atherosclerotic lesion 
formation coincided with increased apoptosis, which might limit lesion cellularity 
and the progression of early lesions in these animals.1,30 During atherosclerotic 
lesion development, macrophages inside the lesion undergo a steady rate of 
apoptosis. In early lesions, apoptotic macrophages are rapidly cleared by other 
macrophages, thereby limiting lesion progression.31,32 In advanced atherosclerotic 
lesions, however, impaired clearance of apoptotic macrophages leads to 
secondary necrosis and the formation of a necrotic core.33 Depending on the stage 
of lesion development, increased apoptosis can thus either enhance or suppress 
lesion development. The increased apoptosis rate observed in lesions of mice 
lacking macrophage ATGL might have prevented the formation of an advanced 
lesion and, at least in part, might have contributed to the observed attenuation 
of lesion development. In isolated ATGL KO macrophages, a shift toward cleaved 
PARP (a marker for apoptosis) was evident, indicating that macrophages lacking 
ATGL are more susceptible to apoptosis, which explains the observed increase in 
intraplaque apoptosis. 
Leukocytes play an essential role in all stages of atherosclerotic lesion 
development.34-36 In humans, increased levels of neutrophils and monocytes 
induce the progression of atherosclerosis.37,38 Conversely, a reduced number of 
circulating monocytes inhibits the initiation and progression of atherosclerotic 
lesions in mice lacking endogenous macrophage colony-stimulating factor 
production.39,40 Importantly, we found a greatly decreased number of circulating 
WBC in WTD-fed ATGL KO→LDLr KO mice. No differences were observed in the 
half-life of WBC of ATGL KO→LDLr KO mice compared with WT→LDLr KO controls, 
suggesting that the reduced number of circulating WBC is merely the consequence 
of impaired cellular recruitment from the bone marrow. 
WBC are produced in the bone marrow by hematopoietic stem and multipotential 
progenitor cells. Virtually all hematopoietic stem and multipotential progenitor 
cell activity is contained within the LSK population in the bone marrow.24-26 
Remarkably, the LSK population from ATGL KO→LDLr KO mice is decreased 
compared with WT→LDLr KO controls, indicating a reduction in WBC-producing 
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cells. This phenomenon most likely contributed to the observed attenuation in 
circulating WBC. 
Furthermore, the production of the proinflammatory cytokine IL-6 was markedly 
reduced in ATGL KO macrophages. IL-6 is one of the most important mediators of 
inflammation because it promotes migration as well as recruitment and activation 
of inflammatory cells. Although ATGL KO macrophages exhibited a decreased IL-6 
production on lipopolysaccharide stimulation, basal IL-6 production was already 
mitigated in ATGL KO macrophages, indicating an impaired proinflammatory 
IL-6 signaling. It is generally accepted that inflammatory responses contribute 
to the development of atherosclerosis. Interestingly, recently Koliwad et al. also 
found that overexpression of macrophage diacylglycerol acyltransferase-1, which 
catalyzes the final step in TG biosynthesis, protects against free FA-induced 
inflammatory activation of the macrophages during diet-induced obesity.41 Thus, 
increasing macrophage TG accumulation by either ATGL deletion or DGAT-1 
overexpression impairs macrophage proinflammatory signaling. 
Moreover, plasma levels of MCP-1, an important chemoattractant for mononuclear 
cells, were drastically reduced in ATGL KO→LDLr KO mice. Deletion of chemokine 
(C-C motif) receptor 2, the receptor for MCP-1, inhibits the egress of monocytes 
from bone marrow into the blood circulation.42 Decreased concentrations of 
MCP-1 in the circulation might thus also have affected the amount of circulating 
mononuclear cells. Mice lacking MCP-1 or its receptor chemokine receptor 
2 develop fewer and smaller atherosclerotic lesions than control mice, as a 
consequence of the reduced ability to recruit monocytes to sites in the arterial 
wall prone to atherosclerotic lesion development.43-45 In addition to the reduction 
in plasma MCP-1 levels, we also observed a reduced migration rate of ATGL 
KO macrophages compared with control cells in response to MCP-1. The highly 
attenuated lesion size of ATGL KO→LDLr KO mice coincided with a decrease in the 
macrophage area of the lesion, indicating that the total number of macrophages 
that had infiltrated into the arterial wall is decreased. These findings suggest that 
ATGL-dependent lipolysis of TG and the mobilization of NEFA as energy substrate 
is necessary for efficient migration. 
In summary, our data indicate that macrophage ATGL plays a significant role in 
atherogenesis independent of its expression in other tissues. The absence of ATGL 
in macrophages resulted in reduced susceptibility to diet-induced atherosclerosis 
in LDLr KO mice because of decreased infiltration of less inflammatory 
macrophages. Therefore, we hypothesize that increasing intracellular TG content 
in macrophages is protective against lesion development and that macrophage 
ATGL is a novel target to attenuate early atherogenesis. 
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Objective: ATP-binding cassette transporter A1 (ABCA1) is an important 
mediator of macrophage cholesterol efflux. It mediates the efflux of 
cellular cholesterol to lipid-poor apolipoprotein A-I. LDL receptor (LDLr) 
knockout (KO) mice deficient for leukocyte ABCA1 show increased 
atherosclerosis and splenic lipid accumulation despite largely attenuated 
serum cholesterol levels. In the present study, we aimed to explore the 
role of the spleen in atherosclerotic lesion development.
Methods: LDLr KO mice were transplanted with bone marrow from 
ABCA1 KO mice or wild-type (WT) controls. After 8 weeks recovery, mice 
were either splenectomized (SP-x) or underwent a sham operation, and 
were subsequently challenged with a Western-type diet (WTD) for 8 
weeks.
Results: In agreement with previous studies, the atherosclerotic lesion 
area in leukocyte ABCA1 KO transplanted sham animals (655±82×103 
µm2) was 1.4-fold (p=0.03) larger compared to sham WT controls 
(459±33×103 µm2) after 8 weeks WTD feeding, despite 1.7-fold 
(p<0.001) lower serum cholesterol levels. Interestingly, deletion of 
ABCA1 in leukocytes led to 1.6-fold higher neutrophil content in the 
spleen in absence of differences in circulating neutrophils. Levels of KC, 
an important chemoattractant for neutrophils, in serum, however, were 
increased 2.9-fold (p=0.07) in LDLr KO mice transplanted with ABCA1 
KO bone marrow. 
SP-x induced blood neutrophilia as compared to WT controls (1.9-fold; 
p<0.05), but did not evoke differences in serum cholesterol and anti-
oxLDL antibody levels. Atherosclerotic lesion development, however, 
was 1.3-fold induced both in the presence and absence of leukocyte 
ABCA1 (WT: 614±106×103 μm2, ABCA1 KO: 786±44×103 μm2). Two-
way ANOVA revealed independent effects on atherosclerosis for both 
leukocyte ABCA1 deficiency and SP-x (p<0.05).
Conclusions: The observed splenic alterations induced by leukocyte 
ABCA1 deficiency do not play a significant role in the anti-atherogenic 
effects of leukocyte ABCA1 on lesion development. 
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Introduction
Reverse cholesterol transport (RCT) is an important mechanism by which HDL 
and its major apolipoprotein A-I (apoA-I) protect against atherosclerosis.1 In this 
process, the cellular cholesterol efflux machinery is essential to maintain cellular 
lipid homeostasis in macrophages and to prevent pathological foam cell formation, 
a hallmark of atherosclerosis. A key regulator of macrophage cholesterol efflux is 
ATP-binding cassette (ABC) transporter ABCA1, which facilitates cholesterol efflux 
to lipid-poor apolipoproteins like apoA-I,2 thereby initiating the generation of 
HDL.3,4 Deficiency of leukocyte ABCA1 on the LDLr KO background led to increased 
atherosclerosis, despite largely attenuated cholesterol levels.5 Interestingly, these 
mice also showed elevated leukocyte counts in the circulation,6 and accumulation 
of macrophages in the peritoneal cavity, liver, and spleen.5 This indicates that 
leukocyte ABCA1, in addition to its role in cholesterol efflux, exerts regulatory 
functions in the recruitment of inflammatory cells to the periphery.
The spleen is the largest lymphoid organ in the body with important 
immunological functions. It produces antibodies, facilitates phagocytosis 
and is capable of eliminating foreign antigens.7,8 However, it also serves as a 
blood filter by removing old and abnormal red blood cells,9 and functions as an 
important monocyte reservoir.10 Since atherosclerosis is believed to result from 
a combination of dyslipidemia and vascular inflammation,11 the role of the spleen 
with respect to atherosclerosis and serum lipid levels has been thoroughly 
investigated.12–16 It has been previously reported that total cholesterol (TC) levels 
increase after splenectomy.12,13 However, Western-type diet fed, splenectomized 
apoE KO mice display increased atherosclerosis as compared to sham-operated 
controls, without changes in TC levels.15,17 
To investigate the possible interplay between the spleen and leukocyte ABCA1 
with respect to the development of atherosclerosis, we transplanted bone 
marrow from ABCA1 deficient mice into LDLr deficient recipient mice, which 
were subsequently either splenectomized or underwent a sham operation. Our 
results evidently show that leukocyte ABCA1 deficiency resulted in decreased 
TC levels, increased inflammation, and lipid and neutrophil accumulation in the 
spleen. However, the observed splenic alterations induced by leukocyte ABCA1 
deficiency did not alter anti-oxLDL antibody levels, nor played a significant role in 
atherosclerotic lesion development as evidenced by splenectomy.
Methods
Animals, bone marrow transplantation, and splenectomy
Animal experiments were approved by the Ethics Committee for Animal Experiments of Leiden University 
(permit number 08015) and performed at the Gorlaeus Laboratories of the Leiden/Amsterdam Center 
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for Drug Research in accordance with the National Laws and the Directive 2010/63/EU of the European 
Parliament.
C57BL/6J mice and ABCA1 KO18 mice (more than 7 times backcrossed onto a C57BL/6J background) 
were used as donors for the bone marrow transplantation. These donor mice were anaesthetized 
subcutaneously with a mix of 70 mg/kg body weight xylazine, 1.8 mg/kg bodyweight atropine and 350 
mg/kg body weight ketamine. Animals were subsequently sacrificed by cervical dislocation. Homozygous 
C57BL/6J LDL receptor knockout (LDLr KO) mice were obtained from The Jackson Laboratory as mating 
pairs and bred at the Gorlaeus Laboratories, Leiden, The Netherlands. Bone marrow transplantations 
into LDLr KO mice were performed as described.19 Briefly, irradiated recipients (≥11 per group) received 
5×106 bone marrow cells by intravenous injection into the tail vein. After 8 weeks, mice were either 
splenectomized (SP-x) or underwent a sham operation. Mice were anesthetized with isoflurane inhalation. 
After anesthesia, mice were surgically prepared by first shaving the incision site, followed by preparing 
the incision site with alcohol. A small incision was made in the left subcostal abdominal wall, through 
which the spleen was exteriorized. Splenectomy was performed by placing ligatures around the splenic 
vasculature and subsequently removing the spleen. The incision was closed in two layers using surgical 
sutures. Mice were monitored for recovery from anesthesia and kept at 37°C until wakeup. Control mice 
underwent a sham operation and were maintained in the same conditions.
After a recovery period of 2 weeks, the animals were challenged with a Western-type diet (WTD; 
0.25% cholesterol and 15% cocoa butter; Special Diet Services, Witham, Essex, UK) for 8 weeks to 
induce atherosclerotic lesion development. At 18 weeks after transplantation, mice were anaesthetized 
subcutaneously with a mix of 70 mg/kg body weight xylazine, 1.8 mg/kg bodyweight atropine and 350 
mg/kg body weight ketamine. Animals were subsequently sacrificed by cervical dislocation. 
Histological analysis of the aortic root and spleen
To analyze the development of atherosclerosis at the aortic root, transplanted LDLr KO mice were 
euthanized 18 weeks after bone marrow transplantation. The arterial tree was perfused in situ with PBS 
(100 mm Hg) for 10 min via a cannula in the left ventricular apex. The heart plus aortic root and the aortic 
arch were excised and stored in 3.7% neutral-buffered formalin (Formal-fixx; Shandon Scientific Ltd, 
Runcorn, UK). Serial sections (10 μm) of the aortic root were cut using a Leica CM3050S cryostat. The 
atherosclerotic lesion areas in oil red-O-stained cryostat sections of the aortic root were quantified using 
the Leica image analysis system, consisting of a Leica DMRE microscope coupled to a video camera and 
Leica Qwin Imaging software (Leica Ltd, Cambridge, UK). Mean lesion area (in μm2) was calculated from 
10 consecutive oil red-O-stained sections of the aortic root, starting at the appearance of the tricuspid 
valves. Sections were stained immunohistochemically for the presence of neutrophils and macrophages 
using a rat Ly6G antibody (monoclonal rat IgG2b, dilution 1:100; eBioscience, San Diego, CA, USA), and 
a MoMa-2 antibody (dilution 1:50; Serotec Ltd, Oxford, UK), respectively. Goat anti-rat coupled to horse 
radish peroxidase (HRP) (1:100) (Dako, Glostrup, Denmark) was used as a secondary antibody and Nova 
red substrate (Vector Laboratories, Burlingame, CA, USA) was used for visualization of HRP. In addition, 
7 µm cryosections of formalin-fixed spleen from the transplanted sham-operated LDLr KO mice were 
prepared and stained for neutrophils using a rat Ly6G antibody (monoclonal rat IgG2b, dilution 1:100; 
eBioscience, San Diego, CA, USA), and counterstained with hematoxylin.
Lipid analysis
At eight weeks after bone marrow transplantation, 100 μL of blood was drawn from each individual 
mouse by tail bleeding after an overnight fasting period. Upon sacrifice, 18 weeks after bone marrow 
transplantation, blood was collected by retro-orbital venous plexus puncture after an overnight fasting 
period. Total cholesterol and triglyceride analyses were performed as described.19
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Serum antibody detection
Murine monocyte chemoattractant protein-1 (MCP-1; BD Biosciences, Erembodegem, Belgium) and 
keratinocyte chemoattractant (KC; Biosource) serum levels were assayed using an ELISA kit according to 
the manufacturer’s protocol. IgM and IgG2a levels against oxLDL were detected in serum using antibodies 
recognizing mouse IgM/IgG2a and HRP-labeled goat anti-rat Ig (BD Pharmingen). OxLDL (5 µg/mL) was 
dissolved in NaHCO3/Na2CO3 buffer (pH 9.6) and was coated overnight onto a flat-bottom 96-well high 
binding plate (Corning, New York, USA). Absorbance was detected at 450 nm.
Flow cytometry
Upon sacrifice, blood was collected from the transplanted animals. Erythrocytes were lysed using 
erythrocyte lysis buffer (0.15 M NH4Cl, 10 mM NaHCO3, 0.1 mM EDTA, pH 7.3). For the detection of 
CD11b+GR-1+ neutrophils, the blood cells were stained with the surface markers CD11b and GR-1 
(0.25 µg Ab/200,000 cells). Antibodies were purchased from eBioscience, Vienna, Austria). Fluorescent 
activated cell sorting (FACS) analyses were performed on a FACS Canto II (BD Biosciences, Mountain 
View, CA, USA). Data were analyzed using FACSDiva software (BD Biosciences).
Statistical analysis
Statistically significant differences among the means of the different populations were tested using 
analysis of variance (ANOVA) and when specifically indicated the unpaired Student’s t-test (GraphPad 
InStat and Prism software). The Student-Newman-Keuls multiple comparison test was performed after 
ANOVA. Two-way ANOVA was used to check possible interactions. The probability level (alpha) for 
statistical significance was set at 0.05. Results are expressed as an average ± SEM.
 
Results
Increased splenic and systemic inflammation in leukocyte ABCA1 KO mice
Deficiency of leukocyte ABCA1 has been shown to induce the number of 
leukocytes in the circulation. In addition, the spleens of these mice exhibited 
increased macrophage accumulation.6 In the current study, we observed induced 


























ABCA1 KOWT ABCA1 KO
Figure 1. Highly induced concentrations of the proinflammatory cytokines MCP-1 and KC (murine IL-8) in 
serum of ABCA1 KO transplanted LDLr KO mice. Serum MCP-1 and KC levels were determined by ELISA. 
n≥4 mice ± SEM per group. *p<0.05.
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KC (murine IL-8; 2.9-fold; p=0.07) in serum of leukocyte ABCA1 KO mice (Fig. 1). 
Interestingly, IL-8 is one of the most potent chemoattractants for neutrophils.20,21 
In agreement, spleen sections stained for Ly6G revealed increased neutrophil 
presence in spleens from leukocyte ABCA1 KO mice. This observation was 
confi rmed by FACS analysis on the spleen, which showed that the splenic 
neutrophil content was increased 1.6-fold (p<0.01) in ABCA1 KO transplanted 
mice compared to WT transplanted controls (Fig. 2). In order to establish the 
importance of the spleen for the atheroprotective effects of leukocyte ABCA1, we 






















WT 8 Chow n.d. 271±33 n.d. n.d. n.d.
18 WTD 27±0.5 1137±71 68±9 1.10±0.38 0.25±0.01
ABCA1 KO 8 Chow n.d. 231±31 n.d. n.d. n.d.
18 WTD 29±1.3 676±30** 62±11 0.85±0.47 0.17±0.02
WT SP-x 8 Chow n.d. 272±19 n.d. n.d. n.d.
18 WTD 27±0.8 1144±177 74±6 1.26±0.15 0.27±0.05
ABCA1 KO SP-x 8 Chow n.d. 239±19 n.d. n.d. n.d.
18 WTD 28±1.4 713±54* 100±26 0.88±0.07 0.21±0.08
Table 1. Serum TC, TG and anti-oxLDL antibody levels were measured at 8 and/or 18 weeks (wks) after 



























Figure 2. Increased splenic neutrophil content in leukocyte ABCA1 KO mice. Splenic neutrophil content 
(CD11b+GR-1+ cells) was analyzed by FACS. Representative spleen sections were stained with an anti-
Ly6G antibody (original magnifi cation 100x; right panels). Values are the percentage of total spleen cells. 
n≥6 mice ± SEM per group. **p<0.01.
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No effects of splenectomy on serum total cholesterol, triglyceride and 
anti-oxLDL levels
Cholesterol levels were measured at 8 weeks (chow diet) and at 18 weeks 
(WTD, containing 0.25% cholesterol and 15% cocoa butter) after bone marrow 
transplantation (BMT; Table 1). On chow diet, total cholesterol (TC) levels were 
not different between the groups. As expected, after feeding WTD, serum TC 
levels of the WT transplanted mice increased ≈4.5-fold. However, in agreement 
with previous studies,6,22,23 deletion of ABCA1 in bone marrow cells resulted in 
an attenuated increase in plasma TC levels upon feeding the atherogenic diet 
(≈2.9-fold as compared to both SP-x (p<0.05) and sham operated controls 
(p<0.01)). No differences were observed between splenectomized animals and 
sham operated controls. In addition, triglyceride (TG) levels were unaffected in 
all experimental groups (Table 1). Splenectomized mice did not show altered 
antibody titers of anti-oxLDL IgM and IgG2a (Table 1). Leukocyte ABCA1 deficiency 
resulted in slightly decreased anti-oxLDL antibody titers as compared to WT 
transplanted controls. However, these values did not reach statistical significance. 
These data indicate that splenectomy did not induce significant changes in TC, TG, 
and anti-oxLDL antibody response.
Increased neutrophil levels in 
splenectomized leukocyte ABCA1 KO mice
Upon sacrifice after 8 weeks of WTD feeding, 
FACS analysis was performed to measure 
neutrophil content in the blood. Although 
ABCA1 KO transplanted mice exhibited 
increased splenic neutrophil content, no 
differences in neutrophil levels were observed 
between WT and leukocyte ABCA1 KO 
sham operated animals. Upon splenectomy, 
however, leukocyte ABCA1 KO mice displayed 
a 1.9-fold increase in neutrophil levels in blood 
compared to splenectomized WT controls 
(p<0.05; Fig. 3).
Increased atherosclerosis in splenectomized transplanted LDLr KO mice
Atherosclerotic lesion size and composition in the aortic root of the transplanted 
animals were analyzed after feeding the mice a WTD for 8 weeks. As expected, 
quantification of the lesion sizes in oil red-O-stained sections of the aortic root of 
sham-operated animals showed that deletion of leukocyte ABCA1 led to a 1.4-
fold increase (t-test; p=0.03) in the mean atherosclerotic lesion size compared 
































Figure 3. Neutrophil content (CD11b+ 
GR-1+ cells) of whole blood was analyzed 
by FACS. Values are the percentage of 
total white blood cell counts. n≥3 mice 
± SEM per group. *p<0.05 compared to 
splenectomized controls.
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μm2, respectively; Fig. 4). Splenectomy induced a 1.2- and 1.3-fold increase in 
atherosclerotic lesion formation in ABCA1 KO transplanted animals (786±44×103 
μm2) and their WT transplanted controls (614±106×103 μm2), respectively (Fig. 
4). In agreement with the observed increased lesion development in ABCA1 KO 
transplanted mice, macrophage content of lesions in these mice was attenuated 
(p<0.05; Fig. 5). Neutrophil content of the lesions, however, was not affected. 
Two-way ANOVA was used to verify the independent effects of leukocyte 
ABCA1 deficiency and splenectomy on atherosclerotic lesion development. This 
test showed significant, independent contributions of both leukocyte ABCA1 
deficiency (p=0.012) and splenectomy (p=0.048) to the observed increases in 
atherosclerotic lesion development, demonstrating the particular importance of 
both leukocyte ABCA1 and the spleen with respect to atherosclerosis.
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Figure 4. Independent effects on atherosclerosis for both leukocyte ABCA1 deficiency and splenectomy. 
Quantification of atherosclerotic lesion size after 8 weeks of WTD feeding (left panel). Representative oil 
red-O-stained cross-sections (original magnification 50x; right panels). Values represent the means of 
10 consecutive aortic root sections of individual mice. n≥8 mice ± SEM per group. *p<0.05 compared to 







































Figure 5. Quantification of macrophage (left panel) and neutrophil (right panel) content after 8 weeks 
of WTD feeding. Values represent the means of 5 consecutive aortic root sections of individual mice. n≥7 
mice ± SEM per group. *p<0.05 compared to respective WT controls.
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Discussion
The importance of ABCA1 in cellular cholesterol transport became clear when 
mutations in the ABCA1 gene were discovered to cause Tangier disease.24 
Additional research revealed a critical role for ABCA1 in leukocytes, as it was 
shown to be responsible for macrophage lipid metabolism.25 As a consequence, 
deficiency of ABCA1 in leukocytes resulted in increased atherosclerotic lesion 
development.6,26 However, more recent findings also suggested an anti-
inflammatory role for leukocyte ABCA1 in atherosclerosis.27–29 In agreement, the 
current study showed highly induced concentrations of MCP-1 and KC (murine IL-
8) in the serum of leukocyte ABCA1 KO mice fed a WTD. MCP-1 is an important 
chemoattractant for mononuclear cells. Mice deficient for MCP-1 or its receptor 
chemokine receptor 2 (CCR-2) develop fewer and smaller atherosclerotic lesions 
than control mice, as a consequence of the reduced ability to recruit monocytes 
to sites in the arterial wall prone to atherosclerotic lesion development.30–32 KC 
(murine IL-8) triggers monocyte arrest on early atherosclerotic endothelium,33 
and plays a central role in macrophage accumulation in established fatty streak 
lesions.34 Interestingly, IL-8 is also one of the most potent chemoattractants for 
neutrophils.20,21 Neutrophils are short-lived phagocytic cells that serve as essential 
early cellular effectors of innate immunity and constitute the “first line of defense.” 
Accordingly, leukocyte ABCA1 KO mice exhibited increased neutrophil presence 
in the spleen. Upon splenectomy, ABCA1 KO transplanted animals exhibited 
blood neutrophilia as compared to WT splenectomized controls. Surprisingly, 
leukocyte ABCA1 deficieny or splenectomy alone did not alter serum neutrophil 
concentrations. In response to inflammatory processes, neutrophils are rapidly 
mobilized from the bone marrow, creating a blood neutrophilia.35 Following their 
accumulation at sites of inflammation, neutrophils become apoptotic and are 
efficiently cleared, primarily by the liver and the spleen,36 in order to prevent 
excessive tissue damage. The observed blood neutrophilia in splenectomized 
ABCA1 KO transplanted animals might be the combined result of a chronic 
advanced inflammatory status because of the lack of macrophage ABCA1, and 
absence of splenic neutrophil clearance.
The spleen is also associated with systemic immune responses in which it is 
the principal organ responding to antigens such as oxLDL.17 OxLDL deposits in 
the arterial wall are believed to be involved in the initiation of atherosclerosis 
by damaging the vascular endothelium and engulfment by macrophages.37 
Accordingly, anti-oxLDL antibody serum titers have been suggested to play an 
anti-atherogenic role.17 Anti-oxLDL antibody production, however, might also 
be increased as a result of enhanced inflammation. No differences in anti-oxLDL 
antibody serum titers were observed upon splenectomy. Unexpectedly, deficiency 
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of leukocyte ABCA1 resulted in a moderate decrease in anti-oxLDL antibody serum 
titers. This might be the direct result of the attenuated serum TC levels in ABCA1 
KO transplanted animals, since serum TC levels have been positively correlated to 
serum titers of anti-oxLDL antibodies.38 
The importance of the spleen in lipid metabolism has been investigated 
previously.12–14 However, differential results were obtained regarding serum 
TC and TG concentrations after splenectomy. Splenectomized apoE KO mice 
displayed increased atherosclerotic lesion development as compared to their 
sham operated littermates, in absence of changes in serum TC levels.15 As 
expected, the current study revealed attenuated TC levels in leukocyte ABCA1 
KO mice. However, no differences in TC levels were observed as a result of 
splenectomy.
Despite the fact that splenectomy did not reveal differences in either serum 
TC and TG levels, or anti-oxLDL antibody titers, splenectomized mice did show 
enhanced atherosclerotic lesion development. As expected, deficiency of 
leukocyte ABCA1 also resulted in an increased atherosclerotic lesion formation. 
Moreover, splenectomized ABCA1 KO transplanted animals exhibited an additional 
increased lesion development. These results suggest that the observed splenic 
alterations induced by leukocyte ABCA1 deficiency do not play a significant role 
in the anti-atherogenic effects of leukocyte ABCA1. Leukocyte ABCA1 deficiency, 
as well as splenectomy independently induce atherosclerotic lesion development, 
demonstrating the particular importance of both leukocyte ABCA1 and the spleen 
with respect to atherosclerosis.
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Objective: ATP-binding cassette transporter A1 (ABCA1) exerts 
important anti-atherogenic functions in the pathogenesis of 
atherosclerosis. In the present study, we aimed to explore the role of 
ABCA1 in heart injury after acute myocardial infarct (MI) induction. 
Methods: MI was induced in ABCA1 knockout (KO) mice and wildtype 
(WT) controls by ligation of the Left Anterior Descending (LAD) coronary 
artery in vivo, after which the mice were allowed to recover for two 
weeks. In addition, isolated hearts from ABCA1 KO and WT mice were 
subjected to MI induction in a Langendorff perfusion system ex vivo.
Results: ABCA1 KO mice exhibited a substantial 59% reduction in MI 
size as compared to WT mice (p=0.03) after LAD coronary artery ligation 
in vivo. Ex vivo MI induction by Langendorff perfusion had no effect on 
infarct size in hearts from ABCA1 KO mice. The smaller infarct size after 
in vivo coronary artery ligation in ABCA1 KO mice is thus likely not due 
to a direct effect of ABCA1 deficiency on myocyte function. Interestingly, 
after in vivo MI induction, a 2.9-fold increase (p=0.01) in circulating 
leukocyte numbers was observed in ABCA1 KO mice as compared to 
WT controls, which was primarily the result of higher levels of CD19+ 
B-lymphocytes (3.0-fold, p=0.02) and CD3+ T-lymphocytes (4.2-
fold, p=0.002). Both CD4+ T-helper lymphocytes (4.6-fold increase; 
p=0.002) and CD8+ cytotoxic T-lymphocytes (3.7-fold increase; 
p=0.002) contributed to the observed increase in CD3+ T-lymphocytes. 
No differences were found in circulating F4/80+ monocytes/macrophages 
and CD11c+ dendritic cells. 
Conclusions: Although ABCA1 has an important protective role in 
atherosclerosis, it exerts detrimental effects on cardiac function after MI, 




Tangier Disease (TD), resulting in extreme HDL deficiency, is caused by 
detrimental mutations in the ABCA1 gene.1–3 Since HDL plays a key protective role 
in atherosclerosis, by exerting several cardioprotective functions, including anti-
oxidative, anti-inflammatory and vasomotor activities,4 the mechanism of action 
of ABCA1 and its regulation have been investigated extensively.5–8 Mice deficient 
for ABCA1 exhibit low plasma HDL levels as well as cholesterol accumulation in 
peripheral macrophages, a phenotype similar to that of TD patients.9 Although 
atherosclerosis-prone mouse models deficient for ABCA1 do display impaired 
cellular cholesterol efflux,10 atherosclerotic lesion development does not increase 
in these mice,11 probably caused by a less atherogenic lipid profile despite the 
almost complete absence of protective HDL. Deficiency of ABCA1 in leukocytes, 
however, did increase atherosclerotic lesion development, coinciding with 
increased numbers of peritoneal foam cells and highly impaired cholesterol efflux 
from macrophages towards HDL, indicating a pronounced anti-atherosclerotic 
effect of leukocyte ABCA1.12,13 In humans, low HDL levels have been correlated 
to an increased risk of myocardial infarction (MI); an acute cardiovascular 
event, often resulting from rupture of advanced atherosclerotic lesions and 
superimposed thrombus formation.14 
Inflammatory responses are a critical factor in the balance between adverse 
ventricular remodeling induced by MI on the one hand,15,16 and cardiac repair 
on the other hand.17 Ischemia induces the Janus kinase 2/signal transducer 
and activator of transcription 3 (JAK2/STAT3) pathway, an important regulator 
of cytokine signaling which plays a vital role in cardioprotection by inducing 
cytoprotective and survival signals in infarcted hearts.18 Interestingly, ABCA1 acts 
as an anti-inflammatory mediator in baby hamster kidney (BHK) cells by inducing 
signaling through the JAK2/STAT3 pathway in response to binding lipid poor 
apoA-I.19 Furthermore, ABCA1 exerts important anti-inflammatory properties, due 
to its key role in modulating cholesterol content both on the plasma membrane 
as well as within intracellular compartments.20,21 ABCA1 is thus anticipated to be 
cardioprotective during MI, indirectly by generating HDL as well as directly by its 
anti-inflammatory effects through JAK2/STAT3 signaling. The actual role of ABCA1 
during MI, however, is currently unknown.
In order to investigate the importance of ABCA1 with respect to MI, we performed 
permanent coronary artery ligation in ABCA1 KO and wil-dtype control mice. Our 
results evidently show that ABCA1 has unfavorable cardiac effects after MI.




Female C57BL/6J mice and ABCA1 KO22 mice (kindly provided by Dr. G. Chimini, Centre d'Immunologie 
de Marseille-Luminy; more than 7 times backcrossed onto a C57BL/6J background), between 15 and 26 
weeks of age, were housed in a temperature and humidity-controlled room with ad libitum access to food 
and water. Body weights were measured weekly. At the end of each experiment the mice were sacrificed 
and hearts and/or blood were isolated for further examination. Animal experiments were approved 
by the Ethics Committee for Animal Experiments of Leiden University and performed at the Gorlaeus 
Laboratories of the Leiden/Amsterdam Center for Drug Research in accordance with the National Laws.
Induction of myocardial infarctions
Mice were anesthetized by intraperitoneal injection of a mixture of dormicum (0.7 mg/kg b.w.), domitor 
(7.2 mg/kg b.w.), and fentanyl (0.07 mg/kg b.w.) (DDF). Body temperature was maintained at 37°C with 
an automatic heating pad. Mice were artificially ventilated using a dedicated rodent ventilator (model 
845, Harvard Apparatus, Holliston, MA, USA). The left anterior descending (LAD) coronary artery was 
ligated with a 7-0 Ethilon suture (Johnson and Johnson, New Brunswick, NJ, USA), just distal to the left 
atrial appendix. Ischemia was confirmed by bleaching of the left ventricle (LV). The thorax was closed 
and the mice received a subcutaneous injection of Anexate (0.5 mg/kg b.w.), Antisedan (2.5 mg/kg 
b.w.), Naloxon (1.2 mg/kg b.w.), and 50 µL Temgesic/PBS (1.5 µg/50 mL PBS). Thereafter the mice were 
allowed to recover on a heating pad. Mice received 50 µL Temgesic/PBS (1.5 µg/50 mL PBS) at 24h after 
operation.
Infarct size and immunohistochemistry
At 2 weeks after induction of myocardial infarction (MI), mice were sacrificed and the arterial tree 
was perfused in situ with PBS (100 mm Hg) for 10 min via a cannula in the left ventricular (LV) apex. 
Subsequently, hearts were isolated and cut into four equal 1-2 mm thick slices, perpendicular to the long 
axis of the heart. The two lower slices, from the middle of the heart to the apex, represent the infarcted 
area, and were used for infarct quantification. These slices were flat-embedded and serial sections (10 
µm) were cut using a Leica CM3050S cryostat. To delineate the LV area and infarct area, sections were 
stained immunohistochemically with Sirius red for collagen. Total LV wall area (including septum) and 
infarct area were measured with cell^D imaging software (Olympus Soft Imaging Solutions). Infarct 
areas were normalized to total left ventricular areas and averaged for individual hearts.
Leukocyte content and flow cytometry
Upon sacrifice, 2 weeks after MI, blood was collected by retro-orbital venous plexus puncture. Leukocyte 
content was analyzed using an automated Sysmex XT-2000iV Veterinary Hematology analyzer (Sysmex 
Corporation, Kobe, Japan). For fluorescent activated cell sorting (FACS) analysis, erythrocytes were lysed 
using erythrocyte lysis buffer (0.15 M NH4Cl, 10 mM NaHCO3, 0.1 mM EDTA, pH 7.3). Blood cells were 
subsequent stained (0.25 µg Ab/200,000 cells) for T-lymphocytes (CD3, CD4, and CD8), B-lymphocytes 
(CD19), monocytes/macrophages (F4/80) and dendritic cells (DC; CD11c). Antibodies were purchased 
from eBioscience, (Vienna, Austria). FACS analyses were performed on a FACS Canto II (BD Biosciences, 
Mountain View, CA, USA). Data were analyzed using FACSDiva software (BD Biosciences).
Ex vivo langendorff perfusion
To properly isolate the heart, the chest was opened excising the sternum and attached costal cartilages 
to give adequate access to the mediastinum. The heart was rapidly removed and placed in ice cold (4°C) 
chapter 8152
Krebs–Henseleit buffer and the aorta cannulated. Hearts were then perfused with a Krebs–Henseleit 
buffer (118.0 mM NaCl; 24.0 mM NaHCO3; 4.0 mM KCl; 1.0 mM NaH2PO4; 2.5 mM CaCl2; 1.2 mM MgCl2; 
0.5 mM EDTA.Na2; 10 mM glucose, pH 7.4; gassed with 95% O2 / 5% CO2 at 37°C) in a retrograde fashion 
with a constant pressure of 110 cm H2O. The coronary fl ow rate was measured by timed collection of 
the perfusate. The hearts were stabilized for 20 min and subsequently exposed to 35 min of no-fl ow 
global ischemia followed by 45 min of reperfusion. At the end of the reperfusion period, the heart was 
immediately frozen. Frozen hearts were cut into 6-7 slices, perpendicular to the long axis of the heart, 
and incubated with triphenyltetrazolium chloride (TTC) to stain viable myocardium. Total myocardium and 
infarcted areas were measured from computed images using NIH Image software.
Statistical analysis
Statistically signifi cant differences among the means of the different populations were tested using 
the unpaired Student’s t-test (GraphPad InStat and Prism software). The probability level (alpha) for 
statistical signifi cance was set at 0.05. Results are expressed as average ± SEM.
Results
Increased myocardial infarction following coronary artery ligation in 
ABCA1 KO mice in vivo
To investigate the effects of ABCA1 defi ciency on MI in vivo, we subjected ABCA1 
KO and WT mice to LAD coronary artery ligation. Two weeks after induction of 
MI, infarct size was quantifi ed in ABCA1 KO mice and WT controls. Surprisingly, 
despite the anticipated cardioprotective functions of ABCA1, ABCA1 KO mice 
displayed a substantial 59% reduction in myocardial infarct size as compared to 
WT mice (p=0.03; Fig. 1, left panel). No differences in total LV wall area were 
found, indicating that the observed reduction in MI did not result from alterations 
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Figure 1. Reduced myocardial infarct size in ABCA1 KO mice after coronary artery ligation in vivo. Two 
weeks after induction of MI by ligation of the LAD coronary artery, infarct size was determined (left 
panel). Representative cross sections are shown, stained with Sirius red to visualize the collagen-rich 
infarcted area (middle panels). Total left ventricle wall area was measured to determine heart size (right 
panel). Values are means ± SEM (n≥4 per group). *p<0.05.
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Higher circulating white blood cell and lymphocyte numbers in ABCA1 KO 
mice after myocardial infaction in vivo
Before MI induction, no differences in 
leukocyte subsets were observed between 
ABCA1 KO and  WT mice (data not shown). 
Two weeks after MI, however, total 
leukocyte counts were 2.9-fold higher in 
ABCA1 KO mice (p=0.01; Fig. 2), which 
was primarily the result of augmented 
numbers of circulating lymphocytes (4.6-
fold; p=0.002). To further investigate 
the increased lymphocyte population in 
the circulation of ABCA1 KO mice after 
MI, blood cells were subjected to FACS 
analysis (Fig. 3). Before MI, no differences 
in T-lymphocytes (CD3+, CD4+, and CD8+), 
B-lymphocytes (CD19+), dendritic cells 
(CD11c+) or monocytes/macrophages 
(F4/80+) were observed between both 
genotypes (Fig. 3A). After MI, however, CD3+ T-lymphocytes increased a striking 
4.2-fold (p=0.002; Fig. 3B). CD4+ T-helper lymphocytes (4.6-fold increase; 
p=0.002) and CD8+ cytotoxic T-lymphocytes (3.7-fold increase; p=0.002) 
both contributed to this phenomenon. In addition, ABCA1 KO mice displayed a 
clear 3.0-fold increase (p=0.02) in CD19+ B-lymphocytes after MI. In contrast, 
monocytes/macrophages (F4/80+) and dendritic cells (CD11c+) did not change 





















Figure 2. Increased white blood cells and 
lymphocytes in ABCA1 KO mice after MI 
induction by coronary artery ligation in vivo. 
Two weeks after induction of MI, total WBC 
and lymphocytes in plasma were determined 
with a hematology analyzer. Values are 



























































Figure 3. Increased circulating T- and B-cells in ABCA1 KO mice after MI induction by coronary artery 
ligation in vivo. Isolated WBC were stained for T-cells (CD3+, CD4+, and CD8+), B-cells (CD19+), 
monocytes/macrophages (F4/80+) and dendritic cells (CD11c+) and analyzed by flow cytometry before 
(A) and after MI (B). Values are means ± SEM (n≥4 mice per group). *p<0.05, **p<0.01.
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KO mice primarily induced common lymphoid progenitor (CLP)-derived cells, such 
as T- and B-lymphocytes, rather than common myeloid progenitor (CMP)-derived 
cells including monocytes/macrophages and dendritic cells.
Unaltered myocardial infarction in a langendorff perfusion system in 
ABCA1-deficient hearts ex vivo
ABCA1 KO mice have been shown to develop cardiomegaly.23 To determine the 
direct effects of ABCA1 deficiency on myocyte function during ischemia, MI was 
induced ex vivo in isolated hearts from ABCA1 KO mice and WT controls using 
the Langendorff perfusion method. After 35 minutes of no-flow global ischemia 
followed by 45 minutes of reperfusion, only a tendency towards a 15% decrease 
(p=0.47; Fig. 4) in infarct size was observed in hearts from ABCA1 KO mice.
Discussion
In the current study we show for the first time that mice lacking ABCA1, 
thereby having reduced HDL levels, are protected against cardiac damage after 
permanent coronary artery ligation. At first sight, this is remarkable as several 





















Figure 4. Unaltered infarcted area of isolated hearts from ABCA1 KO mice subjected to ischemia/
reperfusion ex vivo. Isolated hearts were stabilized for 20 minutes in a Langendorff perfusion system, 
followed by 35 minutes of no-flow global ischemia, and 45 minutes of reperfusion. Infarct size was 
measured with cell^D imaging software. Infarct areas were normalized to total left ventricular 
areas and averaged for individual hearts (left panel). Values are means ± SEM (n≥5 mice per group). 
Representative cross sections are shown, stained with TTC to determine viable myocardium (red staining; 
right panels).
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MI by inhibiting ischemia-induced cardiomyocyte apoptosis and by reducing the 
recruitment of inflammatory neutrophils into the infarcted area.24 In addition, 
intravenous injection of apoA-I before the onset of reperfusion after MI reduced 
TNF-α and IL-6 expression in the heart, as well as suppressed ICAM-1 expression 
in the heart, thereby diminishing neutrophil adherence and subsequent reduced 
myocyte injury.25 On the other hand, mice lacking the HDL receptor scavenger 
receptor BI (SR-BI), have high levels of HDL but spontaneously develop MI.26,27 
Deficiency of ABCA1 not only results in the lack of HDL, but also highly attenuates 
total cholesterol levels.28 Although cholesterol levels are positively correlated 
with MI risk in humans,29 differential results have been obtained in murine MI 
models.30–32
Interestingly, induction of MI in ABCA1 KO mice resulted in a substantial 
increase in circulating leukocytes due to higher numbers of circulating B- and 
T-lymphocytes. No differences in leukocyte numbers or subsets were found prior 
to coronary artery ligation. Therefore, the increased inflammatory environment, 
caused by the induction of MI, might have attributed to induce this phenotype in 
ABCA1 KO mice. Proliferation of LSK stem cells and committed CMPs is regulated 
by cholesterol efflux mechanisms, whereby HDL suppresses proliferation by 
facilitating cellular cholesterol efflux via the ABC-transporters ABCA1 and 
ABCG1.33 However, mice lacking ABCA1 and ABCG1 did not show an increase in 
CLP cells, that give rise to B-and T-lymphocytes.33
Importantly, we have previously shown that deficiency of leukocyte ABCA1 
increases circulating lymphocytes upon induction of atherosclerosis,13 similarly as 
observed in the current study upon coronary artery ligation. Since the infarct size 
in ABCA1 KO mice was drastically attenuated, the higher number of circulating 
lymphocytes might have been mediating tissue repair. This hypothesis is 
strengthened by the fact that isolated hearts from ABCA1 KO and WT mice did not 
display differences in infarct size, induced ex vivo using the Langendorff perfusion 
system. Since these hearts were perfused with a designated buffer instead of 
whole blood, no secondary ABCA1-mediated effects could interfere.
T-lymphocytes rapidly accumulate in the heart after ischemia/reperfusion injury. 
Specifically, CD4+ T-lymphocytes were identified as protective mediators of 
myocardial perfusion injury after MI.33,34 Recently, Wara et al. showed that LSK-
derived CMPs, but not CLPs, can differentiate into proangiogenic cells, thereby 
promoting neovascularization.34 Instead, CD4+ lymphocytes modulate the influx 
of among others monocytes, which is a prerequisite for proper myocardial wound 
healing.35,36 Moreover, intramyocardial injection of B-lymphocytes into early post-
ischemic myocardium has been shown to preserve cardiac function,37 emphasizing 
the protective roles of B- and T-lymphocytes upon MI.
The most pronounced lipid phenotype of ABCA1 deficiency is the near absence 
of HDL cholesterol in the circulation.23 It is therefore plausible to suggest that 
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the absence of HDL, at least in part, promoted the observed secondary effects 
on lymphocyte numbers upon MI. In agreement, Wilhelm et al.38 observed 
increased circulating lymphocytes in Western-type diet fed LDLr KO mice lacking 
apoA-I. ApoA-I KO mice, like ABCA1 KO mice, have virtually no circulating HDL. To 
provide definitive proof for the distinct importance of ABCA1 and HDL, MI should 
be induced in mice lacking apoA-I, which express ABCA1, but have virtually no 
HDL. In addition, bone marrow transplantation experiments might be of interest 
to establish the importance of leukocyte-derived ABCA1 with respect to MI.
In conclusion, despite its protective effects regarding the development of 
atherosclerosis, ABCA1 has adverse effects on cardiac function after MI, probably 
by attenuating the increase in cardioprotective B- and T-lymphocytes. ABCA1 is 
considered to be an important therapeutic target to treat atherosclerosis based 
on its protective effects. However, it is of great importance to further identify the 
possible adverse effects of ABCA1 upregulation on cardiac recovery after MI.
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Atherosclerosis, the underlying cause of most cardiovascular diseases, 
is the consequence of lipid deposition in the arterial wall, mainly as a 
result of high serum cholesterol levels. Currently, the main therapeutic 
strategy to prevent the progression of atherosclerosis is to reduce 
serum cholesterol levels by lipid lowering medication, such as statins. 
Despite impressive progress in the treatment of cardiovascular diseases, 
atherosclerosis associated clinical events are still a major cause of death 
in the Western society.1 This clearly indicates the need for new therapies. 
Numerous epidemiological studies have established high HDL cholesterol 
levels to be protective for the development of atherosclerosis. Besides its 
anti-oxidative and anti-inflammatory functions, HDL plays a crucial role 
in facilitation of reverse cholesterol transport from macrophages in the 
arterial wall to the liver and subsequently to the feces.2
In this thesis, the bone marrow transplantation technique was used to 
specifically investigate the importance of macrophage-derived proteins, 
associated with the removal of lipoproteins and triglycerides, with 
respect to atherosclerosis. In addition, a myocardial infarction model was 
used to establish the role of ABCA1 in an acute cardiovascular event.
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The role of key reverse cholesterol transport genes in macrophage 
cholesterol homeostasis and atherosclerotic lesion development
Reverse cholesterol transport is a pathway by which excess cholesterol is 
transported from macrophages in the arterial wall to the liver for excretion, 
thereby preventing atherosclerosis.2,3 The first step in this process involves 
the efflux of cholesterol from macrophages. This can be facilitated by several 
macrophage proteins including ABCA1, ABCG1 and apoE.4,5 As a transmembrane 
protein, ABCA1 pumps a wide variety of substrates across the cell membrane. 
It plays an essential role in the maintenance of cellular lipid homeostasis by 
facilitating the transport of cholesterol and phospholipids towards lipid-poor 
apoA-I.6,7 In addition, ABCG1 plays an important role in the efflux of cholesterol 
from macrophages. ABCA1-mediated cholesterol efflux results in the lipidation of 
apoA-I, and thus the formation of mature HDL particles, that subsequently act as 
substrate for ABCG1-mediated transport of cholesterol and phospholipids.8–10 As 
a result, combined deletion of macrophage ABCA1 and ABCG1 in mice results in 
massive foam cell formation in peripheral tissues, coinciding with an attenuated 
increase in Western-type diet-induced plasma cholesterol levels.11
ApoE, secreted by macrophages can also induce cellular cholesterol efflux.12 
Interestingly, apoE enhances the efflux of cholesterol both in the presence and 
absence of extracellular cholesterol acceptors.13 In addition, apoE can act as 
a substrate for ABCA1-mediated cholesterol efflux.14 Therefore, in this thesis, 
several studies were performed in order to investigate the (combined) importance 
of these macrophage-derived cholesterol-related proteins on atherosclerotic 
lesion development.
In chapter 3, LDLr KO mice were transplanted with bone marrow from ABCA1/
apoE double KO mice, their respective single knockouts, or WT controls, 
and challenged with a high-fat/high-cholesterol diet for 6 weeks to induce 
atherosclerotic lesion development. Macrophage-derived apoE induces efflux of 
cholesterol, independent of extracellular acceptors.13 However, no added effect 
on cholesterol efflux was observed in dKO macrophages compared to ABCA1 
deficient macrophages, suggesting that endogenously produced apoE requires 
ABCA1 to facilitate macrophage cholesterol efflux. In agreement with previous 
studies,11,15,16 macrophage ABCA1 deficiency resulted in increased atherosclerotic 
lesion development, despite a clear reduction in serum cholesterol levels. Single 
deletion of macrophage apoE led to a comparable increase in atherosclerotic 
lesion development as single macrophage ABCA1 deletion. Circulating TC levels, 
however, were over 2-fold higher in apoE KO transplanted animals compared 
to ABCA1 KO transplanted animals. When adjusted for serum total cholesterol 
exposure, the pro-atherogenic effects of macrophage ABCA1 deficiency became 
even more evident. Surprisingly, TC levels in serum were markedly higher 
upon combined deletion of macrophage ABCA1 and apoE as compared to single 
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deletion of ABCA1 in macrophages. This thus leads to ABCA1 deficiency – a defect 
in cholesterol efflux – combined with elevated serum total cholesterol levels. 
Interestingly, hepatic LPL expression was attenuated in dKO transplanted mice. 
Since LPL is essential for the lipolysis of TG in lipoproteins, LPL facilitates the 
clearance of VLDL and chylomicrons.17 In addition, LPL can also promote LDL18 
and VLDL remnant uptake,19 independent of apoE-recognizing receptors. The 
attenuated LPL expression might thus have contributed to the observed increase 
in serum TC levels compared to ABCA1 KO transplanted animals. 
Importantly, ABCA1/apoE dKO transplanted mice exhibited a large induction of 
the pro-inflammatory cytokines IL-6 and TNFα in the liver. In addition, IL-6 levels 
in the circulation were highly increased in these animals, indicating an enhanced 
inflammatory status. All together, combined deletion of macrophage ABCA1 
and apoE resulted in a defect in cholesterol efflux and, compared to ABCA1 
KO transplanted mice, elevated serum total cholesterol levels, and enhanced 
systemic and hepatic inflammation, together resulting in the observed augmented 
atherosclerotic lesion development. Despite the beneficial function of ABCG1 in 
cellular cholesterol efflux, differential results have been published on the role of 
macrophage ABCG1 in atherosclerosis.20–22 In agreement with its protective role 
in cellular cholesterol efflux, macrophage ABCG1 has been reported to play an 
anti-atherogenic role.21,23 In contrast, studies showing a pro-atherogenic role for 
macrophage ABCG1 suggested that ABCG1 KO macrophages are either more 
prone to undergo apoptosis,20 or exhibit increased ABCA1 expression and apoE 
secretion.22 The effect of combined deficiency of macrophage ABCG1 and apoE on 
atherosclerotic lesion development is described in chapter 4. 
Deletion of macrophage ABCG1 or apoE resulted in a comparable effect on 
cholesterol efflux towards HDL, whereas a larger attenuation of cholesterol 
efflux to HDL was observed in dKO macrophages. Two-way ANOVA analysis 
indicated that the effects of macrophage ABCG1 and apoE on HDL-mediated 
efflux were independent of each other. Similar results were obtained with 
respect to atherosclerotic lesion development in these mice. Single ABCG1 
or apoE KO transplanted mice showed a 1.4-fold increase in atherosclerotic 
lesion development as compared to WT transplanted controls, whereas their 
dKO transplanted littermates revealed a 1.9-fold increase. Furthermore, a 
clear significant inverse relation between HDL-mediated efflux and the size of 
atherosclerotic plaques was apparent. The independent effects of both genes on 
atherosclerotic lesion development was further strengthened by the fact that no 
compensatory upregulations of apoE or ABCG1 protein expression were observed 
in bone marrow-derived macrophages from single ABCG1 KO and apoE KO 
transplanted animals, respectively. The specific role of ABCG1 in atherosclerosis 
was further defined in chapter 5. Total body ABCG1/LDLr dKO mice were used 
to assess the effect of ABCG1 deficiency on different stages of atherosclerotic 
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lesion development. In this study, ABCG1 was shown to be able to induce, as 
well as attenuate atherosclerotic lesion development. Feeding ABCG1/LDLr dKO 
mice a Western-type diet for 10 weeks resulted in a significant increase in early 
atherosclerotic lesion size. However, a significant reduction in more advanced 
lesions was observed after 12 weeks of Western-type diet feeding, indicating that 
the effect of ABCG1 deficiency on atherosclerotic lesion development in LDLr KO 
mice depends on the stage of atherogenesis. 
In order to validate this observation, all studies on the role of ABCG1 in 
atherosclerotic lesion development were compared using correlation analysis, 
including data from eight published studies, the current study, and one 
unpublished study of our group. The correlation analysis revealed that the fold 
increase/decrease in atherosclerotic lesion size of ABCG1 KO mice compared 
to ABCG1 WT mice is highly correlated (R=0.92) with the atherosclerotic lesion 
size. Based on these data, ABCG1 is primarily protective in early atherosclerotic 
lesions as its deficiency causes an impaired cholesterol efflux to HDL, resulting in 
increased atherosclerotic lesion development. In more advanced atherosclerotic 
lesions, however, the role of ABCG1 in atherogenesis switches from anti- to pro-
atherosclerotic, since the persistent impaired cholesterol efflux from ABCG1-
deficient macrophages is likely to induce accumulation of (oxy)sterols. This 
leads to enhanced apoptosis and/or other compensatory mechanisms, and 
subsequently decreased atherosclerotic lesion size. A previous study on the role 
of ABCG1 in atherosclerosis suggested a correlation between serum cholesterol 
levels and the fold increase/decrease in atherosclerotic lesion size compared to 
ABCG1 WT mice, whereby at about 900 mg/dL serum cholesterol a switch from 
the protective function of ABCG1 to lesion formation was noticed.21 Upon inclusion 
of recent studies, as well as the studies described in this thesis, again a high 
correlation between the fold increase/decrease in atherosclerotic lesion size and 
total serum cholesterol is observed. 
Therefore, under normal physiological levels of cholesterol, the role of ABCG1 
in atherogenesis is likely to be protective. Furthermore, since higher serum 
cholesterol levels are associated with a more rapid development of atherosclerotic 
lesions, this correlation is probably also a direct effect of the stage of 
atherosclerotic lesion development.
Role of macrophage ATGL in atherosclerosis
Triglyceride stores are the most important energy reserves in vertebrates. 
Dysfunctional lipolysis affects energy homeostasis and may contribute to the 
pathogenesis of diseases like obesity and insulin resistance. Adipose triglyceride 
lipase (ATGL) is mainly expressed in adipose tissue.24 However, ATGL is also 
expressed at high levels in macrophages and foam cells in atherosclerotic 
lesions,25 raising the possibility that it might impact atherosclerosis. 
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In chapter 6, the specific role of ATGL in macrophages, as well as the 
consequences of macrophage TG accumulation for atherogenesis was examined. 
Hereto, LDLr KO mice were transplanted with bone marrow from ATGL KO mice or 
WT littermates.
Although lack of ATGL in bone marrow-derived cells had no significant 
influence on serum lipid levels, distinct TG loading was observed in BMDM 
of ATGL KO transplanted mice. Surprisingly, despite increased macrophage 
TG concentrations, atherosclerotic lesion formation in the aortic root was 
highly attenuated in ATGL KO transplanted mice. The observed reduction in 
atherosclerotic lesion formation coincided with increased apoptosis, which 
might limit lesion cellularity and the progression of early lesions in these 
animals.26,27 Depending on the stage of lesion development, increased apoptosis 
can either enhance,28 or suppress29,30 atherosclerotic lesion development. In 
agreement, ATGL deficiency in macrophages was recently shown to result 
in enhanced apoptosis involving mitochondrial dysfunction and activation of 
the mitochondrial apoptosis pathway.31 Leukocytes play an essential role in 
all stages of atherosclerotic lesion development,32–34 whereby the amount 
of predominantly neutrophils and monocytes are positively correlated with 
atherosclerotic lesion development.35,36 Importantly, we found highly decreased 
numbers of circulating leukocytes in Western-type diet fed ATGL KO transplanted 
LDLr KO mice. Remarkably, the LSK stem cell population in bone marrow from 
ATGL KO transplanted mice was decreased compared to WT controls. LSK 
cells are the most primitive hematopoietic stem cells, which can give rise to all 
mature cell types found in the circulation. The attenuated LSK population might 
therefore have resulted in a reduction of leukocyte-producing progenitor cells. In 
addition, plasma MCP-1 levels were drastically reduced in ATGL KO transplanted 
animals. Since MCP-1 is an important chemoattractant for mononuclear cells,37 
the observed reduction most likely attributed to the observed attenuation in 
circulating leukocytes. 
Altogether, the absence of ATGL in macrophages resulted in reduced susceptibility 
to diet-induced atherosclerosis in LDLr KO mice due to decreased infiltration of 
less inflammatory macrophages. Based on these data, macrophage ATGL plays 
a significant role in atherogenesis independent of its expression in other tissues. 
A high intracellular TG content in macrophages is therefore, at least under these 
conditions, protective against lesion development, making macrophage ATGL 
a putative novel target to attenuate early atherogenesis when the removal of 
apoptotic cells is still functional.
Further understanding of the role of ABCA1 in cardiovascular disease
Deficiency of leukocyte ABCA1 on the LDLr KO background leads to increased 
atherosclerosis, despite largely attenuated cholesterol levels.38 Interestingly, 
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these mice also showed elevated leukocyte counts in the circulation,39 and 
accumulation of macrophages in the peritoneal cavity, liver, and spleen.38 This 
indicates that leukocyte ABCA1, in addition to its role in cholesterol efflux, exerts 
regulatory functions in the recruitment of inflammatory cells to the periphery. The 
spleen is the largest lymphoid organ in the body, producing antibodies, facilitating 
phagocytosis and being capable of eliminating foreign antigens.40,41 Moreover, 
it functions as an important monocyte reservoir.42 In order to investigate the 
possible interplay between the spleen and leukocyte ABCA1 with respect to the 
development of atherosclerosis, in chapter 7, ABCA1 KO bone marrow was 
transplanted into LDLr deficient recipient mice, which were subsequently either 
splenectomized or underwent a sham operation. Leukocyte ABCA1 KO mice fed 
WTD showed highly induced concentrations of MCP-1 and KC (murine IL-8) in 
the serum. IL-8 is one of the most potent chemoattractants for neutrophils.43,44 
Accordingly, leukocyte ABCA1 KO mice exhibited increased neutrophil presence 
in the spleen. Upon splenectomy, ABCA1 KO transplanted animals exhibited blood 
neutrophilia as compared to WT splenectomized controls. Surprisingly, leukocyte 
ABCA1 deficieny or splenectomy alone did not alter circulating neutrophil 
concentrations. 
The spleen is also associated with systemic immune responses in which it is 
the principal organ responding to antigens such as oxLDL. In addition, the 
titers of anti-oxLDL antibodies in serum have been suggested to play an anti-
atherogenic role.45 However, no differences in anti-oxLDL antibody serum titers 
were observed upon splenectomy. Moreover, whereas leukocyte ABCA1 KO mice 
displayed attenuated serum TC levels, TC concentrations remained unaffected 
after splenectomy. In contrast, splenectomized mice did show enhanced 
atherosclerotic lesion development as compared to sham operated controls. 
Moreover, splenectomized ABCA1 KO transplanted animals exhibited an additional 
increased lesion development. These results evidently show that leukocyte ABCA1 
deficiency resulted in decreased TC levels, increased inflammation, and lipid and 
neutrophil accumulation in the spleen. However, the observed splenic alterations 
induced by leukocyte ABCA1 deficiency did not alter anti-oxLDL antibody levels, 
nor played a significant role in atherosclerotic lesion development as evidenced by 
splenectomy.
The importance of ABCA1 in cellular cholesterol transport became clear when 
mutations in the ABCA1 gene were discovered to cause Tangier disease; a rare 
inherited disorder characterized by a severe reduction in HDL.46 HDL has been 
proposed to exert multiple anti-atherogenic and anti-inflammatory functions 
beyond cellular cholesterol efflux, including the modulation of lymphocyte 
activity,47 endothelial function,48 and anti-oxidative mechanisms.48 Interestingly, 
low plasma HDL is associated with a long-term unfavorable prognosis in patients 
who have recovered from a MI, suggesting detrimental effects of low plasma HDL 
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on post ischemic myocardial function. To investigate the effects of low plasma HDL 
after MI, in chapter 8, ABCA1 KO mice were subjected to MI by ligation of the left 
anterior descending coronary artery. To our surprise, ABCA1 deficiency attenuated 
cardiac ischemia after a myocardial infarction. Thus, although ABCA1 has an 
important protective role in atherosclerosis, it has detrimental effects on cardiac 
function after MI. The presence of ABCA1 in isolated hearts did not contribute 
to the observed effects, indicating that the smaller myocardial infarction area 
was caused by secondary, ABCA1-mediated effects. Although MI did not affect 
leukocyte numbers in control mice, ABCA1 KO mice displayed an induction of 
circulating leukocytes after MI. Most leukocyte subtypes are generally associated 
with increased inflammation and subsequent cardiovascular disease. B- and 
T-lymphocytes, however, exhibit protective effects upon acute cardiovascular 
events,49–51 thereby attenuating adverse effects on cardiac function after MI. 
ABCA1 is considered to be an important therapeutic target to treat atherosclerosis 
based on its protective effects. However, it is of great importance to further 
identify the possible adverse effects of ABCA1 upregulation on cardiac recovery 
after MI.
Considerations
Cardiovascular disease in humans develops over decades, and clinical 
manifestations often only occur as a result of ruptured, advanced atherosclerotic 
plaques. Although the use of animal experiments enables us to induce and 
investigate atherosclerotic lesion development in for example mice and rats, it has 
proven to be challenging to induce ruptures in established atherosclerotic lesions 
in these animal models.
The lack of these so-called “plaque rupture animal models” makes it difficult to 
extrapolate findings to the human situation. On the other hand, the possibility 
of controlled induction of atherosclerotic lesion formation in (genetically 
engineered) mice has resulted in a powerful tool to identify key proteins and 
mechanisms behind the onset and progression of atherosclerosis. Over the last 
decades, these efforts have resulted in an extensive amount of data, which have 
increased our insight in the mechanism of atherosclerotic lesion development, 
and more importantly also provided numerous promising targets for therapeutic 
intervention.
One of the earliest success stories resulting from basic cardiovascular research 
is the development of statins, which inhibit HMG-CoA reductase, the first 
step in cholesterol synthesis.52 By their action on the liver, statins lower 
circulating cholesterol levels and thereby reduce the risk of clinical events from 
cardiovascular disease. More recently, CETP was believed to be a new promising 
target. Inhibiting the action of CETP in genetically engineered CETP-expressing 
mouse models (mice naturally do not express CETP) resulted in highly favorable 
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changes in lipid profile, including increased HDL levels and decreased VLDL/LDL 
levels. The subsequent phase III clinical trial, however, was prematurely stopped 
because patients treated with the CETP inhibitor torcetrapib had a 25% increased 
chance to suffer from major cardiovascular events and a 40% increased chance 
to die from cardiovascular causes as compared to patients treated with placebo.53 
Despite the favorable changes in lipid profile, torcetrapib also caused severe off-
target effects. In addition, very recently, a phase III clinical trial with another 
CETP inhibitor, dalcetrapib, was stopped due to a lack of clinically meaningful 
efficacy.54 These results indicate that the current CETP inhibitors do not result in 
additional lowering of cardiovascular risk on top of statins. Importantly, it also 
demonstrates that the pathways of the underlying basic research have to be 
studied extensively and interpreted with great care. 
The research described in this thesis mainly focuses on the role of important 
lipid-related genes on macrophages. Macrophages play a crucial role in the 
onset and progression of atherosclerotic lesions in the arterial wall by engulfing 
pro-atherogenic lipoproteins. The subsequent transformation of macrophages 
into lipid-rich foam cells - considered the initial step in the development of 
atherosclerosis - underlines the importance of macrophage lipid homeostasis. 
Macrophage reverse cholesterol transport is a pathway by which excess 
cholesterol from peripheral tissues, including macrophages, is transported back 
to the liver for excretion, and thus of potential interest for the prevention of 
atherosclerosis.2,3 Induction of cholesterol efflux from macrophage foam cells in 
atherosclerotic lesions, the first step in reverse cholesterol transport, is therefore 
considered an attractive approach to prevent lesion development or even evoke 
regression of atherosclerotic lesions. ABCA1, ABCG1 and apoE play pivotal 
roles in macrophage reverse cholesterol transport.5,55 Interestingly, expression 
of these proteins can be enhanced upon pharmacological LXR activation.56 Of 
note, systemic application of LXR agonists also induces off-target effects in liver, 
including increased lipogenesis and production of TG.57 However, specific targeting 
of LXR agonists to macrophages inside the atherosclerotic lesion might be a 
potential new therapeutic strategy for inhibiting atherosclerotic lesion progression 
of induction of regression of established lesions.
Another, somewhat underrated part of macrophage lipid homeostasis is the 
storage and metabolism of TG. The rate limiting enzyme in this process is ATGL, 
responsible for the catabolism of TG into DG and FFA. Disruption of ATGL in mice 
results in premature death.58 However, mice lacking ATGL in all tissues except 
cardiac muscle have a normal life expectancy,59 indicating that TG accumulation 
specifically in cardiac muscle has detrimental effects. Surprisingly, accumulation 
of TG in macrophages causes apoptosis and attenuates atherosclerotic lesion 
development in leukocyte ATGL KO mice. In early atherosclerotic lesions, 
macrophage apoptosis results in attenuated progression or even regression of 
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the lesion.29,60 On the other hand, apoptosis of macrophages in advanced lesions 
can lead to increased inflammation and vulnerable atherosclerotic lesions.61,62 
In addition, differential stages of atherosclerotic lesion are present throughout 
the arterial tree.63 It is therefore difficult to regard macrophage apoptosis as a 
possible target against atherosclerosis.
In conclusion, modulating macrophage lipid homeostasis may provide an 
attractive possibility for future drug design in the field of atherosclerosis. However, 
due to the complexity of the disease and difficulties concerning the extrapolation 
of advances in basic cardiovascular research, further investigations are necessary 
before these potential new drug candidates can be applied in clinical research.
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Hart- en vaatziekten zijn de meest voorkomende doodsoorzaken in 
de huidige westerse maatschappij. Een belangrijk kenmerk bij de 
ontwikkeling van hart- en vaatziekten is de vorming van vernauwingen 
in de bloedvaten. Deze vernauwingen zijn het gevolg van een chronische 
ontsteking in het bloedvat wat resulteert in plaatselijke ophoping 
van vetten. Dit proces staat bekend als slagaderverkalking, ook wel 
atherosclerose genoemd.
Atherosclerose ontwikkelt zich al tijdens de adolescentie en manifesteert 
zich door de afzetting van cholesterol in de vaatwand: de zogenoemde 
“fatty streak”. Dit leidt echter niet tot klinische symptomen, omdat 
deze fatty streaks de bloedtoevoer niet geheel blokkeren. In de loop 
der jaren kunnen de fatty streaks veranderen in bloedvatvernauwende 
atherosclerotische laesies. Of en wanneer dit leidt tot klinische 
symptomen is in grote mate afhankelijk van de blootstelling aan 
risicofactoren. Hierbij kan onderscheid worden gemaakt tussen erfelijke 
factoren, zoals een hoge bloeddruk, hoog cholesterol en diabetes, en 
tussen risicofactoren ten gevolge van een ongezonde levensstijl, zoals 
een vetrijk en ongevarieerd dieet, roken, overgewicht en te weinig 
lichaamsbeweging.
De voornaamste behandelmethoden richten zich op het verminderen 
en verlagen van de risicofactoren. Veel voorgeschreven medicijnen 
zijn statines, die niet alleen in staat zijn om het cholesterol niveau in 
het bloed te verlagen, maar ook een ontstekingsremmende werking 
hebben. In geval van acute symptomen wordt veel gebruik gemaakt 
van chirurgische technieken zoals een bypass operatie of het plaatsen 
van stents, om zo de bloeddoorstroming te herstellen. Ondanks deze 
behandelingen blijft het sterftecijfer dat gerelateerd is aan hart- en 
vaatziekten erg hoog. Het ontwikkelen van nieuwe behandelmethoden is 
daarom noodzakelijk.
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Een hoog cholesterol gehalte in het bloed wordt, zoals eerder vermeld, gezien 
als een risicofactor voor atherosclerose. Desondanks is cholesterol één van de 
belangrijkste vetten in het menselijk lichaam, en zorgt het onder andere voor de 
elasticiteit van de huid. Daarnaast kan er onderscheid worden gemaakt tussen 
het zogenaamde “goede” en “slechte” cholesterol. Cholesterol is niet oplosbaar 
in bloed en wordt daarom door het lichaam getransporteerd in lipoproteïnen. Op 
basis van grootte, samenstelling en dichtheid kunnen ze in vier verschillende 
categorieën worden ingedeeld: chylomicronen, zeer lage dichtheids lipoproteïnen 
(VLDL), lage dichtheids lipoproteïnen (LDL), en hoge dichtheids lipoproteïnen 
(HDL). Terwijl het “slechte” LDL cholesterol een belangrijke risicofactor is voor 
het ontstaan van hart- en vaatziekten, speelt het “goede” HDL cholesterol juist 
een beschermende rol in de ontwikkeling van atherosclerose. Tezamen zijn deze 
lipoproteïnen verantwoordelijk voor zowel het cholesterol transport naar de 
ontvangende cellen en organen, als ook het transport van overtollig cholesterol 
naar de lever, vanwaar het wordt hergebruikt of uitgescheiden via de darm in de 
ontlasting. Indien het cholesterolgehalte in het lichaam stijgt, door bijvoorbeeld 
een defect in het verwijderingsmechanisme of een vetrijk dieet, kunnen ook 
macrofagen – de opruimcellen van het lichaam – de cholesterolrijke lipoproteïnen 
opnemen. Overmatige opname transformeert deze macrofagen vervolgens 
in zogenaamde “foamcellen”. De aanwezigheid van foamcellen in de slagader 
markeren het ontstaan van een atherosclerotische laesie.
Omdat macrofagen een cruciale rol spelen in de ontwikkeling van atherosclerose, 
is het belangrijk om te bepalen welke eiwitten in of op deze macrofagen 
verantwoordelijk zijn voor de opname en afgifte van (overtollig) cholesterol. 
Macrofagen worden geproduceerd uit stamcellen in het beenmerg. Door gebruik 
te maken van beenmergtransplantaties is het mogelijk om de aanwezige 
macrofagen te vervangen door macrofagen met een andere genetische 
samenstelling.
De beenmergtransplantatie bestaat uit verschillende stappen: 1) isolatie van 
beenmerg uit de donor, dat bijvoorbeeld een bepaald eiwit mist; 2) uitschakeling 
van het eigen beenmerg in de ontvanger door middel van een hoge dosis 
straling; 3) transplantatie van het donor beenmerg naar de ontvanger. Na deze 
handelingen zal het beenmerg – en dus ook de macrofagen - van de ontvanger 
vervangen worden door beenmerg van de donor. Op deze wijze is het dus 
mogelijk om het effect van de afwezigheid van een bepaald macrofaag eiwit op de 
ontwikkeling van hart- en vaatziekten te onderzoeken.
In tegenstelling tot mensen zijn muizen relatief ongevoelig voor de ontwikkeling 
van hart- en vaatziekten, onder andere omdat ze veel meer cholesterol in 
het goede HDL vervoeren. Met behulp van genetische modificatie zijn muizen 
gegenereerd die wel gevoelig zijn voor de ontwikkeling van atherosclerose. Deze 
muizen missen de receptor voor LDL (LDL receptor), wat zorgt voor een toename 
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van het LDL cholesterol gehalte in het bloed. LDL receptor-deficiënte muizen 
vormen een goed model om de ontwikkeling van atherosclerose te bestuderen. 
In dit proefschrift staat onderzoek beschreven waarin de rol van verschillende 
macrofaag-eiwitten is bestudeerd met behulp van beenmergtransplantatie in 
atherosclerose gevoelige muizen. Daarnaast zijn experimenten beschreven 
over de rol van bepaalde macrofaag-eiwitten bij een acute vorm van hart- en 
vaatziekten zoals een hartaanval.
Evenals vele andere celtypen bezitten macrofagen eiwitten die verantwoordelijk 
zijn voor de opname van lipoproteïnen. Dit kan leiden tot stapeling van grote 
hoeveelheden cholesterol in deze cellen. Omdat macrofagen de opname 
van cholesterol niet kunnen beperken is de verwijdering van cholesterol uit 
macrofagen een belangrijk proces om de vorming van foamcellen en dus de 
ontwikkeling van atherosclerose tegen te gaan. Verwijdering van cholesterol 
uit macrofagen is voor een groot deel afhankelijk van zogenaamde ABC (ATP-
binding cassette) transporters. Deze eiwitten zijn betrokken bij het transport van 
een groot aantal substraten – waaronder ook vetten (cholesterol) – in en uit de 
cel. Eerdere studies hebben aangetoond dat ABCA1 een belangrijke rol speelt 
bij de verwijdering van cholesterol uit macrofagen. De hoeveelheid ABCA1 in 
macrofagen neemt toe in cholesterolrijke macrofagen, waarmee het overmatige 
cholesterol uit de macrofaag kan worden getransporteerd.
Een andere belangrijke groep eiwitten zijn de zogenaamde apolipoproteïnen. Deze 
eiwitten bevinden zich onder andere op macrofagen en lipoproteïnen en dienen 
voornamelijk als herkenningseenheden voor receptoren op cellen. Met behulp 
van apolipoproteïnen zijn lipoproteïnen als LDL en HDL in staat cholesterol op te 
nemen (influx) of af te geven (efflux). Apolipoproteïne E (apoE) is essentieel voor 
de verwijdering van lipoproteïnen uit het bloed via de lever. Daarnaast speelt apoE 
een belangrijke rol bij de verwijdering van cholesterol uit macrofagen, en mogelijk 
stimuleert het ook de ABCA1 afhankelijke cholesterol effux. In hoofdstuk 3 van 
dit proefschrift is de potentiële interactie tussen ABCA1 en apoE in macrofagen 
bestudeerd met betrekking tot de ontwikkeling van atherosclerose. Met behulp 
van de beenmerg transplantatie techniek is beenmerg van muizen – deficiënt voor 
ABCA1, apoE, of beide – getransplanteerd naar LDL receptor deficiënte muizen. 
In overeenstemming met eerdere studies bleek dat deficiëntie van ABCA1 of 
apoE in macrofagen zorgde voor een verhoging van de atherosclerotische laesie 
formatie, wat suggereert dat beide genen een beschermende functie hebben met 
betrekking tot atherosclerose. LDL receptor deficiënte muizen, getransplanteerd 
met beenmerg wat deficiënt is voor zowel ABCA1 als apoE, ontwikkelden nog 
grotere atherosclerotische laesies. Daarnaast vertoonden deze muizen ook 
verhoogde cholesterol concentraties in het bloed en meer ontstekingsmarkers in 
het bloed (IL-6) en in de lever (IL-6 en TNFα). In vitro experimenten bewezen 
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echter dat de capaciteit van ABCA1/apoE dubbel deficiënte macrofagen om 
cholesterol te effluxen naar onder andere het “goede” HDL niet verschilde van 
ABCA1 deficiënte macrofagen. Dit suggereert dat deficiëntie van ABCA1 en apoE 
in macrofagen via verschillende mechanismen een beschermende werking hebben 
met betrekking tot atherosclerose, en dat ze gezamenlijk ontstekingsremmend 
werken.
Naast ABCA1 speelt ook een andere ABC transporter, ABCG1, een belangrijke 
rol in de verwijdering van cholesterol uit macrofagen. Eerdere studies hebben 
aangetoond dat ABCA1 en ABCG1 in macrofagen een cruciale gezamenlijke 
beschermende rol spelen in de verwijdering van cholesterol uit macrofagen. 
Daarnaast is ook een gecombineerde rol voor ABCG1 en apoE in macrofagen 
met betrekking tot cholesterol efflux en atherosclerose verondersteld. In 
hoofdstuk 4 is beenmerg van muizen – deficiënt voor ABCG1, apoE, of beide 
– getransplanteerd naar LDL receptor deficiënte muizen. Deficiëntie van ABCG1 
of apoE in macrofagen resulteerde in de formatie van meer atherosclerotische 
laesies. Daarnaast bleek dat LDL receptor deficiënte muizen, getransplanteerd 
met beenmerg wat deficiënt is voor zowel ABCG1 als apoE, nog grotere 
atherosclerotische laesies ontwikkelden. Omdat zowel in de gecombineerde 
ABCG1/apoE als in de enkelvoudige deficiënte muizen geen regulatie van 
compensatoire mechanismen of genen geobserveerd werd, kan uit deze studie 
geconcludeerd worden dat ABCG1 en apoE in macrofagen geheel onafhankelijk 
van elkaar een beschermende rol spelen in de ontwikkeling van atherosclerose.
Aangezien de precieze rol van ABCG1 (in macrofagen) met betrekking tot 
atherosclerose nog ter discussie staat, is in hoofdstuk 5 onderzocht wat 
de gevolgen zijn van ABCG1 deficiëntie tijdens verschillende stadia van 
atherosclerotische laesie formatie. Het effect van ABCG1 deficiëntie blijkt 
afhankelijk van het stadium van atherosclerose ontwikkeling: in vroege stadia van 
atherosclerose werkt ABCG1 beschermend, waarschijnlijk door een verminderde 
capaciteit van de macrofagen om het cholesterol uit te scheiden. In latere stadia 
daarentegen stimuleert ABCG1 de ontwikkeling van atherosclerose, waarschijnlijk 
als resultaat van verhoogde apoptose (celdood) van deze macrofagen of andere 
compenserende mechanismen. Deze studie toont aan dat ABCG1 een belangrijke 
rol speelt in de ontwikkeling van atherosclerose.
Naast de opname en het transport van vetten speelt ook de afbraak een 
belangrijke rol ter voorkoming van een verstoorde balans in het lichaam. 
ATGL (adipose triglyceride lipase) is een cruciaal eiwit dat verantwoordelijk 
is voor de afbraak van opgeslagen vetten naar vetzuren die belangrijk zijn 
voor de energievoorziening van de spieren. Zonder ATGL is afbraak van 
triglyceriden onmogelijk, ontstaat er overmatige vetstapeling in het lichaam 
en is er verminderde spierarbeid. Muizen die dit eiwit missen sterven dan ook 
vroegtijdig aan complicaties. Omdat ATGL ook in hoge mate wordt geproduceerd 
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door macrofagen, is in hoofdstuk 6 het effect van ATGL in macrofagen met 
betrekking tot de ontwikkeling van atherosclerose bestudeerd. Verrassenderwijs 
leidde de afwezigheid van ATGL in macrofagen tot een vermindering van 
de atherosclerotische laesie formatie. Dit effect bleek samen te vallen met 
een verhoogde apoptose in de laesie en een verminderde concentratie witte 
bloedcellen (leukocyten) in het bloed. Aanvullend onderzoek liet zien dat een 
verlaagde hoeveelheid witte bloedcel producerende stamcellen (LSK cellen) 
hieraan ten grondslag lag. Een verhoging van de hoeveelheid leukocyten in het 
bloed is meestal een indicatie voor een ontstekings- of afweerreactie. Minder 
leukocyten zou dus duiden op een verminderde ontstekingsreactie. Dit zou, in 
combinatie met de waargenomen apoptose in de laesie kunnen verklaren waarom 
ATGL deficiëntie in macrofagen resulteert in een verlaagde atherosclerotische 
laesie formatie. Ondanks de negatieve gevolgen van ATGL deficiëntie voor 
belangrijke lichaamsfuncties, kan ATGL in macrofagen als belangrijke target ter 
preventie van atherosclerose gezien worden.
In het tweede deel van dit proefschrift wordt de belangrijke rol van ABCA1 
bestudeerd. Naast de cruciale rol in atherosclerose, heeft macrofaag ABCA1 ook 
effecten op de milt. De milt speelt een belangrijke rol in de productie van bepaalde 
witte bloedcellen (monocyten) en de afbraak van rode bloedcellen. Daarnaast 
is de milt onderdeel van het lymfesysteem, en resulteert de verwijdering van 
de milt (splenectomie) in een verhoging van atherosclerose. Macrofaag ABCA1 
deficiëntie in muizen resulteert in cholesterol stapeling en een verhoging van het 
aantal neutrofielen in de milt. In hoofdstuk 7 is daarom gekeken naar de rol 
van macrofaag ABCA1 in atherosclerose in de aan- of afwezigheid van de milt. 
Zoals verwacht resulteerde splenectomie in een verhoging van atherosclerose. 
Daarnaast bevatte de milt meer neutrofielen in de afwezigheid van macrofaag 
ABCA1 in vergelijking met controle dieren. Verrassenderwijs speelde de 
absentie van macrofaag ABCA1 geen rol in de ontwikkeling van atherosclerose 
in afwezigheid van de milt. Hieruit valt te concluderen dat de veranderingen in 
de milt, veroorzaakt door macrofaag ABCA1 deficiëntie, geen belangrijke rol 
spelen bij de beschermende effecten van macrofaag ABCA1 met betrekking tot de 
ontwikkeling van atherosclerose.
Vergevorderde atherosclerose leidt in veel gevallen tot levensbedreigende 
complicaties. Omdat (macrofaag) ABCA1 een belangrijke beschermende werking 
heeft met betrekking tot atherosclerose, is in hoofdstuk 8 de rol van ABCA1 in 
een acuut hartinfarct model bestudeerd. Ondanks de beschermende rol van 
ABCA1 bij de ontwikkeling van atherosclerose waren de gevolgen twee weken na 
een hartinfarct veel milder in muizen die ABCA1 deficiënt waren, dan in controle 
dieren. Echter, additionele resultaten wezen uit dat de specifieke aanwezigheid 
van ABCA1 in het hart geen effect had op de gevolgen van een hartinfarct. Dit 
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suggereert dat de waargenomen resultaten veroorzaakt zijn door secundaire, 
ABCA1-gemedieerde effecten op andere plaatsen in het lichaam. Terwijl geen 
zichtbare veranderingen optraden in de witte bloedcel aantallen in de controle 
dieren, was er sprake van een opmerkelijke verhoging van het aantal witte 
bloedcellen in ABCA1 deficiënte muizen na het infarct. Hoewel de meeste witte 
bloedcel subtypen geassocieerd worden met verhoogde inflammatie en kans op 
atherosclerose, zouden deze in een acute situatie een meer beschermende rol 
kunnen spelen.
De afgelopen decennia is veel vooruitgang geboekt betreffende inzichten, 
operatieve ingrepen, en medicijngebruik bij hart- en vaatziekten. Desondanks 
krijgen nog steeds veel mensen te maken met de gevolgen van bijvoorbeeld 
trombose of zelfs een hartinfarct. Het is daarom van belang de zoektocht naar 
nieuwe targets voor medicijnen voort te zetten.
De in dit proefschrift beschreven studies ontvouwen nieuwe inzichten aangaande 
cholesterol- en vet gereguleerde eiwitten in macrofagen, die als potentieel 
interessante targets gezien kunnen worden om hart- en vaatziekten tegen 
te gaan. Waar huidige medicijnen zich vooral richten op het verlagen van het 
cholesterolniveau in het lichaam, lijken macrofagen een veelbelovend potentieel 
doelwit voor de ontwikkeling van nieuwe therapieën en medicijnen. Dit zal in 
de toekomst hopelijk leiden tot de genezing en zelfs voorkoming van hart- en 
vaatziekten.
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